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Abstract 
 
Stroke accounts for 9% of all deaths worldwide and is a major cause of severe disability 
(Donnan et al, 2008). Following ischaemic stroke, the penumbra represents tissue which is 
hypoperfused and functionally impaired but is not yet irreversibly damaged. However, the 
penumbra  has  a  finite  lifespan  and  will  proceed  to  infarction  in  the  absence  of  swift 
reperfusion. Therefore, the identification and potential salvage of penumbral tissue in acute 
ischaemic  stroke  is  the  ultimate  goal  for  both  clinicians  and  experimental  stroke 
researchers. Positron emission tomography (PET) is the „gold standard‟ imaging modality 
for identifying the penumbra, but the complex logistics of PET limit its widespread use.  
Magnetic Resonance Imaging (MRI) is widely used for penumbra imaging in both clinical 
and  pre-clinical  research.  The  MRI  perfusion-diffusion  mismatch  model  provides  an 
approximation of the penumbra, where diffusion weighted imaging (DWI) identifies the 
core  of  ischaemic  injury  and  perfusion  weighted  imaging  (PWI)  reveals  the  perfusion 
deficit. The mismatch between the DWI and PWI provides a measure of penumbral tissue. 
However, there is no consensus on the perfusion and diffusion thresholds used to identify 
mismatch tissue in clinical and preclinical stroke research. Furthermore, in rodent stroke 
models differences in the evolution of ischaemic injury between strains may limit the use 
of a single set of threshold values. Therefore, the first aim of this thesis was to establish 
strain  specific  perfusion  and  diffusion  thresholds  to  compare  penumbra  volume  in  the 
clinically  relevant  spontaneously  hypertensive  stroke-prone  rat  (SHRSP)  and  the 
normotensive control strain, Wistar-Kyoto (WKY) using 3 different methods. The SHRSP 
strain  is characterised by the progressive development of severe  hypertension which  is 
followed by a tendency to spontaneous stroke and an increased sensitivity to experimental 
stroke.  
Experimental stroke was induced by permanent middle cerebral artery occlusion (MCAO) 
by the intraluminal filament method. DWI and PWI were obtained every hour from 1-4 
hours  post-MCAO.  Strain-specific  diffusion  and  perfusion  thresholds  were  established 
from  final  infarct  at  24  hours  post-MCAO,  as  defined  by  T2  weighted  imaging.  The 
calculated ADC thresholds were comparable between the strains but the absolute perfusion 
threshold was significantly higher in SHRSP compared to WKY. This may be indicative of 
an increased sensitivity to ischaemia in the hypertensive strain. Furthermore, application of 
these thresholds to the acute MRI data revealed that the volume of ischaemic injury and the 
perfusion deficit were significantly larger in SHRSP compared to WKY and this was also 
reflected in the significantly larger infarct volume observed in SHRSP at 24 hours post-
MCAO. Interestingly, there was  evidence of a temporal  increase  in the  volume of the   xx 
perfusion deficit in SHRSP and WKY. This may indicate that there is a progressive failure 
of collateral blood supply in both strains following stroke.  
Penumbra volume was then assessed in SHRSP and WKY rats using the mismatch method 
and also indirectly by examining the growth of the volume of ADC derived ischaemic 
injury.  Mismatch  volume  was  determined  by  arithmetic  subtraction  of  the  volume  of 
ischaemic injury from the volume of perfusion deficit (volumetric method) and also by 
manual delineation of mismatch on each of 6 coronal slices (spatial method). There was a 
limited volume of mismatch tissue in either strain from as early as 1 hour post-MCAO and 
the  volumetric  method  generated  smaller  mismatch  volumes  than  the  spatial  mismatch 
method. Mismatch volume was comparable in SHRSP and WKY from 1-4 hours post-
MCAO.  Penumbra  was  also  determined  retrospectively  by  subtracting  the  volume  of 
ischaemic  injury  at  each  time  point  from  final  infarct  volume.  Using  this  method, 
penumbra volume was significantly larger in WKY compared to SHRSP at 30 minutes 
post-MCAO but penumbra volume was comparable at all later time points. This suggests 
that there is reduced potential for tissue salvage in SHRSP compared to WKY within the 
first  hour  following  MCAO  but  from  1  hour  onwards,  there  is  limited  potential  for 
penumbra salvage in both strains.  
In addition, there was evidence of „negative‟ mismatch tissue in SHRSP and WKY rats, 
where the ADC derived lesion expanded beyond the boundary of the perfusion deficit. The 
volume of negative mismatch tissue was comparable between the strains and was persistent 
over  the  4  hour  time  course.  This  phenomenon  may  arise  from  the  spread  of  toxic 
mediators from the ischaemic core.  
Oxidative  stress  is  a  major  mediator of  cellular  injury  following  ischaemic  stroke  and 
reactive  oxygen  species,  like  superoxide,  have  multiple  deleterious  effects  on  the 
components of the neurovascular unit. It is well established that NADPH oxidase is the 
principal  source  of  superoxide  in  acute  ischaemic  stroke  and  is  therefore  a  target  for 
potential neuroprotective strategies (Moskowitz et al, 2010). Consequently, the second aim 
of  this  thesis  was  to  evaluate  the  potential  neuroprotective  effect  of  NADPH  oxidase 
inhibition with low and high dose apocynin following permanent or transient ischaemia. 
Rats were administered apocynin at a dose of 5mg/kg or 30mg/kg or vehicle, at 5 minutes 
post-MCAO. Apocynin treatment had no significant effect on infarct volume or functional 
outcome at 24 hours following permanent MCAO in WKY rats. However, both low and 
high dose apocynin treatment significantly reduced infarct volume at 72 hours post-MCAO 
by 60% following 1 hour of ischaemia in Sprague-Dawley rats. Furthermore, functional 
outcome was improved in the low dose apocynin treated group, although this did not reach 
the  level  of  statistical  significance.  On  the  basis  of  these  results,  low  dose  apocynin   xxi 
treatment was evaluated in SHRSP rats following 1 hour of ischaemia. However, apocynin 
treatment had no effect on the acute evolution of ischaemic injury and failed to improve 
stroke outcome, where the mortality rate was high in both the apocynin treated and the 
vehicle  treated  group.  The  conflicting  effects  of  apocynin  may  be  attributable  to  a 
differential expression of NADPH oxidase subunits in normotensive and hypertensive rat 
strains. These findings may also explain the failure of neuroprotective drugs to translate 
from bench to bedside, as therapies which are neuroprotective in young healthy animals 
may  not  demonstrate  the  same  efficacy  in  animal  models  with  stroke  co-morbidities. 
Therefore,  potential  therapeutic  strategies  should  be  extensively  evaluated  in  animal 
models with stroke risk factors before proceeding to clinical trial.  
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1.1 Stroke 
 
1.1.1  Types of Stroke and Major Risk Factors 
 
Stroke  is  a  common  multifactorial  neurological  disorder,  which  arises  as  a  result  of  a 
severe  reduction  in  cerebral  blood  flow.  The  brain  accounts  for  around  2-3% of  body 
weight yet receives approximately 15% of the total cardiac output. Furthermore, it has high 
metabolic requirements; accounting for around 20% of total body oxygen consumption and 
25% of total body glucose consumption. The brain has a very limited capacity to store 
energy  and  therefore  requires  a  constant  supply  of  substrates  for  normal  metabolic 
function.  This  great  demand  for  substrates  helps  to  illustrate  how  damaging  even  a 
transient reduction in blood flow could potentially be to brain tissue. 
 
Stroke is the third leading cause of death in the Western hemisphere, after heart disease 
and cancer. Every  year  in the UK approximately 150,000 people have a stroke, which 
equates  to  a  stroke  occurring  in  the  population  every  5  minutes  (Office  of  National 
Statistics). In Scotland, there are 13,000 new strokes every year with 3,000 of these new 
cases  occurring  in  people  who  are  under  65  years  of  age  (Chest,  Heart  &  Stroke 
Scotland,www.chss.org.uk/stroke/index.php). Increasing age is a major stroke risk factor 
as most strokes occur in the elderly population, with 75% of first strokes occurring in the 
over 75 age group (Sudlow & Warlow, 1997). In addition to increasing age, hypertension 
is  also  a  powerful  determinant  of  risk  for  stroke,  where  the  lifetime  risk  of  stroke  is 
doubled in hypertensive patients (Lloyd-Jones et al, 2010). Other factors which contribute 
to the incidence of stroke are diabetes mellitus and dyslipidemia, in addition to lifestyle 
factors including being overweight, cigarette smoking and excessive alcohol consumption. 
 
It has been proposed that the incidence of stroke will rise in future years due to the world‟s 
ageing  population,  thereby  further  increasing  the  healthcare  burden  on  the  economy. 
Stroke patients occupy around 20% of all acute hospital beds and 25% of long term beds 
(Department of Health, 2005). The direct cost to the National Health Service is estimated 
to be £2.8 billion per year. This burden is increased further since 50% of stroke patients are 
rendered severely disabled and require day to day care, while 30% of patients die within a 
year of the first stroke onset (Warlow et al, 2003).   
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Figure 1-1. An example of a poster produced by The Stroke Association to promote the FAST 
campaign which aims to raise public awareness of the common visible symptoms of stroke and 
highlights the need for early diagnosis and treatment to limit brain injury. 
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A  recent  campaign  by  The  Stroke  Association  in  the  UK  has  sought  to  raise  public 
awareness of the symptoms of stroke and highlights the importance of getting the stroke  
patient to hospital as quickly as possible in order to limit brain damage and functional 
impairment. This highly successful campaign is called FAST and focuses on recognising 
the common stroke symptoms of Facial weakness, Arm weakness, Speech problems and 
Time to call 999 (Figure 1-1). The FAST campaign has been supported by UK wide 
television commercials, billboard posters and leaflets in hospitals, GPs surgeries and health 
centres. 
 
The reduction in cerebral blood flow observed in stroke can arise from haemorrhage or 
from occlusion of a cerebral blood vessel. These are termed haemorrhagic and ischaemic, 
or occlusive strokes, respectively. Haemorrhagic strokes are less common than ischaemic 
strokes (Figure 1-2), accounting for approximately 20% of all strokes (Warlow et al, 2003).  
 
Haemorrhagic Stroke 
 
Hypertension is a major stroke risk factor and is closely correlated with the incidence of 
haemorrhagic stroke. Excessive alcohol consumption and cigarette smoking have also been 
identified as risk factors for haemorrhagic stroke (Feigin et al, 2005). This type of stroke 
can arise from a subarachnoid haemorrhage or primary intracerebral haemorrhage, where 
the latter is more common, accounting for 75% of all haemorrhagic strokes (Warlow et al, 
2003). 
Subarachnoid haemorrhage results from the rupture of an intracranial aneurysm, leading to 
a build up of blood in the subarachnoid space, which is situated between the arachnoid and 
pia mater meningeal layers. The mortality rate is high and most deaths occur as a result of 
the period of initial bleeding, with over 40% of patients dying within one month following 
aneurysmal  rupture  (Kissela  et  al,  2002).  In  approximately  one  third  of  aneurysmal 
subarachnoid haemorrhage patients the haemorrhage extends into the parenchyma. These 
patients have a higher mortality rate and a reduced functional recovery (van Gijn et al, 
2007). Recently, it has been reported that patients with aneurysms located in the middle 
cerebral artery are at greater risk of intraparenchymal extension (Liu & Rinkel, 2011). 
 
Primary intracerebral haemorrhage may result from rupture of microaneurysms of 1-2mm 
in  diameter,  which  are  most  often  located  deep  within  the  cerebral  hemispheres 
(Standgaard & Paulson, 1990) and are predominantly found in hypertensive patients. Other 
risk factors include long-term alcohol abuse, male sex and increasing age (Ariesen et al,    5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1-2.  Approximate  frequency  of  the  three  main  causes  of  stroke  in  Caucasian 
populations and of the main subtypes of ischaemic stroke. Reproduced from Warlow et al 
(2003). 
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Figure 1-3. Ischaemic stroke arising from a cardiac embolus. The embolus ascends from the 
heart to the cerebral circulation via the aorta and the common carotid artery. It can travel through 
the cerebrovasculature to occlude a cerebral artery. Adapted from Go (2009). 
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2003;  Zia  et  al,  2007).  Mortality  rates  following  intracerebral  or  subarachnoid 
haemorrhage are high, with 50% of patients dying within 1 month of stroke onset (Donnan 
et al, 2008). 
 
Ischaemic Stroke 
 
Occlusive  or  ischaemic  stroke  is  the  most  common  type  and  accounts  for  80%  of  all 
strokes (Figure 1-2). In Western countries, stroke causes 10-12% of all deaths (Brouns & 
De Deyn, 2009). In the Developing World these statistics are likely to be much higher but 
there are difficulties obtaining accurate figures in countries where death certificates are not 
routinely  available or where death certificates  feature unreliable details (Warlow et al, 
2003). 
 
Cerebral  artery  occlusion  most  often  arises  from  the  production  of  an  atherosclerotic 
plaque, or thrombus, or from an embolism, which has travelled through the circulation 
from its origin in the heart (Figure 1-3). The reduction in blood flow can be transient or 
permanent  and  the  territory  of  the  occluded  cerebral  artery  determines  the  brain  area 
affected  by  the  stroke  and  the  symptoms  exhibited  by  the  patient.  Fifty  percent  of 
ischaemic  strokes  are  as  a  direct  result  of  atherothrombotic  disease  of  the  extra  or 
intracranial vessels, although the large intracranial vessels are less commonly the source of 
the thrombus (Warlow et al, 2003). The site of the occlusion is often at bifurcation points 
of the arterial system due to a combination of turbulent flow and weakened vessel walls at 
these regions. 
 
Emboli which arise from the heart account for 20% of occlusive strokes. There are various 
sources of cardiac embolism, the most common being atrial fibrillation and this link has 
been well established (Warlow et al, 2003). Other sources include cardiac valve disease 
and patent foramen ovale, although there has been some difficulty in establishing a causal 
relationship between recurrent ischaemic events and the latter condition (Almekhlafi et al, 
2009). 
 
A quarter of all ischaemic strokes arise from occlusion of small intracranial vessels and 
lacunar stroke, which affects small arterioles, which become tortuous, often as a result of 
chronic hypertension. These vessels are small (≤ 400µm) and are deeply penetrating and 
the resulting tortuosity makes the vessel susceptible to occlusion from micro-thrombi and 
fibrin deposition which can result in lipohyalinosis (Ogata et al, 2011).   8 
1.1.2  Clinical Treatments for Stroke 
 
On admission to hospital following stroke, patients are assessed in order to establish if the 
clinical diagnosis of stroke is  correct and to establish  if the  stroke is  haemorrhagic or 
ischaemic in origin. This is achieved by the use of the brain imaging techniques, such as 
computed  tomography  (CT)  and  magnetic  resonance  imaging  (MRI).  If  the  stroke  is 
ischaemic in origin, then recanalisation of the occluded vessel will allow restoration of 
blood supply to the affected brain region and potential salvage of penumbral tissue. Rapid 
reperfusion  of  the  occluded  artery  with  thrombolysis  has  been  shown  to  result  in 
favourable clinical outcomes (NINDS, 1995). The only licensed therapy currently available 
for  acute  ischaemic  stroke  is  the  administration  of  recombinant  tissue  plasminogen 
activator  (rtPA).  Endogenous  tPA  is  a  serine  protease  which  is  found  in  vascular 
endothelial cells and it catalyzes the activation of plasmin from plasminogen by cleavage 
of the peptide bond between Arg-560 and Val-561. Activated plasmin has a fibrinolytic 
function and dissolves fibrin rich blood clots, leading to recanalisation of the occluded 
blood vessel. 
 
In 1995, the National Institute of Neurological Disorders and Stroke (NINDS) study group 
evaluated  the  use  of  thrombolytic  therapy  with  rtPA  in  ischaemic  stroke  patients. 
Intravenous rtPA (0.9mg/kg) was administered up to 3 hours following stroke onset and 
the authors reported that patients who received rtPA were at least 30% more likely to have 
minimal or no disability at 3 months following stroke, compared to those patients who 
received placebo (NINDS, 1995). However, these authors also reported that there was an 
increased incidence of intracerebral haemorrhage following thrombolysis.  
The  European  Cooperative  Acute  Stroke  Study  (ECASS)  examined  the  effects  on 
neurological outcome when rtPA was administered within 6 hours of stroke onset. This 
study group reported that thrombolytic therapy effectively improved functional outcome in 
patients  who  demonstrated  moderate  to  severe  neurological  impairment.  However,  the 
mortality  rate  at  30  days  following  stroke onset  was  higher  than  that  observed  in  the 
placebo  treated  group  and  there  was  also  an  increased  incidence  of  parenchymal 
haemorrhage. These findings led the ECASS group to conclude that rtPA should not be 
administered to an unselected population of acute ischaemic stroke patients due to the 
increased risk of mortality and haemorrhage asscociated with administration up to 6 hours 
following stroke onset (Hacke et al, 1995). The second ECASS trial (Hacke et al, 1998) 
failed to show a significant improvement in patient outcome following administration of   9 
rtPA  up  to  6  hours  following  stroke onset.  Similarly  to the  original  ECASS  trial,  the 
authors reported an increased risk of haemorrhage following thrombolysis.  
Thrombolytic  therapy  with  rtPA  was  therefore  recommend  for  acute  ischaemic  stroke 
patients  up  to  3  hours  following  stroke  onset  as  it  was  believed  that  the  risk  of 
haemorrhage following administration at later time points outweighed the clinical benefits. 
Despite this recommendation, thrombolytic therapy with rtPA is relatively underused with 
less  than  5%  of  stroke  patients  receiving  treatment  to  restore  cerebral  blood  flow 
(Weinberger, 2006). As a consequence, clinical trials continued to explore the effects of 
administering rtPA outwith the narrow 3 hour time window to increase the number of 
patients who can potentially benefit from thrombolysis. 
 
 The Desmoteplase in Acute Ischemic Stroke Trial (DIAS) evaluated the potential benefit 
of extending the therapeutic time window to 9 hours following stroke onset. The DIAS 
trials  differed  from  those  discussed  previously  in  that  it  used  desmoteplase  as  a 
thrombolytic,  not  alteplase,  which  was  evaluated  in  the  other  thrombolysis  trials.  The 
DIAS authors reported that patients who received intravenous desmoteplase within 9 hours 
of stroke onset demonstrated a higher rate of reperfusion and improved clinical outcome 
compared to placebo treated patients (DIAS, 2005). The potential benefits of extending the 
thrombolysis treatment window were also examined in the third ECASS trial. ECASS III 
reported that intravenous rtPA administered between 3 to 4.5 hours following stroke onset, 
significantly improved clinical outcome in ischaemic stroke patients (Hacke et al, 2008). 
As a result of these findings, the Stroke Therapy Academic Industry Roundtable (Saver et 
al, 2009) recommended that the therapeutic time window should be extended to 4.5 hours 
following stroke onset and this has recently been put into place. This will allow greater 
numbers of stroke patients to benefit from thrombolytic therapy. Despite this extension to 
the thrombolytic time window, the development of new stroke therapies is still urgently 
required, to ensure that a greater proportion of patients can obtain treatment and experience 
an improved outcome following stroke.  
 
It is estimated that up to 30% of first stroke patients are likely to experience another stroke 
within 1 month of stroke onset (Donnan et al, 2008). Therefore, patients may be prescribed 
a daily dose of aspirin to reduce the likelihood of secondary stroke. Aspirin can lower the 
risk  of  stroke  by  around  20%  due  to  its  antiplatelet  actions,  which  are  mediated  via 
inhibition of the cyclo-oxygenase (COX) pathway (Deb et al, 2010). Furthermore, if the 
patient is hypertensive, their anti-hypertensive medication may be reassessed to reduce the 
risk of stroke reoccurrence.     10 
Following  diagnosis  and  administration  of  thrombolytic  therapy,  if  appropriate,  stroke 
patients may be referred to a specialised stroke unit, if the facilities are available. Stroke 
patients who are admitted to a specialist stroke unit  have a  better outcome than those 
patients who are admitted to a general hospital ward (Donnan et al, 2008). Stroke patient 
mortality  is  14-25%  higher  in  general  wards  compared  to  stroke  units  (Clinical  Audit 
Report, Royal College of Physicians, 2001).  
 
1.1.3  Stroke Pathophysiology and the Ischaemic Cascade 
 
The ischaemic cascade describes the complex series of events which contribute to cellular 
injury following ischaemic stroke (Figure 1-4). Occlusion of a cerebral vessel results in the 
initiation  of  multiple  deleterious  pathways  which  converge  to  mediate  irreversible 
ischaemic injury.  
 
Anoxic Depolarisation 
 
Reduced  blood  flow  results  in  complete  absence  or  a  severe  reduction  in  oxygen  and 
glucose delivery to all cell types which comprise the neurovascular unit in the territory 
served  by  the  occluded  vessel.  The  neurovascular  unit  consists  of  neuronal,  glial  and 
vascular cell types which contribute to normal brain function. Lack of nutritive delivery 
renders cells of the neurovascular unit unable to meet their required energy demands via 
oxidative phosphorylation. This in turn reduces ATP levels and decreases cell pH as lactic 
acid accumulates as a result of anaerobic glycolysis. Lack of ATP results in neurons being 
unable to maintain their normal resting membrane potential (-65 to -90mV), since ATP is 
required  to  power  the  Na
+/K
+  ATPase.  Under  normal  conditions,  this  pump  acts  to 
maintain the resting membrane potential by extruding 3Na
+ ions out of the cell and allows 
entry of 2K
+ ions for every molecule of ATP utilised. This preserves a high intracellular 
concentration of potassium and a low intracellular concentration of sodium ions. 
 
Inactivity of the pump due to ATP depletion allows  intracellular sodium  levels to rise 
leading  to  depolarisation  of  the  membrane  potential.  Membrane  depolarisation  triggers 
opening of voltage-gated calcium channels with subsequent influx of calcium down the 
electrochemical gradient. Further calcium entry may occur due to reversal of the sodium-
calcium exchanger, NCX, which is widely expressed in the brain. This transmembrane 
protein uses the sodium gradient generated by the Na
+/K
+ ATPase to catalyze the extrusion 
of one calcium ion and influx of three sodium ions in each reaction cycle, under normal    11 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-4. The Ischaemic Cascade. A wide spectrum of neurochemical alterations are triggered 
following  occlusion  of  a  cerebral  blood  vessel.  Multiple  pathways  converge  to  contribute  to 
irreversible cellular injury and cytotoxic oedema. The ischaemic cascade presents multiple targets 
for neuroprotection following ischaemia. Reproduced from Chavez et al. (2009). 
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resting conditions (Besancon et al, 2008). In severe ischaemia, where ATP levels are low 
and  Na
+/K
+  pump  activity  is  compromised,  intracellular  overloading  of  sodium  causes 
NCX to operate in the reverse mode, leading to entry of 3 calcium ions per cycle. The 
combined influx of calcium via NCX reversal and through voltage gated calcium channels 
can  trigger  spontaneous  release  of  neurotransmitters  from  the  active  zone  of  the 
presynaptic  neuronal  element  via  calcium-mediated  exocytosis.  Glutamate  is  the  major 
excitatory  neurotransmitter of the central  nervous system and when  its release and re-
uptake are not under physiological control, is largely responsible for initiating a cascade of 
excitotoxic events. 
 
Glutamate Excitotoxicity 
 
The mechanism of presynaptic glutamate release may occur via spontaneous exocytosis, by 
reverse  operation  of  the  sodium  dependent  glutamate  uptake  system,  or  by  standard 
calcium-mediated  exocytosis.  However,  the  excessive  extracellular  glutamate  levels 
observed in ischaemia are likely to be attributable to all three modes of release. 
The excess glutamate release into the extracellular space allows for an increased activation 
of postsynaptic glutamate receptors, of which there are four classes: Ionotropic kainate, 
AMPA  and  NMDA  receptors  and  metabotropic  glutamate  receptors  (mGluR).  Kainate 
receptors are found in specific brain regions only, and along with AMPA receptors, they 
mediate basal synaptic transmission. Ligand binding triggers channel opening, allowing 
entry  of  sodium  and  chloride  ions  and  extrusion  of  potassium  ions  along  their 
electrochemical gradients. Water enters the cell passively as a result of high Na
+ and Cl
- 
entry, leading to cytotoxic oedema. This may have an effect on the perfusion of regions of 
brain tissue surrounding the infarct and may also cause a slight rise in intracranial pressure, 
vascular compression and herniation. These are major determinants of whether a patient 
survives beyond the first few hours following a stroke (Dirnagl et al, 1999).  
 
Excessive and prolonged membrane depolarization occurs as a result of AMPA receptor 
stimulation  and  this  in  turn  results  in  activation  of  the  NMDA  receptor.  The  NMDA 
receptor is unique in that it requires both ligand binding and a voltage change to induce 
channel opening. Local depolarisation displaces the voltage-dependent magnesium block 
from the channel to allow entry of sodium and calcium and extrusion of potassium ions. 
 
Additionally, glutamate activation of mGluRs leads to activation of Phospholipase C. This 
enzyme catalyzes the hydrolysis of the membrane protein, phosphatidylinositol 4,5-    13 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5. A representation of the temporal profile of the pathophysiological mechanisms 
underlying acute focal ischaemia and their contribution to cerebral ischaemic injury. In the 
absence of reperfusion, the ischaemic penumbra (shown in grey) will proceed to infarction as the 
ischaemic core expands to encompass the perfusion deficit (shown in black). Reproduced from 
Brouns & De Deyn (2009). 
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bisphosphate (PIP2) to release the 2
nd messengers diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3). DAG activates protein kinase C, which further stimulates voltage-gated 
calcium channels. IP3 mediates the release of calcium from intracellular stores by binding 
to an IP3  sensitive channel located in the membrane of the endoplasmic reticulum (ER). 
The ER is a major source of calcium since under normal conditions, 99% of total cell 
calcium  (1000µmol/l)  is  bound  or  stored,  with  only  0.1µmol/l  free  in  the  cytosol. 
Furthermore, resequestration of calcium into the ER is mediated via a calcium ATPase, so 
re-uptake of calcium into the ER lumen is reduced as a result of decreased ATP levels. 
This further contributes to the increase in intracellular calcium and it is evident that the rise 
in cytosolic calcium associated with ischaemia is derived from multiple pathways (Kristian 
& Siesjo, 1998). 
 
Calcium Activation of the Ischaemic Cascade 
 
Calcium is the major mediator of ischaemic cell damage and death, by triggering a cascade 
of reactions within the cell. It activates a  variety of enzymes  including endonucleases, 
which result in DNA and RNA damage, as well as proteases and lipases, along with other 
factors, which mediate further cell dysfunction and damage. The calcium-mediated cascade 
also involves the production of free radicals including nitric oxide, which have numerous 
effects  on  cell  function  and  viability.  The  temporal  profiles  of  the  components  of  the 
ischaemic cascade are illustrated by Figure 1-5. 
 
Free Radical Generation 
 
Calcium mediated activation of the enzyme phospholipase A2 triggers the breakdown of 
membrane  phospholipids  to  form  arachidonic  acid,  which  then  undergoes  oxidative 
metabolism  via  the  COX  or  lipoxygenase  pathways,  resulting  in  the  synthesis  of 
eicosanoids. Superoxide or hydroxyl free radicals are also released during this process. 
This  pathway  involves  a  positive  feedback  cycle,  as  free  radical  production  further 
stimulates  phospholipase  A2  activity  and  consequently  enhances  the  generation  of  free 
radicals.  Free  radicals  may  also  be  generated  as  a  result  of  hypoxanthine  oxidation. 
Hypoxanthine  accumulates  under  hypoxic  conditions  due  to the  breakdown  of  adenine 
nucleotides. Superoxide radicals are released as xanthine dehydrogenase is converted to 
xanthine oxidase during the metabolism of hypoxanthine. 
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Nitric oxide (NO) production increases in ischaemia as a result of increased intracellular 
calcium levels. Calcium activates calcineurin, which in turn activates neuronal nitric oxide 
synthase  (nNOS).  This  enzyme  catalyzes  the  synthesis  of  NO  from  its  precursor,              
L-arginine. Under normal physiological conditions, NO functions as a neurotransmitter and 
has a role in synaptic plasticity (Pacher et al, 2007) as well as in the control of cerebral 
blood flow, where it acts as a vasodilator. Under ischaemic conditions, NO combines with 
superoxide to form peroxynitrite, which is a highly reactive oxidant. In ischaemia, where 
L-arginine levels may become rate limiting, nNOS may generate peroxynitrite directly by 
producing both NO and superoxide. Peroxynitrite is extremely potent and causes extensive 
tissue  damage  via  inhibition  of  DNA  synthesis  and  nucleic  acid  damage,  lipid 
peroxidation, leading to membrane breakdown. This oxidant also mediates mitochondrial 
dysfunction and activation of poly (ADP-ribose) polymerase (PARP). PARP is a nuclear 
enzyme,  which  is  strongly  activated  by  single  stranded  breaks  in  DNA  caused  by  the 
actions of peroxynitrite and free radicals (as reviewed by Lipton, 1999). PARP upregulates 
the transcription  factors activator protein 1 (AP1) and nuclear  factor kappa B (NFκB), 
which enhance post-ischaemic brain inflammation. PARP toxicity also involves depletion 
of ATP and stimulates release of apoptosis inducing factor (AIF) from mitochondria which 
activates caspase independent apoptosis (as reviewed by Beckman & Koppenol, 1996). 
Therefore PARP neurotoxicity is multifactorial and influences multiple pathways. 
NO may also have an indirect neuroprotective effect by inducing vasodilatation to increase 
local blood flow and enhance collateral circulation. NO also inhibits platelet aggregation 
and  leukocyte  adhesion,  thereby  preventing  microvascular  plugging  and  occlusion. 
Furthermore, vascular NO may inhibit the ischaemic cascade by preventing inflammation, 
oxidative injury and neuronal apoptosis (as reviewed by Pacher et al, 2007). 
 
Free radicals have extremely destructive effects on cells and under ischaemic conditions 
their high production levels completely overwhelm endogenous free radical scavengers, 
like uric acid and glutathione. The brain is particularly susceptible to free radical mediated 
cellular injury due to its limited antioxidant responses (Adibhatla & Hatcher, 2010). Free 
radicals have a range of detrimental cellular effects including enzyme inactivation, release 
of  calcium  ions  from  intracellular  stores,  protein  denaturation,  lipid  peroxidation  and 
damage to DNA and RNA, in addition to cytoskeletal component breakdown (Brouns & 
De Deyn, 2009). Free radicals also act as signalling molecules to induce an inflammatory 
response and trigger apoptosis (Brouns & De Deyn, 2009). Free radicals have detrimental 
effects on mitochondria, where they disrupt the inner mitochondrial membrane via lipid 
peroxidation. In addition, free radicals impair mitochondrial function further by oxidising   16 
the proteins, which are involved in the electron transport chain to mediate ATP production 
and  H
+  extrusion  (Dugan  &  Choi,  1994).  Overall,  free  radicals  result  in  severe 
mitochondrial dysfunction and mediate cellular damage via various actions within the cell. 
 
Peri-infarct Spreading Depolarisations 
 
In the ischaemic core, cells undergo anoxic depolarisation and are unable to repolarise. 
However, in less severely hypoperfused penumbral tissue located at the boundary of the 
ischaemic core, cells retain the ability to repolarise but they do so at the expense of further 
energy  consumption  and  oxygen  extraction  levels  are  increased  to  compensate  for  the 
reduced cerebral blood flow. Once repolarised, these cells can then again depolarize in 
response to high glutamate and potassium ion levels, which accumulate in the extracellular 
space.  This  cycle  can  continue  and  repetitive  depolarisations  are  called  peri-infarct 
depolarisations.  Peri-infarct  depolarisations  occur  spontaneously  over  several  days 
following stroke onset and this has been demonstrated both in pre-clinical (Hartings et al, 
2003)  and  clinical  stroke  research  (Dohmen  et  al,  2008).  This  phenomenon  has  been 
particularly well documented in rodent models of stroke and as the frequency of these 
events increases, greater numbers of cells in the penumbra become incorporated into the 
ischaemic  core  (Mies  et  al,  1993).  This  has  also  been  demonstrated  in  human  stroke 
patients,  where  delayed  ischaemic  brain  damage  was  associated  with  spreading 
depolarisations (Drier et al, 2006). 
 
Inflammatory Responses to Ischaemia 
 
An  inflammatory  response  is  triggered  by  various  factors  in  ischaemic  conditions, 
including increasing free radical levels, calcium activated second messenger systems and 
by the state of hypoxia itself. This results in the synthesis of transcription factors, like 
NFκB  and  hypoxia  inducible  factor  1  (HIF1),  which  promote  expression  of  pro-
inflammatory  genes  to  produce  inflammatory  mediators  like  tumour  necrosis  factor  α 
(TNFα), interleukin1β (IL-1β) and platelet activating  factor (PAF), to name  but a few. 
Production  of  these  mediators  induces  surface  expression  of  adhesion  molecules  like 
intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) 
and  E-selectin.  These  molecules  interact  with  complementary  receptors  located  on  the 
surface  of  neutrophils,  allowing  their  passage  across  the  blood-brain  barrier  (BBB). 
Macrophages and monocytes follow suit, migrating into the ischaemic brain, guided by   17 
chemokine signals produced by cells at the site of the lesion (as reviewed by Dirnagl et al, 
1999). 
Four to six hours following cerebral ischaemia, microglia become activated and attracted 
to the site of injury by monocyte chemoattractant protein 1 (MCP-1) (Brouns & De Deyn, 
2009). MCP-1  is activated by  plasmin  following opening of the BBB due to death of 
endothelial cells in response to ischaemia. Once activated, microglia assume an ambeoid 
appearance and retract their processes (Dirnagl et al, 1999), allowing proliferation to occur. 
They  then  secrete  a  variety  of  neurotoxic  and  neuroprotective  compounds.  The 
neuroprotective factors include plasminogen, thrombospondin and tumour growth factor b1 
(TGFb1), which has a role in angiogenesis and extracellular matrix formation. However, 
there is increasing evidence that post-ischaemic inflammation actually contributes to brain 
injury  via  microvascular  obstruction  by  neutrophils  (Del  Zoppo,  1991).  Activated 
microglia secrete neurotoxins, such as TNFα, which may exacerbate ischaemic neuronal 
damage. Furthermore, TNFα is also released by ischaemic neurons (Barone et al, 1997). In 
addition,  the  ischaemic  inflammatory  response  may  also  be  linked  to  the  initiation  of 
apoptotic  pathways,  since  it  has  been  described  that the  use  of  antibodies  against  cell 
surface  adhesion  molecules,  reduced  ischaemic  cell  damage  and  apoptotic  cell  death 
(Chopp et al, 1996). Therefore, the inflammatory response observed following ischaemia 
appears to have a dual role in both neuroprotection and neurotoxicity, although its principal 
role is not yet clear. 
 
Astrocyte Response to Ischaemia 
 
Within  the  neurovascular  unit,  astrocytes  provide  trophic,  metabolic  and  antioxidant 
support to neurons and also react to ischaemic conditions in the brain (Pastor et al, 2009).  
Within  minutes  of  reduced  cerebral  blood  flow,  astrocytes  swell  and  the  cytoplasm 
becomes  lucent.  This  particularly  occurs  in  perivascular  foot  processes  surrounding 
capillaries. In irreversible ischaemic injury, swelling leads to a doubling of cell volume 
with a reduction in cell organelle content and complete loss of glial fibrillary acidic protein 
(GFAP). Reactive astrocytes are stimulated by the release of TGFb1 by activated microglia 
and they can be distinguished morphologically by the large quantity of GFAP and vimentin 
intermediate filaments in the cytosol (Li et al, 2008). These astrocytes produce a variety of 
neurotrophic  factors,  including  basic  fibroblast  growth  factor  (bFGF)  and  insulin-like 
growth factor 1 (IGF-1), to potentiate recovery of damaged neurons (Ridet et al, 1997). 
However,  the  precise  molecular  mechanisms  involved  in  the  astrocyte  response  to 
ischaemia are not yet clear.   18 
 
 
 
 
 
Figure  1-6.  Apoptosis  cascades  mediated  by  TNFα  and  mitochondrial  pathways.  The 
activation of TNF receptors can induce apoptosis directly by activating caspase cascades  and 
indirectly  by  stimulating  mitochondrial  mediated  apoptosis.  Cytochrome  c  released  from  the 
mitochondrion  mediates  formation  of  the  apotosome  complex  and  subsequent  activation  of 
caspases 9 and 3, leading to induction of apoptosis. Ischaemia induced release of AIF from the 
mitochondrion  promotes  apoptosis  independently  of  caspase  activation.  Reproduced  from 
Weinberger (2006). 
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Mechanisms of Cell Death 
 
Under ischaemic conditions, cells of the neurovascular unit may die either by necrosis or 
by apoptotic pathways which are highly conserved biochemical pathways which signal and 
execute cell death. The mechanism of cell death employed depends on the nature of the 
excitotoxic stimulus, cell type and the stage in development or life cycle (Leist & Nicotera, 
1998). 
Necrosis appears to be the predominant mechanism of neuronal cell death following acute, 
permanent vascular occlusion (Dirnagl et al, 1999). Therefore, necrotic cell death occurs in 
the ischaemic core, where perfusion is most severely reduced and cells are irreversibly 
damaged, since necrosis only occurs following an exogenous insult and is not involved in 
normal physiological processes. If a cell dies through the necrotic pathway,  it releases 
more  glutamate  and  toxic  mediators  into  the  environment,  affecting  surrounding  cells 
(Brouns & De Deyn, 2009).  
 
Apoptosis 
 
Apoptosis is a programmed cell death mechanism, which appears to occur in cells that are 
affected by milder injury and particularly occurs in the ischaemic penumbra (Dirnagl et al, 
1999). Characterization of programmed cell death processes  in  Caenorhabditis elegans 
lead  to  much  greater  understanding  of  the  mechanisms  involved  in  apoptosis  in 
mammalian systems. 
 
Apoptotic pathways can either be caspase dependent or independent (Figure 1-6), although 
neurons are particularly susceptible to caspase mediated cell death programmes following  
focal cerebral ischaemia. Caspase dependent apoptosis involves the release of cytochrome 
c  from  the  mitochondrial  intermembrane  space  as  a  result  of  free  radical  induced 
mitochondrial  dysfunction.  Cytochrome  c  enters  the  cytosol  and  activates  apoptosis 
activating  factor 1 (Apaf-1) and procaspase 9,  which combine to form an  apoptosome 
complex.  This  complex  then  activates  an  apoptosis  effector  system,  which  involves  a 
cascade of endonucleases and caspases.  Caspases are cysteine proteases, which cleave 
proteins of the nuclear lamina and cytoskeleton, including PARP and gelsolin, 
Caspase 3 activation  has  been  shown to be one of the  most critical steps  in apoptosis 
induction and occurs hours before cell death occurs. Following transient middle cerebral 
artery occlusion in the mouse, cytochrome c release was detected after 6 hours, caspase   20 
processing occurred at 9 hours and prominent cell death was not evident until 24 hours 
following occlusion (Endres et al, 1998). 
 
Caspase independent apoptosis is mainly driven by apoptosis inducing factor (AIF). AIF is 
a mitochondrial inner membrane flavoprotein oxioreductase, which acts as a pro-survival 
factor. It is essential for long time mitochondrial function and is important in maintaining 
complex 1 integrity and H2O2 scavenging capability. However, when AIF is released from 
the mitochondrion into the cytosol, it reaches the nucleus, where it has an anti-survival role 
by triggering DNA degradation and cell death. 
 
1.2 Animal Models of Cerebral Ischaemia 
 
1.2.1  Rodent Stroke Models 
 
The main features of human ischaemic stroke can be modelled in animal models of focal 
cerebral ischaemia. Primate and higher mammal models of stroke are of greatest relevance 
to the human condition but such models present a variety of problems. Primate models in 
particular are most relevant when examining the behavioural effects of stroke, especially 
with regards to manual dexterity, which is lacking in lower mammals. However, there are 
many disadvantages to using such models, namely cost of maintenance and the need for 
specialist animal facilities. There are also many ethical considerations as there are lower 
levels of social acceptance with the use of these models (Carmichael, 2005).  
However, there are many advantages in the use of rodent stroke models. Mice are the most 
suitable species when examining the molecular pathophysiology of stroke, since genetic 
modifications can be easily introduced (Fujimura et al, 1999). Rat models are the most 
appropriate to model focal cerebral ischaemia due to their size, which allows physiological 
parameters  to  be  easily  monitored  and  brain  tissue  can  also  be  easily  examined  by 
neuroimaging  techniques  or  histological  staining  methods.  Furthermore,  reproducible 
studies can be conducted with ease due to the relative homogeneity within strains of rat 
(Durukan  & Tatlismak, 2007). However,  by  far the  most convincing argument  for the 
relevance of rat models of stroke, is the similarity between the cerebrovascular systems of 
humans and rats, both on an anatomical and functional  level (Macrae, 1992), with both 
species possessing a circle of Willis (Figure 1-7). 
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Figure 1-7. The cerebrovascular systems of rat (left) and man (right). Both species possess a 
circle of Willis which makes the rat a suitable species for modelling human stroke. In humans the 
middle  cerebral  artery  is  commonly  occluded  and  therefore  most  rat  models  of  focal  cerebral 
ischaemia  involve  occlusion  of  this  artery.  This  procedure  is  most  often  performed  using  the 
intraluminal thread model where a nylon suture (shown in black) is introduced into the internal 
carotid artery and progressed until it blocks the origin of the middle cerebral artery. 
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The middle cerebral artery is the vessel which is most commonly occluded in human stroke 
(Mohr et al, 1986) and therefore, rat models involving middle cerebral artery occlusion 
(MCAO) are of particular relevance to the clinical situation. The intraluminal filament  
model of MCAO was first described by Koizumi et al (1986) and this technique has since 
been refined by various study groups (Belayev et al, 1996; Schmid-Elsaesser et al, 1998). 
This technique involves introducing and passing a filament of a specified diameter along 
the internal carotid artery until the filament reaches the bifurcation point and is lodged at 
the junction of the anterior and middle cerebral arteries, blocking off the proximal origin of 
the middle cerebral artery. This model can induce either transient or permanent ischaemia, 
since the filament can be retracted after a defined time period. There are various factors 
which  can  influence  the  reproducibility  of  this  model,  including  filament  diameter, 
insertion length and filament coating. Filaments coated with silicon have been shown to 
reduce the risk of haemorrhage and premature reperfusion (Belayev et al, 1996; Schmid-
Elsesser  et  al,  1998)  and  the  size  of  the  filament  correlates  well  with  infarct  volume 
(Durukan & Tatlisumak, 2007). However, intraluminal thread MCAO models present their 
own  problems,  primarily  from  the  risk  of  blood  vessel  rupture  and  haemorrhage. 
Furthermore, artery occlusion may be incomplete, allowing some perfusion of the territory 
served by the middle cerebral artery (MCA). Additionally, blood vessels outside of the 
territory of the MCA may also be occluded by the filament. 
 
Although the intraluminal filament model is the most commonly used stroke model, the 
middle cerebral artery can be occluded by other means. For example, the MCA can be 
permanently occluded by electrocoagulating the proximal region of the artery (Tamura et 
al, 1981). This model requires a craniectomy, which reduces the mortality associated with 
ischaemia induced acute brain swelling and produces a highly reproducible infarct, which 
is  smaller  than  that  produced  by  the  intraluminal  filament  model  (Macrae,  1992). 
Experimental  stroke  can  also  be  induced  by  stereotaxic  injection  of  the  potent 
vasoconstrictor, endothelin-1 which can produce selective grey or white matter ischaemia 
depending on the location of the injection. This allows small white matter infarcts to be 
produced (Frost et al, 2006) and can also be used to occlude the middle cerebral artery by 
injecting endothelin-1 into the adjacent grey matter (Sharkey et al, 1993). Embolic stroke 
can  also  be  induced  experimentally  where  an  embolus  is  introduced  into  the 
cerebrovasculature  to  occlude  a  cerebral  artery.  The  embolic  model  is  of  particular 
relevance when examining the effect of thrombolytic therapy (Henninger et al, 2009; Zhu 
et al, 2010). However, infarcts produced by embolic models are generally less reproducible 
than those produced by the intraluminal filament and electrocoagulation models of MCAO.   23 
This  is  likely  to  arise  from  variations  in  clot  stability  and  the  final  lodgement  of  the 
embolus within the cerebrovasculature (DiNapoli et al, 2006). 
 
There are many who question the validity of rat stroke models and their relevance to the 
human condition due to the lack of research using aged animals with stroke risk factors and 
poor  study  design.  In  addition,  experimental  strokes  are  highly  reproducible  in  rodent 
models  but  in  the  human  stroke  patients  the  size  and  location  of  the  stroke  is  highly 
variable. The  intraluminal  filament  model of  MCAO  in particular, produces very  large 
infarcts which may not model the most treatable and common human strokes (Carmichael, 
2005). In addition, many of the anaesthetics commonly used during stroke surgery, have 
been demonstrated to have neuroprotective effects, which will influence stroke outcome. 
Therefore,  the  choice  of  anaesthetic  used  during  the  experiment,  must  be  carefully 
considered. 
 
1.2.2 Neuroprotection in Animal Models of Stroke 
 
In animal models of stroke, pharmacological targeting of the pathways involved in the 
ischaemic cascade have been successful in reducing infarct size and the extent of neuronal 
damage as well as improving functional outcome. However, when these treatments were 
introduced into human clinical trials, their efficacy was lost and in some cases, even led to 
exacerbation of ischaemic damage (Internet Stroke Centre:www.strokecenter.org/trials/). 
There are many hundreds of published pre-clinical articles reporting the neuroprotective 
effects of drugs which target the mechanisms involved in stroke pathophysiology but to 
date, none of these therapeutic strategies have translated to human stroke patients. There 
are many reasons why this may occur, including the increased age of clinical trial patients 
compared  to the  use  of  young  adult  animals,  as  well  as  anatomical  and  physiological 
differences  between  the  brains  of  humans  and  animals,  poor  study  design  and  lack  of 
penumbral imaging for patient recruitment in clinical trials (Dirnagl et al, 1999; Röther, 
2008;  Chavez  et  al,  2009).  Despite  these  disappointing  results,  the  pathophysiological 
pathways involved in stroke remain a prime target for the development of future stroke 
therapies. Therefore understanding the pathophysiological mechanisms underlying stroke 
can  identify  targets  for  possible  pharmacological  intervention  to  allow  development of 
stroke therapies, which will reduce the high mortality rates and the degree of disability 
associated with this disorder. 
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1.2.3  The Spontaneously Hypertensive Stroke-Prone Rat (SHRSP) 
 
The spontaneously hypertensive stroke-prone rat (SHRSP) is commonly utilised in models 
of  malignant  hypertension  and  cerebrovascular  disease,  including  stroke.  This  strain 
develops  progressive  hypertension  at  a  young  age  and  is  prone  to  spontaneous  stroke, 
which is similar to the human condition. Hypertension is well established as a major risk 
factor for human stroke and contributes to the development of stroke in the SHRSP.  
 
The SHRSP was developed in 1974 by Okamoto and colleagues, by selective inbreeding of 
spontaneously hypertensive rats (SHR). The offspring produced, where at least one of the 
breeding  pair  experienced  spontaneous  stroke,  were  maintained  over  successive 
generations. The SHR strain had been previously developed from selective inbreeding of 
normotensive  Wistar-Kyoto  (WKY)  rats  which  exhibited  elevated  blood  pressure 
(Okamoto & Aoki, 1963). 
 
Both  SHR  and  SHRSP  show  increased  sensitivity  to  experimental  stroke  compared  to 
normotensive  rat  strains  (Duverger  &  MacKenzie,  1988).  However,  the  SHRSP  strain 
demonstrates  more  severe  hypertension  and  an  increased  susceptibility  to  spontaneous 
stroke. There are many factors implicated in the increased stroke sensitivity observed in the 
SHRSP,  including  an  enhanced  inflammatory  response,  impaired  collateral  flow  and  a 
variety  of  other  anatomical  and  physiological  abnormalities,  in  addition  to  genetic 
hypertension.  
 
Furthermore, the SHRSP can also be used as a model of metabolic syndrome, which is a 
complex multifactorial disease linked to insulin resistance. Hypertension is a known risk 
factor for metabolic syndrome and feeding SHRSPs a 60% fructose diet induces impaired 
glucose tolerance, dyslipidaemia and increased adiposity compared to WKY rats (Strahorn 
et al, 2005).  
 
1.2.4  Genetic Background of SHRSP 
 
The  structural  and  physiological  differences  that  are  demonstrated  by  the  SHRSP, 
compared to SHR and WKY, are determined by their genetic background. At least three 
major genes are known to influence the development of severe hypertension and the gene  
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Figure  1-8.  Hypothetical  genetic  make-up of  SHR  and  SHRSP.  SHRSP  possess  additional 
genes which contribute to increased sensitivity to experimental stroke which are independent of 
blood  pressure  since  larger  infarcts  are  observed  in  SHRSP  before  the  development  of 
hypertension. Reproduced from Nabika et al (2004). 
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loci which contribute to the development and maintenance of hypertension are different 
depending on the age of the animal (Mashimo et al, 1999). In young animals, quantitative 
trait  loci  (QTLs)  on  chromosomes  1,  3  and  4  contribute  to  the  elevated  basal  blood 
pressure observed in the stroke-prone strain. However, the rise in blood pressure observed 
following salt-loading can be linked to a QTL on chromosome 10. In addition, there are 
other genes which are involved in stroke which are independent of blood pressure since 
SHRSP show increased stroke sensitivity before the onset of hypertension, indicating other 
genetic factors (Figure 1-8). 
 
The increased stroke sensitivity demonstrated by the stroke-prone strain has been shown to 
be  inherited  as  a  dominant  trait.  Gratton  et  al  (1998)  reported that the  offspring  of  a 
SHRSP/WKY cross (WKY father) exhibited infarcts following experimental stroke which 
were directly comparable with that observed in the SHRSP strain, indicating a dominant 
mode of inheritance for increased stroke sensitivity. Furthermore, Carswell et al (1999) 
reported  that  male  offspring  from  a  WKY/SHRSP  cross,  where  the  father  was  of  the 
stroke-prone  strain,  demonstrated  reduced  sensitivity  to  experimental  stroke than  those 
with a WKY father. The authors proposed that this effect may be attributed to the increased 
blood pressure exhibited by males with a Y chromosome inherited from SHRSP, since they 
demonstrated that there was a significant negative correlation between high blood pressure 
and small infarct volume following permanent MCA occlusion. 
 
 Jeffs et al (1997) proposed that increased sensitivity to experimental stroke in the SHRSP 
was linked to a QTL on chromosome 5, which co-localises with the genes which encode 
atrial natriuretic factor (ANF) and brain natriuretic factor (BNF). Both of these proteins are 
vasoactive and may play a role in the control of vasoreactivity, growth and remodelling of 
cerebral blood vessels (Jeffs et al, 1997). However, in a later study by the same group, the 
genes  encoding  ANF  and  BNF  were  excluded  as  candidates  for  the  increased  stroke 
sensitivity demonstrated by SHRSP as they were unable to identify any differences in the 
coding regions of these genes between the stroke-prone and the normotensive reference 
strain. In addition, there was no difference in the expression of ANF and BNF between 
strains, even following MCA occlusion (Brosnan et al, 1999).  
 
Rubbatu and colleagues (1999) examined the genes involved in stroke proneness and these 
authors did  identify strain differences  in the sequence coding atrial  natriuretic peptide, 
resulting in altered structure of the gene product in the stroke-prone strain. The conflicting 
findings of these studies show that the genes involved in the risk of spontaneous stroke    27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-9.  The range of systolic pressures of the SHRSP and normotensive WKY strain, 
measured using the tail cuff method at weeks 8, 12 and 16. Both sexes of the stroke-prone 
strain display higher pressures than the normotensive reference strain WKY. However, female 
SHRSP develop hypertension which is not as severe as that observed in male SHRSP. Adapted 
from Davidson et al (1995). 
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differ from those genes which predispose SHRSP to increased sensitivity to experimental 
stroke although both QTLs are localised on chromosome 5. 
1.2.5  Development of Hypertension in SHRSP 
 
Immature SHRSP are normotensive, with blood pressure values which are comparable to 
that of the reference strain WKY (Davidson et al, 1995). When the animals reach around 8 
weeks  of  age,  systolic  blood  pressure  begins  to  rise  progressively  from  approximately 
140mmHg to 175mmHg by 16 weeks. Blood pressure of the normotensive WKY remains 
at  around  135mmHg.  However,  Okamoto  et  al  (1974)  reported  frequent  severe 
hypertension in the SHRSP of up to 250mmHg by 20 weeks of age, while maximal blood 
pressure observed in the stroke-resistant SHR strain did not rise above 200mmHg.  
Therefore,  the  increased  susceptibility  to  stroke  demonstrated  by  the  SHRSP  may  be 
attributed to the increased blood pressure observed in this strain since induction of severe 
hypertension (>225mmHg) in normotensive rats using a kidney clip procedure, resulted in 
spontaneous stroke and infarct sizes comparable to that observed in SHRSP (Zeng et al, 
1998). Despite this, other genetic factors must contribute to stroke susceptibility in the  
SHRSP,  since  experimental  stroke  produces  significantly  larger  infarcts  in  this  strain 
compared to WKY, even before hypertension develops (Coyle & Jokelainen, 1983). 
Interestingly, females develop hypertension much more slowly and to a much lesser degree 
than their  male counterparts (Figure 1-9). In  immature SHRSP  females, systolic  blood 
pressure is comparable with that of the male and also begins to rise at around 8 weeks. By 
week 12, female systolic blood pressure has reached a peak of around 150mmHg (Ibrahim 
et  al,  2005).  Chronic  hypertension  is  associated  with  growth  and  remodelling  of  the 
cerebral vasculature, where the lumen diameter of vessels is reduced and the vascular wall 
is thickened in response to increased pressure. This results in an increased wall to lumen 
ratio and increased vascular resistance. Thickening of the vascular wall is an adaptation to 
the increased intraluminal pressure and serves to counteract the increased wall tension and 
protect the vessel against high pressure changes (Izzard et al, 2003). The autoregulation 
curve is shifted to the right as the resistance vessels act to regulate diameter at a higher 
pressure  range  and  the  vasodilatory  response  to  lower  pressures  is  impaired  as  a 
consequence of reduced  lumen diameter (Izzard et al, 2003). This  means that cerebral 
blood flow will be compromised at blood pressure values which are capable of maintaining 
cerebral blood flow (CBF) in normotensive rats. 
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1.2.6  Spontaneous Stroke 
 
Okamoto and colleagues (1974) reported a high incidence of spontaneous stroke in both 
sexes of adult SHRSP, although the likelihood of stroke in males was markedly greater 
than that observed in females, where incidence of spontaneous stroke was 80% in males 
aged over 100 days and 60% in females over 150 days old.   
 
Common  symptoms  of  spontaneous  stroke  in  the  SHRSP  include  hyperirritability, 
aggression,  and  motion  disturbances,  comprising  of  episodes  of  repetitive  paw  lifting, 
ataxia and paralysis (Okamoto et al, 1974). Following the appearance of these symptoms, 
the rats typically survived from a couple of days to 24 weeks. Just prior to death, many  
animals displayed additional symptoms of apathy and urinary incontinence and a small 
group of animals also demonstrated self-biting behaviours. 
 
Examination  of  brains  following  death  revealed  cerebral  lesions  resulting  from  fresh 
intracerebral  haemorrhage  or  infarction.  In  some  cases,  infarcts  were  accompanied  by 
evidence of previous haemorrhage (Okamoto et al, 1974). Most lesions were located in the 
cortex or subcortical region of the left occipital area but around 15% of animals which had 
experienced spontaneous stroke demonstrated lesions in the basal ganglia. Occasionally, 
lesions were observed in the frontal cortex. Okamoto et al (1974) recognised that cerebral 
lesions correspond to the boundary areas between the three major cerebral arteries and that 
anastomoses  between  these  vessels  were  scarcely  observed.  This  suggests  a  vascular 
abnormality in this strain of rat and it has been widely reported that spontaneous stroke in 
the SHRSP occurs as a result of pathological changes in small perforating arteries, leading 
to fibrinoid necrosis and brain oedema. This mirrors the clinical situation of malignant 
hypertension in humans (Ogata et al, 1980). In addition, the onset of spontaneous stroke 
can be accelerated by feeding the animals a salt-loaded diet or by administration of 1% 
sodium chloride in their drinking water (Okamoto et al, 1974). 
 
Furthermore, the incidence of stroke is highly correlated with a rapid increase in blood 
pressure and also with the severity of hypertension. This may give some explanation why 
the incidence of stroke in higher in male SHRSP than females, as hypertension progresses 
more quickly in males and increases to a greater level, as previously discussed. This means 
that  females  may  die  of  another  condition,  like  pneumonia,  before  spontaneous  stroke 
occurs (Okamoto et al, 1974), since this strain is particularly susceptible to respiratory   30 
infections, as a result of an impaired immune system and may die before there is evidence 
of hypertensive vascular changes (Ogata et al, 1982). 
 
1.2.7 Increased Sensitivity to Experimental Stroke 
 
It  is  well  established  that  SHRSP  are  more  sensitive  to  experimental  stroke  than  the 
normotensive control strain, WKY (Coyle & Jokelainen, 1983; Carswell et al, 1999; Marks 
et al, 2001). Following permanent middle cerebral artery occlusion  via electrocoagulation 
of the distal portion of the artery, infarct volume was significantly greater in the ipsilateral 
hemisphere  of  the  SHRSP  compared  to  that  observed  in  the  WKY  (36.6%  of  the 
hemisphere vs. 14.0% respectively – see Figure 1-10), as reported by Carswell et al (1999). 
Similarly, Marks and colleagues also reported significant differences in infarct volume  
following  permanent  distal  MCAO,  between  the  two  strains.  Twenty  four  hours  post 
occlusion, infarct volume in the SHRSP was recorded as 135mm
3. In comparison, infarct 
volume in the ipsilateral hemisphere of the WKY was measured as 102mm
3 (Marks et al, 
2001).  However,  a  more  accurate  representation  of  infarct  volume  is  given  by  the 
percentage of the hemisphere, rather than actual volume, since there are differences  in 
overall brain volume between the two strains and this method does not take brain oedema 
into account and therefore may overestimate infarct size. 
 
There are many factors which may account for the increased sensitivity to stroke exhibited 
by the SHRSP. It has been demonstrated that the stroke-prone strain display  increased 
release  of  glutamate  during  cerebral  ischaemia,  compared  to  normotensive  WKY  and 
stroke-resistant SHR (Gemba et al, 1992). This may contribute to increased excitotoxicity 
and neuronal damage contributing to the increased infarct volume observed in SHRSP. 
There are many additional anatomical and physiological factors which may contribute to 
the  increased  sensitivity  to  experimental  stroke  in  this  strain  and  these  shall  now  be 
discussed. 
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Figure 1-10. The topography of the infarct observed in WKY and SHRSP across 8 coronal 
levels following distal middle cerebral artery occlusion. The shaded bar (scale 0 to 4) indicates 
the infarct areas observed, where 4 represents areas which were infarcted in 100% of animals; 3- 
areas infarcted in 75% of animals; 2- areas infarcted in 50% of animals and 1- areas infarcted in 
25% of animals. Note the greater infarct density in SHRSP compared to WKY. Reproduced from 
Marks et al (2001). 
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1.2.8  Anatomical and Physiological Characteristics of SHRSP 
 
Vascular Abnormalities 
 
Many  studies  have  reported  impaired  collateral  flow  and  other  anatomical  vascular 
abnormalities  in  the  SHRSP.  Coyle  and  Jokelainen  (1983)  observed  that the  collateral 
circulation of the SHRSP was inadequate compared to that of the WKY and proposed that  
this may contribute to the increased infarct size following experimental stroke. A later 
study examined collateral flow a month after MCA occlusion and reported that the number 
of collateral vessels to the territory of the middle cerebral artery was the same in both the 
SHRSP and the normotensive WKY strain. However, the internal diameter of anastomoses 
was reduced  in the SHRSP, 33μm compared to 50μm  in the  WKY (Coyle & Heistad, 
1987). These authors also reported that some collateral vessels had an internal diameter 
which  was  often  less  than  half  the  diameter  of  the  upstream  arteriole,  creating  a 
“bottleneck effect” leading to increased resistance to flow. The reverse was observed in 
WKY rats, where the collateral vessels were larger in diameter than the cortical penetrating 
arterioles (Figure 1-11). In addition, large diameter branches of the anterior and middle  
cerebral arteries were significantly smaller in aged SHRSP (40-69 weeks old) compared to 
age matched WKY. However, there was no difference between the strains in the young 
animal  groups  (5-10  weeks  old).  This  illustrates  the  vascular  effects  of  progressive 
hypertension in the aged SHRSP. Since the internal diameter of ACA-MCA anastomoses  
was smaller in SHRSP in both age groups, this study suggests that the vascular resistance 
in fully relaxed collaterals is greater in the SHRSP, which compromises dorsal collateral 
flow even before the onset of hypertension (Coyle, 1987). This may partly explain why 
SHRSP  demonstrate  larger  infarcts,  compared  to  WKY,  even  before  hypertension 
develops. 
 
Vascular function also appears to be impaired in the SHRSP strain. Volpe and colleagues 
(1996)  demonstrated  that  in  the  thoracic  aorta  and  the  basilar  artery  of  the  SHRSP, 
endothelium-dependent vasodilatation was strikingly reduced compared to the vessels of 
the SHR. This is particularly interesting since the SHRSP and SHR strains show similar 
development of hypertension and therefore this observation must be independent of blood 
pressure. This may contribute to the reduced regional cerebral blood flow and increased 
infarct size observed in the SHRSP following experimental stroke, relative to that of the 
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Figure 1-11. End-to-end anastomosing branches of the anterior and middle cerebral artery in 
young WKY and SHRSP. (A) In 8 week old WKY, the anastomoses are larger in internal diameter 
than cortical penetrating branches (green arrows) (B) in 5 week old SHRSP, the anastomoses 
(denoted by  yellow arrows) are often less than 50% of the internal diameter of the supply vessels 
and the collaterals are smaller in diameter than cortical penetrating arterioles. Adapted from Coyle 
(1987). 
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SHR (Volpe et al, 1996). Therefore, impaired endothelium dependent vasodilation may 
account for part of the increased stroke sensitivity demonstrated by the stroke-prone strain.  
With  greater  relevance  to  experimental  stroke,  Izzard  et  al  (2003)  examined  the 
vasoreactivity of the middle cerebral arteries of both hypertensive strains and discovered 
that the ability to autoregulate was reduced in the vessels of the SHRSP. Furthermore, they 
reported that the diameter of these arteries progressively increased as a linear function with 
increasing  hypertension,  presumably  as  a  result  of  increased  growth  in  response  to 
increased  wall  stress.  Therefore  the  impaired  autoregulatory  ability  of  SHRSP  vessels 
compared to that of SHR may play a role in the increased stroke susceptibility observed in 
the stroke-prone strain (Izzard et al, 2003). 
 
Dysfunction of the Blood-Brain Barrier 
 
Dysfunction of the BBB has also been reported in SHRSP. The BBB is characterized by 
the presence of tight-junctions between endothelial cells and decreased levels of vesicular 
transport, which serves to limit passage of materials between the cerebral circulation and 
the brain parenchyma (Yamagata et al, 1997).  There are many reports of an increased 
permeability of the BBB in SHRSP, although the underlying mechanisms involved are not 
clear. The functions of the BBB are supported by astrocytes and it has been demonstrated 
by Yamagata and colleagues (1997) that in vitro, the astrocytes of SHRSP show a reduced 
ability to support the BBB, compared to WKY astrocytes.  
There  is  also  evidence  of  differences  in  the  structure of  tight  junctions  of  SHRSP,  in 
addition to an alteration in the polarity of endothelial cells of the BBB prior to stroke onset.  
This may predispose the SHRSP to stroke-induced BBB breakdown rather than contribute 
to stroke onset per se (Lippoldt et al, 2000).   
Although there are reports of structural differences and increased BBB permeability in the 
SHRSP, the contribution to stroke pathogenesis is not yet clear, however BBB dysfunction 
is likely to enhance cerebral oedema formation following stroke.  
 
Oxidative Stress 
 
Increased levels of oxidative stress are also thought to contribute to increased sensitivity to 
experimental stroke in SHRSP. In both SHR and SHRSP, production levels of superoxide 
anions  have  been  shown  to  be  higher  than  that  observed  in  normotensive  rats  in  the 
vasculature  and  the  brain  (Suzuki  et  al,  1995;  Kerr  et  al,  1999;  Kishi  et  al,  2004) 
Furthermore,  reactive  oxygen  species  (ROS),  such  as  superoxide  anions  and  hydroxyl   35 
radicals have been implicated in the pathogenesis of hypertension (Kerr et al, 1999). In 
addition,  superoxide  dismutase  (SOD)  activity  is  reduced  in  SHRSP  in  comparison  to 
WKY (Kishi et al, 2004). This enzyme is an endogenous antioxidant and catalyzes the 
formation of oxygen and hydrogen peroxide from superoxide anions. Therefore, reduced 
SOD activity will result in increased superoxide levels, contributing to increased oxidative 
stress. 
 
Increased superoxide levels may result in increased damage following stroke by disrupting 
the blood-brain  barrier,  leading to brain oedema and also by  lipid peroxidation of cell 
membranes,  increasing  cellular  damage.  Kim-Mitsuyama  and  colleagues  (2005) 
demonstrated that superoxide production in the cortex and hippocampus was increased in 
SHRSP. Furthermore, they identified that NADPH oxidase was the source of the increase 
in  superoxide  anions,  since  inhibition  of  NADPH  oxidase  significantly  reduced  the 
elevation in superoxide levels.  
 
It has also been reported that levels of the eicosanoid 20-hydroxyeicosatetraenoic acid (20-
HETE)  are  twice  as  high  in  SHRSP  as  that  observed  in  WKY.  20-HETE  is  a  potent 
vasoconstrictor and has been reported to contribute to the enhanced stroke sensitivity of 
SHRSP.  It mediates endothelial dysfunction and increased oxidative stress by stimulating 
superoxide  production  via  interactions  with  NADPH  oxidase  and  uncoupling  of  NOS 
(Cheng  et  al,  2008).  Inhibition  of  20-HETE  with  N-hydroxy-N‟  –(4-butyl-2-
methylphenyl)-formamidine (HET0016) significantly reduced  infarct volume  in SHRSP 
following transient MCA occlusion but had no effect on the WKY infarct size (Dunn et al, 
2008).  
 
Heightened Inflammatory Response 
 
In  addition  to  increased  levels  of  oxidative  stress,  it  has  been  reported  that  SHRSP 
demonstrate an increased inflammatory response to focal cerebral ischaemia compared to 
the  reference  strain  WKY.  Following  permanent  MCA  occlusion,  SHRSP  showed 
significantly greater numbers of activated  microglia. In the  ischaemic core region, 183 
activated microglia were identified per mm
2, compared to 156/mm
2 in WKY rats (Marks et 
al,  2001).  It  has  been  proposed  that  the  increased  level  of  microglial  activation  may 
contribute to the increased infarct volume observed in SHRSP, since activated microglia 
release neurotoxins including oxygen radicals, nitric oxide and glutamate, leading to lipid 
peroxidation, oedema and necrosis. Rather interestingly, this team of investigators also    36 
 
 
 
 
 
 
 
 
 
 
 
Figure  1-12.  Reduced  functional  recovery  in  the  SHRSP  2  days  following  experimental 
stroke. Note the asymmetrical placement of the forepaw and the hindpaw location for the SHRSP 
(red arrows). Adapted from Coyle & Jokelainen (1983). 
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observed that levels of resting and activated microglia in control SHRSP were increased 
relative to control WKY rats. This may account for the increased inflammatory response in 
the stroke-prone strain. 
 
1.2.9  Reduced Functional Recovery in SHRSP 
 
SHRSP  display  a  poorer  functional  recovery  following  experimental  stroke  when 
compared to their  normotensive control, the WKY (Figure 1-12), even when the  focal 
ischaemic insult has been manipulated to produce comparable infarct volumes (McGill et 
al,  2005).  Despite  similar  neurological  deficits  in  both  strains  2  hours  post  occlusion, 
SHRSP rats scored significantly lower on the 33 point neurological test at days 3, 7 and 28 
post  surgery.  Long-term  impairment  of  contralateral  limb  use  in  the  SHRSP  was  also 
accompanied  by  a  decline  in  general  health,  with  a  reduction  in  body  weight  and 
dishevelled coat appearance. A similar study examined functional deficits in SHRSP in 
comparison to SHR following permanent MCAO (Maguire et al, 2004). This team reported 
prolonged  behavioural  deficits  in  SHRSP  despite  almost  identical  infarct  size  to  that 
observed  in  SHR.  This  suggests  that there  is  a  genetic  basis  for the  reduced  recovery 
shown by the stroke-prone strain, since the degree of brain damage was comparable in both 
strains. The authors of both behavioural studies have suggested that this phenomenon may 
be indicative of impaired brain plasticity but the possible mechanisms involved have yet to 
be examined. 
 
1.3  Imaging the Ischaemic Penumbra 
 
1.3.1  Ischaemic Core and Penumbra 
 
The observed haemodynamic, metabolic and ionic changes observed following stroke do 
not  occur  in  a  homogenous  manner  across  the  ischaemic  territory.  In  the  severely 
hypoperfused  core,  cells  are  irreversibly  damaged  as  permanent  anoxic  depolarization 
begins to develop within minutes of the onset of ischaemia. Cell damage occurs as a result 
of  ionic  homeostatic  breakdown,  and  activation  of  multiple  cellular  pathways  which 
converge  to  initiate  the  irreversible  degradation  of  cellular  components,  as  previously 
described in this chapter.  
 
The  concept  of  the  ischaemic  penumbra  arose  from  a  series  of  seminal  experiments 
performed in the 1970s which measured the effects of progressive reductions in cerebral   38 
blood flow on the baboon cortex (Branston et al, 1974; Branston et al, 1977; Astrup et al, 
1977).  These studies examined cortical-evoked responses to determine the reduction in 
CBF required to abolish electrical activity and established the principle that there are two 
ischaemic thresholds which exist in the pathogenesis for cerebral infarction; one threshold 
for  morphological damage and a  less severe threshold  for functional  impairment.  The 
concept  of  two  separate  blood  flow  thresholds  for  the  disruption  of  functional  and 
structural  integrity  was  refined  by  Symon  and  colleagues  (1977).  This  team  of 
investigators  used  a  primate  model  to  identify  that  cerebral  blood  flow  below 
12ml/100g/min rendered neurons non-functional. In brain areas where cerebral flow was 
above 20ml/100g/min, neurons were fully functional and evoked somatosensory responses. 
At a flow rate of 15ml/100g/min the evoked somatosensory response sharply declined and 
therefore marks the threshold for disruption of function (Symon et al, 1977). 
These experiments led to the definition of the ischaemic penumbra as a region of brain 
tissue  which  is  functionally  impaired  but  structurally  intact  surrounding  a  severely 
hypoperfused central core where both functional and structural damage is evident (Astrup 
et al, 1981, Figure 1-13). Over the past 30 years, the definition of the ischaemic penumbra 
has evolved as a result of advances in neuroimaging and in light of both clinical and pre-
clinical studies which have examined the characteristics and lifespan of the penumbra. A 
revised definition of the penumbra defines it as  
“ischaemic tissue which is functionally impaired and is at risk of infarction and has the 
potential to be salvaged by reperfusion and/or other strategies. If it is not salvaged this  
tissue is progressively recruited into the infarct core which will expand with time into the 
maximal volume originally at risk” (Donnan et al, 2007). 
 
Furthermore,  a  set of  criteria  have  been  established  to  define  the  ischaemic  penumbra 
(Donnan et al, 2007):  
 
(1) The penumbra is a region of hypoperfused, abnormal tissue with physiological and 
biochemical  characteristics  consistent  with  cellular  dysfunction  but  not  cellular 
death. 
(2) The tissue is located within the same ischaemic territory as the infarct core. 
(3) The tissue can either survive or progress to necrosis. 
(4) Salvage of the tissue is associated with better clinical outcome. 
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Figure 1-13. The Ischaemic Core and Penumbra.  Following occusion of a cerebral vessel, most 
commonly the middle cerebral artery, a core of severely hypoperfused injured tissue is found within 
the territory of the occluded vessel. Outwith the ischaemic core, there is a region of less severely 
hypoperfused  tissue  which  is  still  metabolically  active.  This  is  the  ischaemic  penumbra  and 
represents tissue which may be salvaged following stroke but has a finite lifespan and will proceed 
to infarction in the absence of reperfusion. Reproduced from Allan & Rothwell (2001). 
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Characteristics of the Ischaemic Penumbra 
 
Advances in neuroimaging have allowed the biochemical and metabolic characteristics of 
the ischaemic penumbra to be defined. Positron emission tomography (PET) has allowed 
measurement  of  regional  CBF  (rCBF),  cerebral  metabolic  rate  of  oxygen  (CMRO2), 
regional  cerebral  metabolic  rate  of  glucose  (rCMRglc)  and  oxygen  extraction  fraction 
(OEF).  In  humans,  regional  CBF  below  12ml/100g/min  and  rCMRO2  below 
65µmol/100g/min corresponds to the infarct core (Ackerman et al, 1981). The penumbra 
has  been  defined  as  rCBF  decreased  to  12-22ml/100g/min  with  the  rCMRO2  above 
65µmol/100g/min.  This  relative  preservation  of  CMRO2  is  an  indicator  of  maintained 
neuronal  metabolism. Hypoperfused tissue where rCBF  is greater than 22mL/100g/min 
represents benign oligaemic tissue which will not proceed to infarction (as reviewed by del 
Zoppo et al, 2011). In addition, the penumbra displays an increased OEF compared to 
normal brain tissue in an attempt to compensate for the reduction in blood flow. In the 
penumbra  OEF  is  increased  to  50-90%  (Heiss,  2000)  compared  to  an  OEF  of 
approximately 40% in normal tissue (del Zoppo et al, 2011). 
 
In addition to biochemical and  metabolic alterations, the  ischaemic penumbra  has also 
been characterised at the molecular level. As regional CBF decreases to approximately 
30% to 50% of baseline CBF, a reduction in protein synthesis is observed. In the severely 
hypoperfused  infarct  core,  the  ability  to  synthesise  proteins  is  lost  relatively  early 
following ischaemia and is associated with ATP depletion. However, in the penumbra, 
ATP levels are maintained and protein synthesis is initially depressed but recovers over 
time  (Hossman,  1994).  It  has  been  suggested  that  the  loss  of  protein  synthesis  in  the 
ischaemic core is a protective function to prevent the formation of partially denatured or 
incorrectly processed proteins. It is not yet understood why protein synthesis resumes in 
penumbral tissue but this area is currently under study (del Zoppo et al, 2011). 
 
There is also compelling evidence that heat shock protein 70 (Hsp70) is upregulated in 
penumbral tissue. Under normal conditions, Hsp70 is expressed in brain cells at levels 
which  are  almost  undetectable.  However,  in  ischaemic  conditions,  Hsp70  is  massively 
induced and it can promote cell survival by refolding denatured proteins or alternatively, it 
can  allow  protein  degradation  and  progression  to  cell  death  (Hohfeld  et  al,  2001). 
Following MCA occlusion, Hsp70 mRNA has been shown to be expressed throughout the 
MCA territory. However, in the ischaemic core, Hsp70 mRNA is not translated into the 
Hsp70  protein  (Kinouchi  et  al,  1993).  Conversely,  in  the  ischaemic  penumbra  both   41 
transcription and translation of Hsp70 occur, allowing refolding of proteins to occur and 
promoting cell survival.  
 
The ischaemic penumbra is of great interest to both clinicians and stroke researchers as it 
represents  tissue  which  may  be  potentially  salvaged  following  stroke.  However,  the 
penumbra has a finite lifespan and as time passes without reperfusion, the penumbra can 
progress  to  become  part  of  the  ischaemic  core  as  a  result  of  ongoing  excitotoxicity, 
spreading depolarization, post ischaemic inflammation and apoptosis. This illustrates that 
the penumbra is not a fixed structure; it is highly dynamic and changes its boundaries over 
time. The existence of the penumbra is well established in rat models of focal cerebral 
ischaemia  but  in  human  stroke  patients  the  extent,  location  and  the  lifespan  of  the 
penumbra is highly variable. 
 
1.3.2  Multi-Modal Identification of the Penumbra 
 
Identification of potentially salvageable penumbra, a region of hypoperfused but viable 
tissue  which  is  at  risk  of  infarction,  is  of  the  utmost  importance  to  clinicians  and 
experimental  stroke  researchers.  Clinically,  the  presence  of  a  significant  volume  of 
penumbral tissue can be used to identify those patients who are most likely to benefit from 
thrombolytic therapy. Furthermore, penumbra imaging can be potentially utilised to group 
stroke patients together in clinical trials, where the extent and location of the penumbra is  
similar. This will allow potential therapeutic strategies to be assessed in comparable groups 
of patients. In experimental stroke, identification of the penumbra can allow the efficacy of 
neuroprotective  agents  to  be  assessed.  In  this  setting,  the  use  of  magnetic  resonance 
imaging (MRI) is favoured. Although, positron emission tomography (PET) is considered 
to be the „gold standard‟ imaging modality for penumbra imaging and is still used as a 
clinical  research  tool,  MRI  is  now  becoming  the  modality  of  choice  for  identifying 
potentially  salvageable  tissue  in  clinical  research.  In  addition,  the  use  of  computed 
tomography (CT perfusion) to identify the penumbra  is  being  increasingly used  in the 
clinical setting due to its cost effectiveness and availability (Heiss & Sorensen, 2009). 
 
1.3.3  Positron Emission Tomography 
 
PET is widely regarded as the „gold-standard‟ imaging modality for clinical identification 
of the ischaemic penumbra as it provides quantitative assessment of cerebral blood flow 
and oxygen metabolism. This technique involves intravenous administration of a positron   42 
emitting radioisotope bound to a ligand.  The radioactivity emitted is then reconstructed to 
produce a tomographic image. Multi-tracer PET, using the ligands H2 
15 O and 
15 O, has  
been used to quantitatively measure cerebral blood flow (CBF), cerebral metabolism of 
oxygen (CMRO2 ) and oxygen extraction fraction (OEF) (Ebinger et al, 2009, Figure 1-14). 
The penumbra can therefore be identified as a hypoperfused region, where oxygen 
metabolism  is  preserved  and  oxygen  extraction  is  increased,  to  compensate  for  the 
reduction in cerebral blood flow. This phenomenon was described as „misery-perfusion‟ by 
Baron  et  al  (1981).  Clinical  studies  have  defined  irreversibly  damaged  tissue  using 
thresholds  of  oxygen  metabolism  and  cerebral  blood  flow  of  65µmol/100g/min  and 
12ml/100g/min respectively and defined penumbra as tissue where regional CBF decreased 
to 12-22ml/100g/min, with a CMRO2 above 65µmol/100g/min and OEF increased to 50-
90% (Heiss, 2000).  
 
Modern PET tracers like 
18 F-fluromisonidazole (FMISO) and 
11 C-flumazenil (FMZ) can 
also  be  used  to  identify  potentially  salvageable  tissue  post-stroke.  FMZ  is  a  central 
benzodiazepine receptor ligand, a marker of neuronal integrity and has been used to detect 
neuronal damage within the first few hours of the onset of cerebral ischaemia. FMISO is a 
tracer  of  hypoxic  viable  tissue  and  can  therefore  be  used  to  identify  the  ischaemic 
penumbra in the acute phase of stroke, where increased areas of tracer uptake are detected 
(Heiss, 2003).  
 
In experimental stroke, serial multi-tracer PET studies in the baboon (Touzani et al, 1995) 
and the cat (Heiss et al, 1994) have demonstrated the spatial and temporal evolution of the 
ischaemic penumbra following occlusion of the middle cerebral artery. Both studies have 
demonstrated the progressive incorporation of the penumbra into infarct core and that this 
process is complete at 24 hours or later post-MCAO. This aids to reinforce the dynamic 
nature of the penumbra and that the life-span of this tissue is finite. 
 
Despite the ability of PET to provide quantitative measurements of cerebral blood flow and 
oxygen metabolism, there are a variety of factors which limit its use, both clinically and 
experimentally. Primarily, the availability of PET has been hampered by its expense and 
the fact that it requires experienced chemists to synthesise short half-life radioisotopes, in 
addition to physicists and radiographers who run the scans. Furthermore, it is limited in the 
clinical setting due to the necessity to cannulate arteries  for arterial  blood sampling to 
allow quantitative measurements of cerebral blood flow. This invasive procedure and the 
need for exposure to radioisotopes therefore limits the clinical use of this imaging    43 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-14. Identification of the ischaemic penumbra using positron emission tomography. 
18  F-fluromisonidazole  (FMISO)  PET  scan  was  performed  7  hours  after  stroke  onset,  where  a 
significant volume of penumbral tissue surrounds the infarct core. The yellow outline denotes the 
final infarct as defined by CT 7 days post stroke onset, indicating penumbral tissue which has been 
incorporated into the infarct. Adapted from Ebinger et al (2009). 
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modality.  The cost of PET is also a major limiting factor in experimental stroke research 
in addition to the poor resolution in small rodent brains and as a consequence, MRI is more 
widely utilised to image the penumbra in this setting.  
 
1.3.4  Perfusion Computed Tomography 
 
Computed tomography (CT) is one of the most readily available imaging modalities and is 
becoming increasingly utilised in the clinical identification of the penumbra in acute stroke 
patients. Perfusion CT in particular can help to predict the fate of ischaemic tissue (Ebinger 
et al, 2009). This technique  involves the  intravenous  injection of an  iodinated contrast 
agent and the bolus is tracked through the cerebral circulation. Parametric maps of cerebral 
blood volume (CBV), cerebral blood flow (CBF) and mean transit time (MTT) can be 
generated and quantified using post-processing software (Figure 1-15). However, there can 
be qualitative differences in the software used and currently there is a lack of agreement 
with regards to quantification of the perfusion CT parameters (Ebinger et al, 2009). 
In  the  ischaemic  penumbra,  tissue  perfusion  is  reduced  leading  to  vasodilatation  and 
recruitment of collaterals in an attempt to restore cerebral blood flow. This results in an 
increased cerebral blood volume in the penumbra, compared to the infarct core, where 
severe  hypoperfusion  induces  loss of the ability to autoregulate and as a  consequence, 
cerebral  blood  volume  falls.  Following  a  systematic  evaluation  of  130  acute  stroke 
patients, Wintermark et al (2006) reported that the infarct core is most accurately described 
by absolute CBV, with an optimal threshold of ≤2ml/100g. The parameter which optimally 
defines the penumbra is the relative MTT, where the threshold for this parameter is ≥145% 
of the contralateral tissue MTT (Wintermark et al, 2006).  
 
Earlier clinical perfusion CT studies used absolute CBF thresholds or combined CBF and 
CBV  thresholds  to  identify  the  ischaemic  penumbra.  However,  as  discussed  by 
Wintermark et al (2006), these were small pilot studies, each with less than 23 acute stroke 
patients.  Furthermore,  these  studies  defined  the  penumbra  using  parameters  where  the 
thresholds were arbitrarily selected. 
 
In  addition,  the  ability  of  this  technique  to  define  the  ischaemic  penumbra  has  been 
assessed against MR measurements of perfusion-diffusion mismatch, with a significant 
correlation (r
2 =0.81, P<0.001) between the two imaging modalities (Schaefer et al, 2008). 
Despite these results, perfusion CT has yet to be sufficiently validated for the identification 
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Figure 1-15. Identification of the penumbra by perfusion CT. The patient was imaged with 
multimodal  CT  at  3.5  hours  after  stroke  onset  with  National  Institute  of  Health  Stroke  Scale 
(NIHSS) of 14. Vessel occlusion was demonstrated by CT angiography (CTA, bottom left). A small 
area of reduced cerebral blood volume (CBV) was apparent in the lentiform nucleus and deep 
white matter but surrounded by much larger areas of reduced cerebral blood flow (CBF)/prolonged 
mean transit time (MTT) consistent with the ischaemic penumbra. Minimal change was detected by 
non-contrast CT (NCCT). The patient was treated with intravenous thrombolysis and had major 
early improvement of neurological symptoms. Magnetic resonance angiography (MRA) indicated 
complete recanalization (lower right) and only a small volume of tissue infarction on the follow-up 
diffusion weighted images (DWI). Reproduced from Ebinger et al (2009). 
 
 
 
 
   46 
of the ischaemic penumbra and standardisation of the perfusion CT definitions for core and 
penumbral tissue  has  not yet been performed. However, when this technique  has  been 
extensively validated it is likely to become one of the most widely used imaging modalities 
to approximate the ischaemic penumbra and identify those acute stroke patients who are 
most likely to benefit from tissue salvage therapies. At present, some stroke centres are 
using  a  multi-modal  CT  approach  to  identify  patients  who  are  potentially  eligible  for 
thrombolytic therapy, using perfusion CT in combination with CT angiography and non-
contrast  CT,  which  detects  isolated  focal  swelling  associated  with  tissue  at  risk  of 
infarction (Wintermark et al, 2006). 
 
1.3.5  Magnetic Resonance Imaging 
 
Nuclear magnetic resonance analysis is used to determine the presence and concentration 
of certain atomic nuclei within a sample. In MRI, hydrogen atoms are the nuclei of choice 
in medical imaging since they are the most abundant nuclei in the body. Each hydrogen 
nucleus consists of a single positively charged proton. The proton behaves like a small 
magnet since it continually spins and has an electrical charge. This also means that protons 
can be influenced by external magnetic fields. Under normal conditions, these protons spin 
with their axes pointing in random directions. However, in the presence of an external 
magnetic  field,  a  proportion  of  hydrogen  nuclei  will  align  in  parallel  to  the  external 
magnetic field. In order to record the magnetic resonance signal, protons are excited from a 
low to a high energy state, by exposure to electromagnetic radiation of radio frequency 
(RF). Excitation of protons causes them to spin with their axes pointing in the opposite 
direction. This alters their magnetic effect and the resulting deflection in the angle of the 
magnetization vector can be recorded. In MRI, the magnetization vector is deflected by 90
o 
or 180
o by exposure to precise radio frequencies, called the 90
o RF pulse and 180
o RF 
pulse, respectively. 
 
Following excitation of protons and subsequent deflection of the magnetization vector, the 
time taken for the magnetic resonance (MR) signal to fade is measured, as the protons 
return to a low energy state and magnetic equilibrium is regained. This parameter is termed 
the  relaxation  time.  The  return  to  equilibrium  results  from  two  independent  processes 
called  spin-lattice  interaction  and  spin-spin  interaction.  Spin-lattice  relaxation,  or  T1 
relaxation as it is otherwise known, involves the dissipation of energy from the excited 
nuclei to their surroundings in order to return to steady state. This time constant, T1, is 
dependent on the strength of the external magnetic field, where the greater the magnetic   47 
field strength, the longer it takes for excited nuclei to return to steady state. Spin-spin 
interaction results in transverse relaxation. This process involves the interaction of adjacent 
nuclear spins. The MR signal fades as the magnetic fields of adjacent nuclei interfere with 
each  other.  The  time  constant  for  transverse  relaxation  is  known  as  T2.  Unlike  T1 
relaxation,  T2  relaxation  time  is  independent  of  magnetic  field  strength.  Furthermore, 
despite T1 and T2 relaxation being completely independent processes, they occur almost 
simultaneously. 
 
The  MR  image  is  constructed  from  the  MR  signal  and  there  are  three  factors  which 
influence the contrast of the image by determining how bright the image appears. Firstly, 
the proton density of the biological tissue determines the maximum signal which can be 
obtained. MR images in which contrast is determined mainly by proton density are called 
proton density-weighted images. The T1 relaxation time of the tissue also has an affect on 
image contrast and those images where contrast is determined mainly by T1 are called T1-
weighted images. Similarly, T2-weighted images are produced when T2 relaxation time is 
used to determine image contrast. 
 
Magnetic resonance imaging techniques have also allowed the penumbra to be identified, 
by  the  use  of  diffusion  and  perfusion  weighted  imaging.  The  logistics  of  magnetic 
resonance imaging are less complex than PET and are therefore more widely available in 
both the clinic and the laboratory. 
 
Diffusion Weighted Imaging (DWI) 
 
The production of diffusion-weighted images display signal changes which are dependent 
on the diffusion of water protons in biological tissues. The diffusion of water protons is 
quantified by the diffusion constant, which varies with the direction of movement. In an 
isotropic  medium,  water  molecules  move  randomly  in  all  directions,  according  to 
Brownian motion. However, in biological tissues, diffusion may be impeded by natural 
barriers like cell membranes and protein structures, resulting in anisotropic diffusion. For 
example, in axons, protons will tend to travel along the axis of the fibre due to the barrier 
presented  by  the  myelin  sheath.  This  results  in  a  greater  diffusion  constant  along  the 
longitudinal axis of the axon, compared to that of the perpendicular axis, across the myelin 
sheath.  The  degree  of  signal  loss  on  the  diffusion-weighted  image  increases  with  the 
diffusion constant. Therefore tissue areas with restricted diffusion will have greater signal   48 
intensity than those tissues where diffusion is normal and signal loss is greater. DWI can 
therefore be used to obtain a quantitative measure relating to diffusion within a voxel.    
In biological tissues, the diffusion constants can be measured and are represented by the 
apparent diffusion coefficient (ADC), which can then be used to construct ADC maps. 
Tissue areas where diffusion is restricted will appear dark on an ADC map due to the 
reduced value of the diffusion constant. Compare this to the diffusion-weighted image, 
where the same area of tissue will appear bright due to increased signal intensity, resulting 
from reduced mobility of water protons. 
In acute stroke, diffusion of water molecules becomes restricted as a result of cytotoxic 
oedema following ischaemic injury (Moseley et al, 1990a). Diffusion of water molecules is 
reduced by the redistribution of water from the extracellular to the intracellular space and 
increased tortuosity or viscosity as failure of the Na
+/K
+ pump ensues (Abe et al, 2003). 
The  reduction  in  ADC  produces  a  hyperintense  signal  on  diffusion-weighted  images, 
identifying the bright region of ischaemic tissue damage within the first 6 hours of stroke 
onset  (Moseley  at  al,  1990a).  This  timescale  gives  DWI  a  great  advantage  over 
conventional MRI techniques. 
 
In animal models of stroke, DWI can be used to identify ischaemic damage within minutes 
of MCA occlusion (Moseley et al, 1990b; Hoehn-Berlage et al, 1995). Similarly, in human 
stroke patients, this imaging technique has been used to detect ischaemic lesions less than 
40min following stroke onset (Yoneda et al, 1999). If the stroke patient is untreated, the 
diffusion lesion will expand over time and follows a relatively consistent pattern of growth  
during the first 3 days after stroke onset and will then decrease in size up to day 7 (Baird et 
al, 1997; Beaulieu et al, 1999; Lansberg et al, 2001). This is reflected in the changes in 
ADC which occur following stroke. As the ischaemic lesion evolves over the first 24h 
post-stroke, the ADC will decrease further and the lesion will appear brighter on diffusion 
weighted images. In the subacute and chronic phases of stroke, the ADC will start to return 
to normal. However, since the tissue is infarcted and can never recover, this process is 
termed „pseudonormalization‟. Later in the chronic phase (>7 days  from  stroke onset), 
ADC will further increase (Warach et al, 1995). This allows acute and chronic stroke to be 
confidently distinguished using DWI. This is in contrast to T2 weighted imaging, where 
similar signal intensity is displayed by the infarct in both the subacute and chronic stages 
of stroke. 
 
However, areas of hyperintense signalling on DWI are not always associated with low 
ADC values, since T2 also has an effect on signal intensity and in some cases the effect of    49 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
Figure 1-16. MR images produced 3 hours following stroke onset in a 75 year old female 
patient. In the acute phase of stroke, there is no evidence of abnormal signal intensity in the T2-
weighted  image  (A).  However,  examination  of  the  diffusion  weighted  image  (B)  reveals  a 
hyperintense lesion in the left caudate body and corona radiata (red arrow). Adapted from Abe  
et al (2003). 
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an elongated T2 can result in hyperintense signalling, even when diffusion is normal or 
increased. This effect  is called T2 shine-through and can  be reduced  by  increasing the 
amount  of  diffusion-weighting.  Furthermore,  hyperintense  signalling  on  diffusion-
weighted images may also be attributable to a previous stroke or susceptibility artefacts 
(Baird  &  Warach,  1998).  Therefore,  DWI  should  always  be  examined  alongside  the 
appropriate T2 image and/or the calculated ADC map to assess the extent and severity of 
ischaemic injury and identify brain tissue which is likely to proceed to infarction (Figure 1-
16). 
 
Perfusion Imaging 
 
 
Brain blood flow can be evaluated by MR perfusion imaging techniques. These techniques 
can provide quantitative assessment of tissue perfusion regardless of whether the blood is 
delivered by the main artery supplying the brain territory, or by collaterals. This type of 
imaging is dependent on signal changes that are induced by an exogenous or endogenous 
tracer and there are two techniques which are commonly utilised in clinical and preclinical 
research: contrast agent bolus tracking and arterial spin labelling. 
 
Contrast Agent Bolus Tracking 
 
Contrast agent bolus tracking is the most commonly utilised perfusion imaging technique 
and it involves the intravenous introduction of gadolinium-based contrast agents into the 
circulation.  These  contrast  agents  are  paramagnetic  and  therefore  result  in  magnetic 
inhomogeneity  when  administered  into  the  bloodstream.  This  increases  magnetic 
susceptibility and reduces T2 relaxation time, resulting in decreased signal intensity as the 
agent passes through blood vessels. Homogeneity of the magnetic field is restored as the 
contrast  disappears  from  the  detection  plane  and  the  intensity  of  the  signal  returns  to 
normal. This allows the contrast agent to be tracked throughout the cerebral circulation. 
This type of imaging is commonly performed using T2
*-weighted 2D or 3D echo planar 
sequences, which allow fast image acquisition, where a new image can be produced every 
second (Weishaupt et al, 2006). 
 
A  time-intensity  curve  can  be  constructed  from  the  changes  in  signal  intensity  as  the 
contrast agent passes through the circulation. The amount of signal loss is proportional to 
the concentration of the contrast agent and in healthy brain tissue, is directly proportional 
to cerebral blood volume (CBV) (Belliveau et al, 1990). From the curve, the time to peak   51 
(TTP) is the time from the start of the scan to the point where signal intensity is maximal. 
The mean transit time (MTT) is the time taken for the contrast bolus to pass from the 
arterial cerebral circulation to the venous side. 
 
 In healthy humans, to calculate CBF and MTT, an estimate of arterial input function is 
required. Where the blood-brain barrier is disrupted, both cerebral blood volume and blood 
flow are represented by changes in signal intensity (Edelman et al, 1990) and the latter part 
of the time-intensity curve can be examined to estimate the permeability of the blood-brain 
barrier. However, in acute stroke patients, blood-brain barrier permeability is likely to be 
small, since disruption of the BBB does not predominantly occur until 24 hours following 
stroke onset (Baird & Warach, 1998). Following acute ischaemic stroke, this technique 
reveals well demarcated reductions in cerebral blood flow (Fisher et al, 1995). 
 
Arterial Spin Labelling 
 
Cerebral blood flow can also be assessed using perfusion imaging techniques which use 
blood  itself  as  a  tracer,  rather  than  gadolinium  based  contrast  agents,  as  previously 
described. This technique allows MR imaging of blood flow by spin labelling of water 
protons in an artery supplying the anatomical area of interest. It involves inversion of the 
longitudinal magnetization of the arterial blood and a decrease in signal is produced as the 
labelled blood reaches its target anatomy before relaxation of its magnetization. However, 
the decrease in signal is too small to be viewed directly and therefore in order to view the 
contrast, two image sets are used to highlight the contrast by image subtraction, where one 
image set shows inversion of inflowing water protons in the blood and the other does not 
(Weishaupt et al, 2006).  
 
Arterial spin labelling has been widely used in animal models to quantify the perfusion 
deficit following experimental stroke in rodent models (Shen et al, 2003; McCabe et al, 
2009; Foley et al, 2010) and is advantageous over other perfusion imaging techniques in 
that it is non-invasive, can be repeated to assess temporal changes in CBF and does not 
require administration of an exogenous tracer into the circulation. It also provides a more 
direct  assessment  of  cerebral  blood  flow  and  can  generate  absolute  blood  flow 
quantification (Baird & Warach, 1998). However, this technique is less widely used than 
contrast agent bolus tracking because it is relatively more difficult to perform (Duong & 
Fisher, 2007) 
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1.3.6 MRI Perfusion-Diffusion Mismatch 
 
The use of DWI and PWI in stroke neuroimaging led to the emergence of a new concept 
for defining the ischaemic penumbra using MRI. The perfusion-diffusion mismatch model 
was constructed to identify potentially salvageable penumbral tissue following stroke. The 
mismatch  model  arose  from  observations  that  diffusion  lesions  expand  over  time  to 
encompass the region of PWI defined perfusion deficit in the absence of early reperfusion 
(Baird et al, 1997). According to the model, the DWI lesion represents the ischaemic core, 
where severely hypoperfused brain tissue is experiencing bioenergetic failure and becomes 
irreversibly damaged. PWI reveals hypoperfused tissue and the mismatch between the PWI 
and  the  DWI  lesions  provides  an  approximation  of  the  ischaemic  penumbra,  which 
represents tissue which is hypoperfused but is not yet experiencing  bioenergetic failure 
(Schlaug et al, 1999, Figure 1-17). As time progresses, mismatch tissue will reduce as the 
diffusion lesion expands and penumbral tissue becomes incorporated into the ischaemic 
core. 
 
Clinical Use of Perfusion-Diffusion Mismatch 
 
The  perfusion-diffusion  mismatch  model  has  been  widely  used  in  clinical  research  to 
define the  ischaemic penumbra (Figure 1-18). Darby  and colleagues demonstrated that 
despite the presence and volume of mismatch decreasing over time, up to 70% of patients  
will display substantial regions of mismatch up to 24 hours following stroke onset (Darby 
et al, 1999).  
 
The mismatch model has been used in clinical trials to assess the efficacy of thrombolytic 
therapy. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS) was the first phase II  
clinical trial which employed the perfusion-diffusion mismatch model as a criterion for 
selecting patients suitable for thrombolytic therapy. All stroke patients recruited into the 
trial showed evidence of a perfusion-diffusion mismatch of ≥20% of perfusion deficit and 
those  patients  who  received  intravenous  desmoteplase  within  9  hours  of  stroke  onset 
demonstrated  a  higher  rate of  reperfusion  and  improved  clinical  outcome  compared  to 
placebo  treated  patients  (Hacke  et  al,  2005).  A  phase  III trial  was  then  undertaken  to 
confirm the findings of DIAS but unfortunately the results were negative (Hacke et al, 
2009). The DIAS-2 study reported no improvement in clinical outcome with administration 
of desmoteplase 3-9 hours following stroke onset. In this trial however, patients were  
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Figure 1-17. The Perfusion-Diffusion Mismatch Model.  The diffusion abnormality represents 
the irreversibly damaged ischaemic core and the perfusion abnormality represents hypoperfused 
tissue. The mismatch between the diffusion and perfusion abnormalities provides an approximation 
of the ischaemic penumbra. Reproduced from Kidwell et al (2003). 
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Figure  1-18.  Identification  of  the  penumbra  in  a  stroke  patient  by  magnetic  resonance 
imaging. The arrow denotes the acute diffusion weighted imaging (DWI) lesion (left image). The 
area  in  red  signifies  the  perfusion  deficit  (centre)  and  the  penumbra  as  defined  by  diffusion-
perfusion mismatch (right). Reproduced from Ebinger et al (2009). 
 
 
 
 
 
 
 
 
 
 
 
 
   55 
selected by the presence of penumbra as determined by perfusion-diffusion mismatch or by 
perfusion  CT  and  the  pooling  of  these  data  may  not  be  appropriate  since  the  authors 
reported inconsistencies between MRI and CT. 
 
The  DIAS  trial  was  followed  by  the  Diffusion  and  Perfusion  Imaging  Evaluation  for 
Understanding Stroke Evolution (DEFUSE) Study, which sought to validate the use of 
perfusion-diffusion mismatch to identify those patients who were likely to benefit from 
thrombolytic therapy administered 3-6 hours following stroke onset (Albers et al, 2006). 
Patients were categorised into „mismatch‟ and „no mismatch‟ groups, where the mismatch 
profile was defined as a PWI lesion which was greater than 10ml and at least 120% of the 
DWI lesion. In cases where the PWI lesion was less than 120% of the DWI lesion patients 
were assigned to the „no mismatch‟ group. Patients with the „no mismatch‟ profile did not 
appear to benefit from early reperfusion with rtPA. However, patients who were identified 
as  having  the  target  mismatch  profile  demonstrated  a  significantly  improved  clinical 
outcome  following  early  reperfusion.  This  study  indicates  that  the  perfusion-diffusion 
mismatch  model  is  a  useful  tool  for  identifying  potentially  salvageable  tissue  in  acute 
stroke.  
 
Similar observations were reported from the Echoplanar Imaging Thrombolytic Evaluation 
Trial (EPITHET), where patients who received thrombolytic therapy within 3-6 hours of 
stroke onset demonstrated reduced infarct growth and increased reperfusion when there 
was  evidence  of  mismatch  tissue.  Increased  reperfusion  was  also  associated  with  an 
improved functional outcome (Davis et al, 2008). However, this study differs from the 
earlier DEFUSE study as the presence of mismatch was not used for patient selection as 
the sample size was small and the authors were keen  to include patients who did not show 
evidence of mismatch tissue for the purpose of exploratory analysis.  
 
The DIAS, DEFUSE, and EPITHET trials have demonstrated that the perfusion-diffusion 
mismatch model can be successfully used to identify patients who are likely to benefit 
from thrombolytic therapy and demonstrate an improved clinical outcome following  
stroke. The mismatch model can be used to identify groups of stroke patients with similar 
lesion  size  and  location  to  improve  the  characterization  of  therapeutic  efficacy  (or 
inefficacy) in clinical trials (Baird & Warach, 1998). 
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Perfusion-Diffusion Mismatch in Experimental Stroke Models 
 
The perfusion-diffusion mismatch model has been used in animal stroke models to assess 
the temporal evolution of the ischaemic penumbra but the use of the mismatch model to 
assess  potential  neuroprotective  strategies  in  experimental  stroke  models  is  notably 
lacking. In animal models, the mismatch model could be used to evaluate the potential 
therapeutic window of interventions to salvage penumbra following stroke. 
 
Meng and colleagues (2004) defined the temporal evolution of the penumbra in Sprague-
Dawley rats following permanent or transient MCAO using perfusion-diffusion mismatch. 
These authors reported that following permanent MCAO, the diffusion lesion expands to 
encompass the larger perfusion deficit and as a consequence, the volume of penumbra, as 
defined  by  the  mismatch  model,  decreases  over  time.  By  2-3  hours  post-MCAO  the 
diffusion lesion has fully evolved and no penumbral tissue remains. This suggests that in 
Sprague-Dawley rats, there may be a narrow time window for penumbra salvage.  
 
In a transient stroke model, perfusion-diffusion mismatch was used to evaluate the effect of 
reperfusion following 60 minutes of ischaemia in Sprague-Dawley rats (Meng et al, 2004). 
The  authors  observed  that  the  diffusion  lesion  at  3  hours  post-MCAO  and  2,3,5-
triphenyltetrazolium  chloride  (TTC)  infarct  volume  at  24  hours  post-MCAO  were 
significantly  smaller  than  those  observed  following  permanent  MCAO,  indicating  that 
early reperfusion had successfully salvaged penumbral tissue. 
The  same  study  group  also  used  perfusion-diffusion  mismatch  to  assess  the  temporal 
evolution of ischaemic injury in Wistar rats following permanent MCAO (Bardutzky et al, 
2005a). It was reported that 90 minutes post-MCAO, Wistar rats demonstrated a mismatch 
volume which was significantly larger than that observed in Sprague-Dawley rats at the 
same  time  point.  Recently,  Foley  and  colleagues  (2010)  defined  quantitative  temporal 
profiles of penumbra  in Sprague-Dawley rats using dual  parameter voxel  analysis.  All 
voxels  which  had  normal  ADC  values  but  an  abnormal  CBF  value  were  defined  as 
penumbra. This  method revealed that penumbra persisted even after 4 hours  following 
MCAO, which conflicts with previous reports in the Sprague-Dawley strain (Shen et al, 
2003; Meng et al, 2004). 
 
The perfusion-diffusion mismatch model has also been used to assess penumbral tissue in 
rat models with genetic stroke risk factors. McCabe and colleagues reported that mismatch 
area was reduced in the spontaneously hypertensive stroke-prone rat (SHRSP) compared to   57 
the  normotensive  control,  Wistar-Kyoto  (WKY)  (McCabe  et  al,  2009).  Similarly, 
Letourneur  and  colleagues  reported  a  reduced  perfusion-diffusion  mismatch  in 
spontaneously hypertensive rats (SHR) compared to WKY rats following permanent focal 
ischaemia (Letourneur et al, 2011). These studies illustrate how the mismatch model can 
be used to assess differences in the temporal evolution of perfusion-diffusion mismatch 
between rat strains. 
 
The potential use of the mismatch model to assess neuroprotective strategies has not been 
widely investigated in experimental stroke. Bardutzky and colleagues (2005b) evaluated 
the neuroprotective effects of dimethylsulphoxide (DMSO) in a rodent permanent stroke 
model  and  reported  that  administration  of  33%  DMSO  at  60  minutes  post-MCAO 
preserved the mismatch region and therefore salvaged penumbra and prevented it from 
proceeding to infarction. The efficacy of normobaric hyperoxia has also been evaluated in 
rat stroke models using perfusion-diffusion mismatch as an outcome measure. Kim and 
colleagues (2005) reported that normobaric hyperoxia initiated at 30 minutes following 
permanent MCAO, reduced the growth of the diffusion lesion and therefore preserved the 
lifespan  of  the  penumbra.  However,  the  treatment  effect  was  only  observed  during 
treatment and the neuroprotective effect is lost when treatment stops.  
 
Preservation of the perfusion-diffusion mismatch has also been examined in rodent models 
with  genetic  risk  factors.  It  has  been  reported  that  Sprague-Dawley  rats  display  a 
significant  mismatch  which  is  maintained  until  150  minutes  post-MCAO  and 
administration  of  a  selective  endothelin  receptor  antagonist  successfully  reduced 
progression to infarction (Legos et al, 2008). However, the authors reported that there was 
little evidence of  mismatch  in SHR rats from  as early as 60  minutes post-MCAO and 
consequently, administration of endothelin receptor antagonist had no protective effect and 
did not reduce infarct volume. These studies illustrate how perfusion-diffusion mismatch 
can be used in animal models of stroke to evaluate potential neuroprotective strategies but 
at present, there is a notable lack of such investigations in the pre-clinical literature.  
 
1.3.7  Challenges to the Mismatch Model 
 
Despite  the  widespread  use  of  the  diffusion-perfusion  mismatch  model  in  both 
experimental and clinical stroke studies, its definition of the penumbra has been widely 
challenged by various study groups. The first challenge to the model is the inability of 
perfusion imaging to distinguish between the penumbra and tissue which is experiencing   58 
benign oligaemia. Although this region of tissue displays a perfusion deficit, it functions 
normally and is not at risk of infarction. Therefore perfusion weighted images are likely to 
overestimate the outer boundary of the penumbra. This problem has been addressed by 
several groups by studying the evolution of the diffusion and perfusion abnormalities in 
untreated patients. This allows identification of the penumbra, as tissue which proceeds to 
infarction and areas of benign oligaemia, which does not become part of the infarct. These 
studies allowed a range of ADC and perfusion thresholds to be identified, designed to 
differentiate between penumbra and benign oligaemia (Kidwell et al, 2003). 
 
In addition, the mismatch model has been challenged for the apparently clear distinction 
between  the  penumbra  and  ischaemic  core  tissue.  The  model  assumes  that  the  initial 
diffusion  abnormality  represents  tissue  which  is  irreversibly  damaged  and  cannot  be 
salvaged even if reperfused. However, animal models have shown that the diffusion lesion 
can be partially or fully reversed if reperfused within 3 hours (Kidwell et al, 2003). This 
has  also  been  demonstrated  to  occur  in  human  stroke  patients  following  intra-arterial 
thrombolytic therapy, although some tissue redevelops diffusion abnormalities as late  
secondary injury (Kidwell et al, 2002). These findings are significant as they demonstrate 
that patients who do not show evidence of diffusion-perfusion mismatch may still benefit 
from  thrombolytic  therapy.  These  findings  have  led  to  the  construction  of  a  modified 
perfusion-diffusion mismatch model (Figure 1-19). 
 
Furthermore, it has recently been reported that penumbra as defined by perfusion-diffusion 
mismatch does not reliably reflect the PET defined penumbra (Zaro-Weber et al, 2009). 
Areas  of  mismatch  were  compared  with  areas  of  increased  OEF.  All  of  the  13  stroke 
patients examined in the study demonstrated areas of mismatch but only 8 of those patients 
showed  evidence  of  penumbra  as  defined  by  OEF  elevation  using  PET.  However, the 
mismatch model could potentially be improved by refining the perfusion and diffusion 
thresholds  which  are  used  to  define  tissue  at  risk  of  infarction  by  distinguishing  the 
penumbra from the ischaemic core and benign oligaemic tissue. 
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Figure 1-19. The current concept of the ischaemic penumbra.   This model recognises that 
tissue within the diffusion abnormality is not necessarily irreversibly damaged and may recover with 
early reperfusion. It also recognises the perfusion abnormality may include benign oligaemic tissue 
which is not at risk of infarction. The arrow shows penumbral tissue which is at risk of infarction but 
is  potentially  salvageable  with  adequate  reperfusion.  In  this  model  the  penumbra  includes  a 
component of the diffusion abnormality in addition to the perfusion abnormality, with the exclusion 
of benign oligaemic tissue. Reproduced from Davis & Donnan (2004). 
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1.4  Aims of the Thesis 
 
The aims of the  first study were to define strain-specific  MRI perfusion  and diffusion 
thresholds  in  the  SHRSP  and  WKY  rat.  These  thresholds  would  then  be  applied  to 
quantitative  perfusion  and  diffusion  MRI  data  acquired  in  the  acute  phase  following 
experimental  stroke to  allow  the  temporal  evolution  of  ischaemic  injury  and  perfusion 
deficit to be assessed and compared between the strains. The acute MRI data would then be 
used to assess and compare three different methods of calculating penumbra volume to 
evaluate the strengths and limitations of each method. Each calculation method would be 
used to compare the extent and lifespan of the ischaemic penumbra following permanent 
MCAO in SHRSP and WKY rats.  
 
The aim of the second study was to evaluate the neuroprotective efficacy of the NADPH 
oxidase  inhibitor,  apocynin,  in  rodent  stroke  models.  First,  the  effects  of  apocynin 
treatment on stroke outcome following permanent MCAO would be assessed. Apocynin 
treatment would then be evaluated in a model of transient ischaemia. Finally, the effect of 
apocynin treatment on the acute evolution of the ischaemic penumbra would be assessed in 
a  rat  model  with  stroke  co-morbidities  (SHRSP)  using  the  MRI  perfusion-diffusion 
mismatch model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2. 
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2.1 Animal and Surgical Procedures 
 
2.1.1 Animal Preparation 
 
All animal procedures were performed under licence from the UK Home Office (Personal 
Licence number 60/11949, working under Project Licence numbers 60/3759 and 60/3618) 
and in accordance with the Animals (Scientific Procedures) Act, 1986. Prior to surgery, all 
animals were housed in groups with water and food freely available and were kept on a 12 
hour light/dark cycle. All surgical procedures were performed by Emma Reid. 
 
On the day of surgery, rats were weighed following transfer from the animal housing unit 
to the operating theatre. Anaesthesia was initially induced in an anaesthestic gas chamber, 
where  5%  isofluorane  (Baxter  Healthcare  Ltd,  UK)  was  administered  in  a  30%/70% 
mixture of oxygen and nitrous oxide, respectively. Depth of anaesthesia was assessed by 
means of the withdrawal reflex, where the footpad of the hindlimb is tightly squeezed to 
evoke a reflex withdrawal of the foot. If this reflex absent then the animal is deep enough 
to  proceed  with  surgery.  This  reflex  was  assessed  at  regular  intervals  during  surgical 
procedures to establish if the anaesthetic dose needed to be adjusted.  
 
Once deeply  anaesthetised the rat was removed  from the chamber  and was artificially 
ventilated  following  tracheal  intubation  or  tracheotomy.  In  experiments  where  animals 
were not allowed to recover following surgery, a surgical tracheotomy was performed. 
Following removal from the anaesthetic chamber, the rat was transferred to a face mask 
where the dose of isofluorane was reduced to between 2% and 3% in the same gas mixture 
stated previously, to maintain surgical anaesthesia. The animal was positioned on its back 
and hair was shaved from the neck using an electrical shaver (Wahl, UK). A tracheotomy 
was then performed to allow artificial ventilation of the animal and removal of the face 
mask.  An  incision  was  made  in  the  neck  using  large  scissors  and  the  underlying 
musculature was split by blunt dissection to expose the trachea. Two ligatures of 2-0 thread 
(Davis & Geck, UK) were loosely tied around the proximal and distal ends of the trachea, 
approximately 1-1.5cm apart. A small incision was then made in a ring of tracheal muscle 
equidistant between the ties using microscissors. The ventilation tube (Linton Instruments, 
UK) was then quickly inserted into the incision and advanced down the trachea towards the 
bronchi. Particular care was taken not to advance the tube more than 2cm distal to the 
incision site to prevent the tube from blocking off one of the bronchi. The ventilation tube 
was then connected to the ventilator (Ugo Basile, Linton Instuments, UK) where the stroke   63 
volume  was set to ~3ml at a  frequency of 45  strokes per  minute to  maintain surgical 
anaesthesia and was secured by tightening the ligatures and tying them around the tube. 
The neck of the rat was stitched using 4-0 silk suture (Covidien, UK). 
 
 In  experiments  where  the  animal  was  allowed  to  recover  following  surgery,  artificial 
ventilation was maintained by intubation, where the tube can be removed without trauma 
to the trachea. Following removal from the anaesthetic chamber, the rat was placed in an 
upright position against a cork board by hooking a loop of 2-0 thread, which was pinned to 
the top of the cork board, around the upper incisors to secure the position of the rat. The 
mouth was opened and the tongue was pulled to the side of the mouth using small forceps 
to allow the trachea to be observed. A fibre optic light (Meiji Techno) was shone onto the 
neck  to  gain  a  clear  view  of  the  vocal  cords  and  trachea  and  a  16  gauge  catheter 
(MillPledge  Veterinary,  UK)  was  then  swiftly  inserted.  The  intubation  tube  was  then 
connected to the ventilator and anaesthetic dose was adjusted until breathing was steady 
and in time with the ventilator, where the stroke volume was set to 2.5-3ml with a stroke 
frequency of 60 strokes per minute. The anaesthetic dose was maintained via this method 
and the intubation tube was secured by stitching it to the side of the mouth using 4-0 silk 
suture to prevent it being pulled out during transfer of the rat to the MRI scanner. 
 
In  all  experiments,  with  the  exception  of  the  permanent  stroke  model  in  Chapter  5, 
cannulation of the right femoral artery was performed to allow continual monitoring of 
blood pressure. The right hindlimb and groin were shaved and an incision was made using 
large scissors. Blunt dissection of the underlying musculature was performed to expose the 
right femoral artery. The artery was then isolated from the femoral vein by blunt dissection 
using small curved and straight-edged forceps. Two ligatures (4-0 silk suture) were loosely 
tied at the proximal and distal ends of the artery, approximately 2cm apart. The ligatures 
were pulled tightly by using sticky tape to secure the ends of the ties to the cork board and 
a small incision was made into the artery using microscissors, equidistant between the two 
ligatures. The artery was then cannulated using a length (25cm) of PE-50 tubing (Portex, 
UK) which was advanced approximately 2-3cm along the vessel. The cannula was secured 
in place by tying 4-0 silk suture around the tubing and the artery. The cannula was then 
connected to a transducer which was linked to a computer, where physiological parameters 
including  heart  rate  and  mean  arterial  blood  pressure  were  recorded  (Biopac, 
Acqknowledge).  Mean  arterial  blood  pressure  was  maintained  within  the  range  of  85-
95mmHg in normotensive rats and was maintained within the range of 105-115mmHg in 
hypertensive rats. Body temperature was monitored with a rectal themal probe (Physitemp,   64 
New Jersey, USA) and was maintained at 37±0.5
o C using an angle poise heat lamp. Care 
was taken to avoid burning the skin of the animal by placing a layer of gauze (Vernon-
Carus Ltd, UK) over the body.   
 
2.1.2 Focal Cerebral Ischaemia 
 
Permanent MCAO 
 
Occlusion of the middle cerebral artery was then performed according to the model first 
described by Koizumi et al (1986) with subsequent modifications (Longa et al, 1989). All 
surgery was performed under a light microscope (Zeiss, Germany). First, blunt dissection 
of  the  shaved  tissue  of  the  neck  revealed  the  tracheal  strap  musculature,  which  was 
retracted to expose the common  carotid artery.  The  surrounding connective tissue was 
dissected and the vessel was tied off using 4-0 silk thread. The external carotid artery was 
then  identified  and  securely  tied  at  an  intermediate  position  between  the  ascending 
pharyngeal  artery  and  the  lingual  and  maxillary  branches.  The  three  branches  of  the 
external carotid where then subjected to cauterisation using diathermy forceps (Eschmann 
Equipment, UK). The external carotid artery itself was then cauterised above the tie and 
the three branches of this vessel were cut when it had been established that the vessels had 
been sealed off to prevent any  bleeding.  At this point the occipital artery, which runs 
alongside the internal carotid, was identified, cauterised and cut in the same manner as 
described previously. Any excess connective tissue was removed from the internal carotid 
artery and the vessel was subsequently tied loosely with 4-0 thread. Following this, the 
pterygopalatine  artery  was  securely  tied  off  to  prevent  the  intraluminal  thread  from 
entering this vessel instead of following the course of the internal carotid artery (Figure 2-
1). 
 
In the stroke reproducibility study, described later in this chapter, the intraluminal thread 
was constructed from a length of 3-0 nylon monofilament (Covidien, UK) where a small 
diameter bulb was created using a cauterising pen (Aaron Medical, FL, USA). In all other 
experiments, a nylon filament with a silicon tip of length 5-6mm and of diameter 0.31-
0.35mm (Doccol Corporation, CA, USA) was used. The length of filament was then  
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Figure 2-1. A schematic diagram of the intraluminal thread model of middle cerebral artery 
occlusion. The external carotid artery is ligated and all branches are transected to allow the artery 
to be manipulated for ease of passage of the nylon monofilament. The pterygopalatine artery is 
ligated  and  the  monofilament  is  introduced  into  the  internal  carotid  artery  by  arteriotomy.  The 
filament  is  advanced  along  the  internal  carotid  until  it  lodges  in  the  narrow  proximal  anterior 
cerebral artery, where it blocks the origin of the middle cerebral artery. This method of middle 
cerebral  artery  occlusion  can  be  transient  or  permanent.  Image  reproduced  from  Hunter  et  al 
(1995). 
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measured and at the point of 22mm, a bend was introduced. This ensured that the filament 
would block the vessel at the proximal origin of the middle cerebral artery. 
 
The external carotid artery was then cut using microscissors resulting in an arterial stump 
which can be then be manipulated to aid the passage of the filament. The internal carotid 
tie  can  then  be  pulled  tightly  to  limit  blood  loss  as  a  small  incision  is  made  at  the 
bifurcation point of the common carotid artery. The filament was then carefully advanced 
along the internal carotid artery until some resistance is felt, which should correspond to 
the point where only the bend of the filament is visible outwith the vessel. The internal 
carotid tie was then be tightened to secure the filament firmly in place. Furthermore, in 
permanent occlusion models the entry point of the filament was sealed using the diathermy 
forceps to further secure its position. The tissue of the animal was then sutured using 4-0 
thread to prevent infection and dehydration. 
 
Transient MCAO 
 
In the transient MCAO  models, a  modified  version of the occlusion  method was used 
instead of the technique described in detail previously. Animal recovery following surgery 
may be impinged as a result of difficultly in eating and drinking, as transection of the 
external carotid artery renders the muscles of mastication and swallowing ischaemic. This 
may lead to weight loss and increased mortality following surgery. In the transient stroke 
experiments, animals were allowed to recover for 72 hours following stroke and it was 
decided that to aid eating and improve recovery, a modified filament model would be used. 
This model preserves the integrity of the external carotid artery and its branches. Two 4-0 
thread ligatures were tied round the common carotid artery, one tied loosely at the carotid 
bifurcation and the other tied tightly approximately 1mm  below the  bifurcation. Loose 
ligatures were also tied around the external carotid, internal carotid and the pterygopalatine 
artery. A small incision was made between the two ligatures on the common carotid artery 
to allow insertion of the filament. All ligatures were pulled tightly at this point to limit 
blood loss. Once the filament had been advanced to block the origin of the middle cerebral 
artery,  the  pterygopalatine  artery  tie  was  removed  and  the  other  ties  were  secured  to 
prevent blood loss and to secure the filament in place until it is removed after a fixed time 
period.  In  all  transient  MCAO  experiments  the  filament  was  removed  after  1  hour  of 
ischemia. This was achieved by releasing the ligature around the internal carotid artery and 
the ligature at the common carotid artery bifurcation was also loosened. This allowed the 
filament to be retracted and subsequently removed. The incision point was then cauterised   67 
using diathermy forceps and the external carotid ligature was removed, leaving only the 
common carotid tie in place. The wound was then flushed with sterile saline and stitched 
using 4-0 silk suture. 
 
2.1.3 Perfusion Fixation 
 
Animals were transcardially perfused with fixative to allow histological examination of the 
brain following stroke. Firstly, animals were deeply anaesthetised using 4-5% isofluorane 
delivered in a 30%/70% mixture of oxygen and nitrous oxide administered via a face mask 
to ensure the animal was deeply anaesthetised prior to opening up the chest cavity. An 
incision was made below the sternum and the skin overlying the chest was cut to expose 
the underlying musculature and the diaphragm, which were also incised. The ribcage was 
cut on both sides to allow the tissue of the chest to be retracted and clipped securely to 
expose the viscera of the chest cavity. The beating heart was then gently pulled down to 
allow detection of the aorta. A large needle which is connected to a flask of 0.9% saline 
containing heparin (10ml/Litre) and a flask containing 4% paraformaldehyde (PAM) was 
inserted into the left ventricle and advanced into the aorta. The heart was then clamped to 
secure the position of the needle and the right atrium was cut to allow blood to drain out of 
the heart. At this point, around 200-250 ml of heparinised saline was pumped through the 
circulation at a pressure of around 100mmHg to flush all of the blood out from the animal. 
Once the perfusate ran clear, indicating that all of the animal‟s blood had been flushed out, 
200ml of 4% PAM was then pumped through the circulatory system at the same pressure 
to  fix  the  animal.  Spontaneous  limb  movement  was  observed  as  the  fixative  travelled 
through the circulation, indicating successful fixation. 
 
2.2 Assessment of Final Infarct and Stroke Reproducibility 
 
2.2.1 Haematoxylin and Eosin Staining 
 
Following successful fixation, the animal was immediately decapitated and the entire head 
was stored in 4% PAM for 24 hours. The brain was then removed and post-fixed in 4% 
PAM  for  a  further  24  hours  before  being  embedded  in  paraffin  wax.  The  embedding 
procedure was carried out in a paraffin processor (Miles Scientific) which undergoes many 
cycles of tissue dehydration and clearance, using alcohols and xylene respectively, before 
the brain is embedded in paraffin wax (Table 2-1). The entire procedure takes a total of 59 
hours to complete. The embedded brain was then cut into 6 micron thick sections of the 8    68 
 
 
 
 
 
 
 
 
Stage  Process  Time Period (Hours) 
1  70% Alcohol  2 
2  80% Alcohol  3 
3  95% Alcohol  4 
4  Absolute Alcohol 1  4 
5  Absolute Alcohol 2  5 
6  Absolute Alcohol 3  5 
7  Absolute Alcohol 4  6 
8  50% Alcohol/50% Xylene  4 
9  Xylene 1  5 
10  Xylene 2  5 
11  Paraffin Wax 1  5 
12  Paraffin Wax 2  5 
13  Paraffin Wax 3  6 
 
 
Table 2-1. Paraffin wax processing schedule for rat brains. Following an extensive period of 
dehydration by alcohol immersion and tissue clearance using xylene, the brains are immersed in 
paraffin wax at 60
o C for a period of 16 hours. 
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Stage  Process  Time Period (minutes) 
1  Histoclear 1  4-5 
2  Histoclear 2  4-5 
3  Histoclear 3  4-5 
4  Absolute Alcohol 1  3 
5  Absolute Alcohol 2  3 
6  90% Alcohol  3 
7  70% Alcohol  3 
8  Wash in running water  4 
9  Haematoxylin Staining  4-5 
10  Wash in running water  1-2 
11  Differentiate in Acid Alcohol  A few dips only 
12  Wash in running water  3 
13  Scott’s Tap Water Substitute  2 
14  Wash in running water  2 
15  70% Alcohol  2 
16  90% Alcohol  2 
17  Alcoholic Eosin (95%) Staining  4 
18  Absolute Alcohol 1  4 
19  Absolute Alcohol 2  4 
20  Absolute Alcohol 3  4 
21  Histoclear 1  4 
22  Histoclear 2  4 
23  Histoclear 3  4 
 
 
Table 2-2. Haematoxylin and eosin staining procedure for paraffin embedded sections. 
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coronal levels (Osborne et al, 1987) using a microtome (Leica, UK) to allow determination 
of infarct volume following haematoxylin and eosin (H & E) staining. The sections were 
placed on poly-L- lysine coated slides and were left to dry overnight.  
 
The  paraffin  wax  was  removed  from  the  sections  by  immersing  them  in  histoclear 
(National Diagnostics, UK) and the sections were then immersed in a series of graded 
alcohols before haematoxylin (Surgipath, UK) staining was performed. Following a period 
of washing and differentiation in acid alcohol, the sections were again dehydrated before 
eosin (Surgipath, UK) staining took place (Table 2-2). Further dehydration was followed 
by  immersion  in  histoclear prior to mounting the slides using DPX  mounting  medium 
(Raymond  Lamb  Laboratory  Supplies).  H  &  E  staining  can  be  used  to  detect 
histopathological  changes  following  focal  cerebral  ischaemia.  Haematoxylin  stains 
basophilic structures blue and eosin stains eosinophilic structures bright pink. Thus, under 
the light microscope, the neuronal nuclei are stained blue and the surrounding cytoplasm 
and  extracellular  components  appear  pink.  However  ischaemic  damage  can  be  readily 
detected as ischaemic neuronal cell bodies become dark and shrunken and can be easily 
distinguished  from  healthy  neurons.  There  are  other  clear  signs  of  ischaemic  damage 
including pallor of eosin staining and vacuolation of the neuropil. 
 
In order to assess infarct volume, 8 coronal levels spanning the territory of the middle 
cerebral artery (Osborne et al, 1987) were examined under a light microscope (Leica, UK) 
at a range of magnifications (x5, x10, and x20) to identify ischaemic neuronal damage.  
The cell soma of normal healthy neurons appears rounded with a clearly visible nucleus. 
However, ischaemic neurons become pyknotic in appearance, where they appear dark and 
shrunken into a triangular shape.  The surrounding neuropil also becomes sponge-like in 
appearance and demonstrates pallor of eosin staining (Figure 2-2). These attributes can be 
identified under the microscope and the areas of ischaemic damage can then be transcribed 
by hand onto line diagrams at pre-determined coronal levels (Osborne et al, 1987) (Figures 
2-3 & 2-4). This process is repeated 3 times for each animal on separate occasions to 
ensure reproducibility. The line diagrams are then scanned onto a computer and analysed 
using image analysis software, ImageJ (http://rsb.info.nih.gov/ij/). The area of ischaemic 
damage  is  directly  measured  on  each  coronal  level.  The  total  volume  of  damage  is 
calculated by the integration of the areas and the distance between each level using the 
stereotaxic co-ordinates (Paxinos & Watson, 1998).  
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Figure 2-2.  Light microscopic images (x20) depicting representative H & E staining of the 
ipsilateral hemisphere of a rat following 4 hours permanent MCAO.  Image A shows normal, 
unaffected  cortical tissue,  where  healthy  neurons  appear  round  and  uniform.  Image  B  depicts 
ischaemic tissue. Note the pallor of eosin staining of the neuropil and pyknotic neurons. Image C 
shows  the  border  zone,  where  normal  neurons  appear  alongside  ischaemic  neurons.  Scale 
bars=25µm. 
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         Level 1: Bregma = 3.20mm                   Level 5: Bregma = -1.80mm 
                                              
 
         Level 2: Bregma = 1.20mm                    Level 6: Bregma = -3.14mm 
                                      
                        
         Level 3: Bregma = -0.26mm                   Level 7: Bregma = -4.80mm 
 
                                    
  
         Level 4: Bregma = -0.80mm                   Level 8: Bregma = -6.30mm 
 
                                   
 
 
 
Figure  2-3.  The  eight  coronal  levels  defined  by  Osborne  et  al  (1987).  The  figures  are 
reproduced from the stereotaxic atlas of Paxinos & Watson (1998) with the distance from bregma 
defined at each level, where levels 1 and 2 are anterior to bregma and the remaining levels are 
found posteriorly. 
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                                    Level 1                           Level 5 
                 
 
                                    Level 2                                               Level 6 
                                          
 
                                    Level 3                                              Level 7 
                                       
 
                                     Level 4                                            Level 8 
                                     
    
Figure 2-4. Line diagrams of the 8 coronal levels defined by Osborne et al (1987) with the 
area of ischaemic damage, as observed by light microscopic examination of H & E stained 
sections, manually traced onto the images (Paxinos & Watson, 1998). The images represent 
the ischaemic damage observed in the median animal of the H & E staining group in the stroke 
reproducibility study. 
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2.2.2 2,3,5-triphenyltetrazolium chloride (TTC) Staining 
 
TTC has been utilised for over 50 years to identify areas of ischaemic tissue damage. It is a 
water-soluble salt which in normal brain tissue is reduced by mitochondrial dehydrogenase 
enzymes to form a deep red, fat soluble compound called formazan. However, in ischaemic 
tissue,  these  mitochondrial  enzyme  systems  are  incapacitated  and  consequently,  these 
tissue  areas  remain  unstained  (Figure  2-5).  It  is  therefore,  a  rather  crude  yet  reliable 
method  used  to  delineate  areas  of  ischaemic  damage  following  middle  cerebral  artery 
occlusion. 
 
For  TTC  processing  of  the  brain,  the  animal  was  deeply  anaesthetised  by  using  5% 
isofluorane  delivered  in  a  30%/70%  mixture  of  oxygen  and  nitrous  oxide  before 
decapitation. The brain was then immediately removed from the skull and bathed in ice-
cold  0.9%  saline.  The  brain  was  then  placed  in  a  rat  brain  matrix  (World  Precision 
Instruments, UK) and microtome blades (Feather, Japan) were positioned 2mm apart to cut 
6 coronal brain slices simultaneously. The slices were then incubated in a pre-warmed 
40ml  solution  of  1%  TTC  (Sigma,  Switzerland)  in  phosphate  buffered  saline,  for  15 
minutes  at  37
o  C.  The  brain  sections  were  then  removed  from  the  TTC  solution  and 
allowed to incubate in PAM overnight. Following fixation, both faces of each brain slice 
were photographed using a digital video camera (Canon, UK) which was secured onto a 
stand (Kaiser, Germany) to keep the camera at the same height for all photographs. A 
graticule (Imaging Research Inc.) was used to determine scale for subsequent calibration. 
This allowed the infarct area of each slice to be determined by manually tracing the area of 
ischaemic damage using ImageJ software. The infarct area on both faces of each slice were 
added together and divided by 2 to give the mean infarct area for each slice. The total 
infarct volume was calculated by multiplying the sum of the infarct areas of each slice by 
the slice thickness (2mm). 
 
A stroke reproducibility study was undertaken to assess surgical ability to induce MCAO 
and also to compare final infarct volume at 4 hours post-MCAO using both haematoxylin 
& eosin and TTC staining methods. Permanent stroke was induced in 12 Sprague-Dawley 
rats (300-350g, Harlan, UK) by the intraluminal filament model, as described earlier in this 
chapter. Following 4 hours of MCAO, 6 animals were sacrificed by perfusion fixation to 
allow H  & E staining of  brain tissue and 6 animals were sacrificed  for TTC staining. 
Infarct volumes were determined for both techniques and compared between the groups. 
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Figure 2-5. TTC staining of coronal brain slices following middle cerebral artery occlusion 
identifies area of ischaemic injury. The image on the left depicts the level of contrast observed 
when the staining is performed 4 hours post occlusion. Note that the delineation of the infarcted 
tissue is not as great as that observed when TTC staining is performed 24 hours following middle 
cerebral  artery  occlusion  (right  image).  Both  images  depict  coronal  level  three  as  defined  by 
Osborne et al (1987). 
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Infarct volume as derived by TTC staining was significantly greater than infarct volume 
defined by histopathological examination of brain sections stained with H & E (Figure 2-
6). Despite this, within each staining group the calculated infarct volumes were consistent, 
indicating stroke reproducibility. However, one rat was excluded from the H & E staining 
group as microscopic examination revealed no evidence of ischaemic damage. The median 
infarct  volume  in  the  TTC  staining  group  was  268mm
3  compared  to  a  median  infarct 
volume of 121mm
3 in the H & E group. The data were analysed using non-parametric 
statistical  tests  due  to  the  skewed  data  in  the  TTC  group,  where  two  rats  displayed 
particularly large infarcts. Statistical analysis using the non-parametric Mann-Whitney test, 
revealed that the two groups were significantly different at the 95% level of significance 
(P=0.0043). 
 
The ability of TTC staining to accurately identify cerebral infarction was examined by 
Bederson  and  colleagues  (1986a).  These  authors  reported  that  when  the  infarct  was 
allowed to develop for 24 hours, there was no significant difference between the infarct 
volume determined by TTC staining or by H & E staining. However, when animals were 
sacrificed  less  than  6  hours  post  occlusion,  it  became  more  difficult  to  assess  infarct 
volume  via  the  TTC  method,  as  the  lesions  are  stained  pink  and  it  can  be  extremely 
difficult to delineate the  borders of the  lesion,  since the  contrast with the surrounding 
normal brain tissue is often very poor (Figure 2-5). By contrast, at the 24 hour time point, 
the infarct can be very clearly distinguished from brightly stained normal tissue. This was 
clearly  evident  in the stroke reproducibilty  study, as there was  no clear differentiation 
between  normal  and  infarcted  tissue  after  four  hours  of  MCAO,  thereby  making  it 
extremely difficult to demarcate the borders of ischaemic damage.  
 
The difficulty in distinguishing ischaemic from normal tissue in TTC stained brain slices 
may  account  for the  significant overestimation  of  infarct  volume  demonstrated  by  this 
method, since the process of delineation is extremely subjective. However, the same can be 
said when transcribing areas of ischaemic damage onto line diagrams from H & E stained 
sections. It can be difficult to determine the boundaries of ischaemic tissue damage when 
there is evidence of a substantial border zone, where both ischaemic and normal neurons 
are identified. Since transcribing areas of ischaemic damage onto line diagrams corrects for 
brain swelling and prevents overestimation of infarct volume, it was considered that this 
may  explain  the  larger  infarct  volumes  demonstrated  with  the  TTC  staining  method. 
However, when the hemispheric areas of TTC stained brain slices were examined, there  
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Figure 2-6. Comparison of the TTC and H & E staining methods for determination of infarct 
volume following 4 hours permanent MCAO in the  Sprague-Dawley rat.  Infarct volume as 
determined  by  TTC  staining  (n=6)  is  significantly  greater  than  infarct  volume  calculated  by 
examination of H & E stained brain sections (n=5) *p=0.0043.  
 
 
 
 
 
 
 
 
   78 
was  no  significant  difference  between  the  ipsilateral  and  contralateral  hemispheres, 
indicating that there was no evidence of cerebral oedema. This result was as expected since 
brain oedema is not usually evident until at least 4 hours post ischaemia in permanent 
rodent stroke models (Tyson et al, 1982). 
 
Therefore, the results of the stroke reproducibility study indicate that in order to determine 
infarct volume following permanent MCAO of 4 hours duration, H & E staining of brain 
tissue should be the preferred method. Despite TTC determination of infarct volume being 
comparable to that observed by the H & E staining method following 24 hours of MCAO, 
at earlier time points there is no clear delineation between ischaemic and unaffected brain 
tissue. 
 
 
2.2.3 MRI RARE T2 Weighted Imaging 
 
In chapters 3, 4 and 5, infarct volume was determined using MRI RARE T2 weighted 
imaging. T2 weighted imaging can be reliably used to identify ischaemic brain tissue 12 to 
24 hours following stroke but during the critical period of 6-12 hours, this method does not 
adequately assess the severity and extent of ischaemia (Baird & Warach, 1998). In acute 
stroke, the changes in blood flow and tissue swelling which occur are associated with very 
subtle signal changes in T2 images. Areas of injured tissue produce higher signal intensity 
than normal brain tissue allowing the infarct to be clearly distinguished. 
 
All MRI data were acquired using a Bruker Biospec 7T/30cm system with a gradient coil 
(internal diameter=121mm, 400mT/m) and a 72mm birdcage resonator. MRI RARE T2 
weighted imaging was used to calculate infarct volume at 24 hours following permanent 
MCAO  or  at  72  hours  following  transient  MCAO.  Rats  were  anaesthetised  in  an 
anaesthetic chamber, as described previously, and were then immediately transferred to the 
MRI scanner, secured within the cradle by tooth and ear bars, to restrict head movement, 
and  a  4-channel  phased  array  surface  receiver  coil  was  placed  on  the  head.  Body 
temperature  was  maintained  within  physiological  range  (37±0.5
oC)  during  the  MRI 
scanning procedure by a closed circuit thermal jacket. 
 
Once a pilot sequence had been obtained to ensure correct geometry, a RARE T2 weighted 
sequence was acquired (TE=72.7ms, TR=5086.1ms, matrix=256x256, 16 coronal slices; 
0.75mm thick) to allow calculation of final infarct volume.   79 
 
Final infarct was defined as the hyperintense area on T2 weighted images. The hyperintense 
area was manually delineated on each of the 16 T2 slices spanning the territory of the 
middle cerebral artery using Image J software (Figure 2-7). The area of the contralateral 
and  ipsilateral  hemisphere  on  each  slice  was  also  measured.  The  volumes  of  the 
contralateral and ipsilateral hemispheres and infarct volume were calculated by multiplying 
the total area across the 16 slices by the slice thickness (0.75mm). Total infarct volume 
was  corrected  for  oedema  using  published  equations  which  take  compression  of  the 
contralateral hemisphere into account (Gerriets et al, 2004), in addition to swelling of the 
ipsilateral hemisphere (Swanson et al, 1990). 
 
For the calculation of infarct volume corrected for swelling of the ipsilateral hemisphere 
the following equation was used: 
 
 Corrected lesion = volume of contralateral   -  ( volume of ipsilateral – lesion volume) 
        volume                      hemisphere                         hemisphere 
 
 
A correction factor which accounts for compression of the contralateral hemisphere is 
calculated by the following equation: 
 
Compression Factor=(ipsilateral volume + contralateral volume)/(2 x contralateral volume) 
 
To calculate infarct volume which is corrected for both ipsilateral swelling and 
contralateral compression, the following equation was used: 
 
Infarct volume = corrected lesion volume x compression factor 
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Figure 2-7. MRI RARE T2 images from a representative SHRSP rat acquired at 24h following permanent occlusion of the middle cerebral artery. Row A shows 
6 coronal slices spanning the territory of the MCA. Infarcted tissue is clearly visible as the hyperintense area within the ipsilateral hemisphere. Note also the extensive 
swelling of the ipsilateral hemisphere and compression of the contralateral hemisphere. Image J software was used to delineate the infarcted tissue, as shown in red in 
row B. Infarct volume was calculated by multiplying the summation of infarct area across 16 coronal slices and multiplying by slice thickness. Infarct volume was 
corrected  for  both  ipsilateral  swelling  and  contralateral  compression  using  published  equations  (Swanson  et  al,  1990;  Gerriets  et  al,  2004).  81 
2.3 Behavioural Assessment 
 
2.3.1 Modified Bederson Scale 
 
In  chapter  5,  neurological  function  following  stroke  was  assessed  using  a  modified 
Bederson  Scale.  The  original  4  point  scale  was  developed  by  Bederson  et  al.  (1986b) 
(Table  2-3a)  and  was  used  to  grade  stroke  severity  in  rats  following  occlusion  of  the 
middle cerebral artery. The original Bederson scale has been modified and expanded by 
various  study  groups  (Suzuki  et  al,  2004;  Braeuninger  et  al,  2010  and  others).  The 
modified scale used in chapter 5 to assess functional outcome was a 6 point scale, where 
animals were assigned a grade of 0 to 5 (Table 2-3b). Animals were assessed by gently 
holding the base of the tail to suspend the rat in the air and the normal response is to extend 
both  forelimbs.  However,  rats  with  infarction  will  consistently  flex  the  forelimb 
contralateral to the ischaemic hemisphere. Rats which displayed no observable deficit and 
extended both forelimbs were scored a grade 0 and rats which exhibited flexion of the 
contralateral  forelimb  but  no  other  deficits  were  scored  a  grade  1.  Rats  were  then 
suspended by the base of the tail and allowed to grip the bars of their cage while being 
gently  pulled  away  from  the  cage  to  assess  grip  strength.  If  any  weakness  of  the 
contralateral forelimb was observed by the loss of grip, then the rat was scored a grade of 
2. Rats were then allowed to move freely on the floor to assess circling behaviour. Rats 
that consistently circled to the paretic side, in addition to forelimb flexion and reduced grip 
strength, were assigned a grade of 3. In more severe cases, animals which exhibited no 
spontaneous movement were given a grade of 4 and rats which died prior to functional 
testing were assigned a grade of 5.  
 
2.3.2 Vibrissae-evoked Forelimb Placement 
 
In addition to the modified Bederson Scale, functional outcome was also assessed by the 
vibrissae-evoked  forelimb  placement  test.  This  test  assesses  sensorimotor  function  and 
proprioceptive capacity and is sensitive to damage to the striatum and sensorimotor cortex 
in addition to the spinal cord and other sensorimotor structures (Schallert et al, 2000). It 
assesses placement of the forelimb in response to detection of a table top by the vibrissae. 
When the vibrissae of either side are brushed against a table top, the normal response is the 
placement of both forelimbs on to the table top. In functionally impaired animals, there is a 
reduced capacity to place the affected forelimb.  
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A 
 
 
 
B 
 
Neurological Assessment Scale  Observed Functional Deficits 
Grade 0  No observable deficit 
Grade 1  Flexion of the contralateral forelimb 
Grade 2  As grade 1 and with reduced grip 
strength of the contralateral forelimb 
Grade 3  As grade 2 and with consistent circling 
Grade 4  No spontaneous activity 
Grade 5  Dead 
 
 
Table 2-3. Neurological tests developed to assess function in rats following middle cerebral 
artery  occlusion.  Table  A  illustrates  the  original  grading  system  devised  by  Bederson  and 
colleagues. Reproduced from Bederson et al, (1986b). Table B shows the modified and extended 
neurological grading scale used to assess functional outcome in chapter 5. 
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In chapter 5, the vibrissae-evoked forelimb test was performed as described by Schallert et 
al (2000). All rats were handled frequently in the week prior to performing this test to  
ensure that they would not be stressed during the procedure. The test involved holding the 
rat loosely in the palm of the hand so that all four limbs were hanging freely. The rat is 
then moved laterally towards the table top and the vibrissae ipsilateral to the damaged 
hemisphere are gently brushed against the table top, whilst the contralateral forelimb is 
restrained by the forefinger so that only placement of the ipsilateral forelimb is assessed. 
This is repeated to assess the placement of the contralateral forelimb by restraining the 
ipsilateral forelimb and brushing the ipsilateral vibrissae against the table top. A successful 
placement is given a score of one. This is repeated ten times on each side to obtain a score 
out  of  ten  for  the  number  of  successful  placements  achieved  by  the  ipsilateral  and 
contralateral forelimbs. Animals with unilateral brain damage will display varying degrees 
of impaired contralateral limb placing ability while the unaffected ipsilateral forelimb will 
typically show no evidence of impairment. The severity of brain injury can then be graded 
by  calculating  the  percentage  of  unsuccessful  contralateral  placements  (number  of 
incorrect placements x 10).  
This test was performed prior to surgery to ensure that there was no evidence of functional 
impairment  or  limb  preference  before  experimental  stroke  was  induced.  There  was  no 
evidence of limb preference or functional impairment in any of the rats tested prior to 
stroke surgery. 
 
2.3.3 18 point Neurological Score 
 
In addition to the modified Bederson Scale and the vibrissae-evoked forelimb placement 
test, an 18 point composite  neurological  score (Garcia et al, 1995) was used to assess 
functional outcome in rats where transient ischaemia was induced (Chapter 5). This score 
comprises  6  neurological  tests  which  assess  spontaneous  activity,  symmetry  in  limb 
movement, forepaw outstretching, climbing ability, body proprioception and response to 
vibrissae touch, with each test scored with a maximum of 3 points. The maximum score 
which can be achieved is 18, which indicates that there is no neurological deficit and the 
lowest score which can be achieved is 3, for animals with the most severe impairment 
(Table 2-4). 
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Test  Neurological Score 
 
0  1  2  3 
 
Spontaneous activity (in 
cage for 5 min) 
No movement  Barely moves  Moves but does not 
approach at least three 
sides of cage 
Moves and approaches 
at least three sides of 
cage 
Symmetry of movements 
(four limbs) 
Contralateral side: no 
movement 
Contralateral side: 
slight movement 
Contralateral side: moves 
slowly 
Both sides: move 
symmetrically 
Symmetry of forelimbs 
(outstretching while held 
by tail) 
Contralateral side: no 
movement, no 
outreaching 
Contralateral side: 
slight movement to 
outreach 
Contralateral side: moves 
and outreaches less than 
right side 
Symmetrical outreach 
Climbing wall of wire cage  ...  Fails to climb  Contralateral side is weak  Normal climbing 
Reaction to touch on 
either side of trunk 
...  No response on 
contralateral side 
Weak response on 
contralateral side 
Symmetrical response 
Response to vibrissae 
touch 
...  No response on  
contralateral side 
Weak response on 
contralateral side 
Symmetrical response 
 
 
 
Table 2-4. The 18 point composite neurological score to test functional outcome in rats following middle cerebral artery occlusion.  This neurological 
evaluation comprises 6 tests which are each given a score up to 3. The scores for each test are added to given an overall score of functional outcome, where the 
maximum score of 18 indicates no observable deficit and the minimum score of 3 indicates severe neurological impairment. Adapted from Garcia et al (1995). 
 1. Spontaneous Activity 
The rat was observed for a period of 5 minutes in its home cage with the cage top removed. 
 
The spontaneous activity of the rat was assessed by its ability to approach all four
 walls of 
the cage and was scored from 0 to 3. A score of 3 indicates that the rat moved around the 
cage, explored the environment and approached at least three walls of the cage. A score of 
2 was given if the rat moved around in the cage but didn‟t approach all four walls, although 
it eventually reached at least one upper rim of the cage. A score of 1 indicates that the rat 
barely moved in the cage and didn‟t rise up on its hindlimbs to approach any of the cage 
walls and a score of 0 was given if the rat did not move at all during the observation 
period. 
 2. Symmetry in the Movement of Four Limbs 
Symmetry in the movement of the four limbs was assessed by suspending the rat in the air 
by holding the base of the tail. Scores were assigned as follows: a score of 
 3 was given if 
all four limbs extended symmetrically and scored 2 if the limbs on the contralateral side
 
extended less or more slowly than those on the unaffected side. A score of 1 was assigned 
if limbs
 on the contralateral side showed minimal movement and 0, if the contralateral 
forelimb did not move at all.
  
3. Forepaw Outstretching 
The rat was held by the base of the tail so that it had to walk along the surface of the table 
using  its  forelimbs  only.  The  hindlimbs  were  kept  in  the  air  and  symmetry  in  the 
outreaching  of  both  forelimbs  was  observed.  Scores
  indicate  the  following:  3,  both 
forelimbs  were  outstretched,
  and  the  rat  walked  symmetrically  on  forepaws;  2,  the 
contralateral forepaw outstretched
 less than the ipsilateral forepaw, and forepaw walking 
was  impaired;  1,  the  contralateral
  forelimb  exhibited  minimal  movement;  and  0,  the 
contralateral forelimb did not move at all.
  
4. Climbing 
The rat was placed on wire grid and was then pulled off the wire by gripping the base of 
the tail and the
 strength of attachment was noted. A score of 
 3 was given if the rat climbed 
easily  and  gripped  tightly  to  the  wire.  The  rat  scored  2  if  the  contralateral  side  was 
impaired while climbing or did not grip as hard as
 the ipsilateral side and a score of 1 
indicates that the rat failed to climb or tended to circle
 instead of climbing.
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5. Body Proprioception 
The rat was sharply prodded with a blunt wooden pencil on each side of the body, and
 the 
reaction to the stimulus was observed. A score of 
 3 indicates that the rat reacted by turning 
head and was equally startled by the
 stimulus on both sides. A score of 2 was given if the 
rat reacted slowly to stimulus on
 the contralateral side and a score of 1 if the rat did not 
respond to the stimulus at all
 on the contralateral side.
  
6. Response to Vibrissae Touch 
A wooden pencil was brushed against the vibrissae on each side;
 the stick was moved 
toward the whiskers from the rear of the animal
 to avoid entering the visual fields. A score 
of 
 3 was assigned if the rat reacted by turning head or was equally startled by the
 stimulus 
on  both  sides.  A  score  of  2  indicates  that  the  rat  reacted  slowly  to  stimulus  on
  the 
contralateral side and a score of 1 was given if there was no response to the stimulus on the 
contralateral
 side.
  
 
The  scores  from  each  test  are  added  to  give  an  overall  neurological  score,  where  the 
maximum score of 18 is achieved where there is no observable deficit and the minimum 
score of 3 indicates the most severely impaired animals. 
 
2.4 Blood Pressure Determination 
 
2.4.1 The Tail Cuff Method 
 
It is necessary to regularly monitor systolic blood pressure in both the SHRSP and the 
WKY  to  ensure  that  the  stroke-prone  strain  is  indeed  hypertensive  compared  to  the 
normotensive  control  strain.  The  American  Heart  Association  recommends  indirect 
measurement of blood pressure to detect substantial group differences in systolic blood 
pressure  (Kurtz  et  al,  2005).  The  tail  cuff  method  of  systolic  blood  pressure  (BP) 
measurement is a non-invasive technique which was developed by the West of Scotland‟s 
Department  of  Clinical  Physics  and  Bioengineering,  based  at  the  Southern  General 
Hospital in Glasgow (Evans et al, 1994). This technique involves the placement of a cuff 
around the proximal end of the rat‟s tail which is then inflated with air until the point at 
which  the  pressure  in  the  cuff  matches  that  of  the  tail  artery,  resulting  in  a  transient 
occlusion of the vessel. This leads to an absence of a pulse which is detected by a signal 
transducer, which is also located on the tail of the rat, at a more distal position than the tail   87 
cuff. The signal is relayed to a central monitoring system which is connected to a laptop 
(Dell, UK) which then displays the systolic blood pressure reading in mmHg and the cuff 
is then deflated. This technique is advantageous as it does not require catheterisation of an 
artery  as  required  for  direct  methods  of  blood  pressure  measurement  and  has  been 
validated  against  direct  measures  of  blood  pressure  measurement  (Feng  et  al,  2008). 
Furthermore, it allows BP measurements to be obtained in conscious animals without the 
influence of anaesthesia on BP, as is the case with invasive methods. However, there may 
be an element of stress associated with the mild restraint involved which will be reflected 
in the measurements obtained but this can be minimised by incorporating an extensive 
acclimatisation and training period into the regime. 
 
2.4.2 Tail Cuff Apparatus 
 
Prior  to  BP  measurement,  the  animals  must  be  pre-warmed  to  induce  maximal 
vasodilatation of the tail artery. This is achieved by placing the animals in an insulated heat 
box (dimensions 37cm x 35cm x 40cm) (Figure 2-8). The upper surface of the box has a 
circular opening (diameter 7cm) to allow the box to be warmed to a temperature of 34
oC 
using a hairdryer (Boots, UK) with temperature maintained by positioning an angle poise 
lamp over the opening of the box. A thermometer situated on the inner wall of the chamber 
is used to monitor the temperature within the box. The front panel of the heat box has a 
door to allow ease of removing animals from the chamber and an insulating tile can be 
removed from the door to observe the animals through a perspex screen. The screen also 
promotes heat loss if the temperature rises above 35
oC. 
The tail cuff is constructed by cutting the medial portion of a 5ml syringe (Plastipak, UK) 
to a length of 2cm and a length of latex tubing (length 6cm, width 1.5cm) is inserted into 
the syringe. A 10 gauge catheter, cut to 4cm in length was inserted into the latex tubing 
and secured in place by tying 5-0 thread around the tubing. The opposite end of the latex 
tubing was turned over to the outer face of the syringe and was secured using a plastic o-
ring (1.7cm diameter) (Figure 2-9). The catheter was then connected to the central BP 
measurement system. The central monitoring system was also connected to a cylinder of 
medical  air  (BOC  Gases,  UK)  via  a  hose,  a  laptop  (Dell,  UK)  and  a  piezoceramic 
transducer (Figure 2-8). 
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Figure 2-8. The tail cuff apparatus. The top image shows the central blood pressure monitoring 
system  which  is  connected  to  a  laptop,  where  the  systolic  blood  pressure  measurements  are 
displayed and recorded. A heat mat and a towel are used to keep the rat warm and lightly restrain 
movement. The bottom image shows the heat box, which is pre-warmed to 34
oC. The rat is placed 
in the box for 10-15 minutes to induce maximal vasodilation of the tail artery prior to blood pressure 
measurement. 
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Figure 2-9. The tail cuff and transducer. The top image shows the tail cuff which is placed on the 
base of the tail and inflates and deflates in cycles. The bottom image shows the piezoceramic 
transducer which relays the blood pressure signal to the central blood pressure monitoring system.  
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2.4.3 Animal Training Procedure 
 
All  rats  were  subjected  to  an  intensive  5  day  training  period  to  acclimatise  them  to 
handling and the tail cuff apparatus. On day one of training rats were taken to the room 
where the tail cuff apparatus was set up in their home cage. The animals were then handled 
for a period of 20-30 minutes and were allowed to explore the table where the tail cuff 
apparatus  was  set  up.  They  were  also  wrapped  in  a  towel  to  accustom  them  to  mild 
restraint. On day two, rats were subjected to the same handling procedure as the previous 
day, with the addition of being placed in the heat box for 10 minutes, which had not been 
pre- warmed. The training on day 3 was the same as day two, except that the heat box was 
pre-warmed to 34
oC prior to the animals entering it. On day 4, the training procedure was 
as described for day 3 and then the tail cuff and transducer were positioned on the rats tail 
(Figure 2-10) whilst the rat was being mildly restrained within a towel. On the final day of 
training, the tail cuff apparatus was again positioned on the rat‟s tail following 10 minutes 
in the heat box and the cuff was inflated and deflated to allow the rat to acclimatise to the 
pressure of the tail cuff. At the end of each training day, rats were rewarded with a treat of 
10 pumpkin seeds each. 
 
2.4.4 Systolic BP Measurement Protocol 
 
The tail cuff method was used to measure systolic blood pressure in WKY and SHRSP 
rats, three times a week for at least 2-3 weeks prior to the induction of experimental stroke. 
All BP measurement was performed in the afternoon between the hours of 2-3pm. BP 
measurement was not performed on a Monday afternoon, as the rats tended to be more 
stressed on this day and I discovered that their cages were cleaned out every Monday and 
this was likely to be the cause of their increased stress levels. 
Rats were placed in the pre-warmed heat box with their cage-mates for 10-15 minutes and 
no longer than 20 minutes. Care was taken to regularly assess the temperature in the box 
by looking at the thermometer attached to the inner wall of the box. If the temperature was 
above 36
oC, then the front panel of the box was removed to aid heat loss. The front panel 
of the heat box also allowed the animals to be observed. The rats were deemed to be warm 
enough when there was very little spontaneous movement and the ears looked very pink.  
At this stage the rat was removed from the box and swiftly wrapped in a towel with only 
the tail exposed. The rat was placed onto the heat mat to keep it warm and the tail cuff and 
the signal transducer were positioned on the tail (Figure 2-10). Once the rat was settled and 
was sitting on the heat mat, wrapped in the towel, with no need for restraint, then BP    91 
 
 
 
 
 
 
 
Figure  2-10. The  tail  cuff  method of  non-invasive  blood  pressure  measurement.  The  top 
image illustrates the positioning of the tail cuff and the signal transducer on the tail of the rat, where 
the cuff is positioned at the base and the transducer is placed distal to the cuff. The bottom image 
shows the computer screen as displayed when blood pressure measurements are being recorded. 
The strength of the signal is shown in the green box in the top right hand corner of the display and 
the measurements are recorded in the box on the bottom right corner.    92 
measurements were taken. The laptop was used to inflate and deflate the cuff in cycles to 
obtain measurements of systolic blood pressure. This was repeated until 8-10 consistent 
measurements  of  systolic  blood  pressure  were  acquired  and  the  mean  and  standard 
deviation  were  then  calculated.  Only  the  most  consistent  measurements  were  used  to 
calculate the  mean systolic  blood pressure  for each animal. Measurements which were 
acquired when an animal was visibly stressed were excluded. After the tail cuff procedure, 
the rats were returned to their home cage and were rewarded with pumpkin seeds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter 3. 
Establishing strain-specific MRI perfusion and diffusion 
thresholds in SHRSP and WKY rats 
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3.1 Introduction 
 
MRI  perfusion-diffusion  mismatch  is  widely  used  to  identify  potentially  salvageable 
penumbra in both clinical and pre-clinical research. Perfusion weighted imaging identifies 
tissue  at  risk  of  infarction,  while  diffusion  weighted  imaging  identifies  the  core  of 
ischaemic injury. The mismatch between the perfusion deficit on PWI and the region of 
abnormality on DWI provides an approximation of the ischaemic penumbra. Despite this 
technique being used for well over a decade, there is still no consensus on where to set 
perfusion and diffusion thresholds to accurately define the penumbra in both clinical and 
pre-clinical stroke research. This is particularly important where the presence of penumbra 
is  used  as  a  criterion  for  recruiting  stroke  patients  into  clinical  trials.  If  the  diffusion 
threshold  is  set  too  low  then  irreversibly  injured  tissue  could  be  identified  as  being 
potentially  salvageable  and  the  penumbra  will  be  overestimated.  Conversely,  if  the 
diffusion threshold is set too high, then the ischaemic core will include a component of the 
penumbra, where tissue is hypoperfused but not yet experiencing bioenergetic failure. If 
the  perfusion  threshold  is  set too  high,  then  the  outer  boundary  of  the  penumbra  will 
include benign oligaemic tissue which is not at risk of infarction, thereby overestimating 
the penumbra and if the threshold is set too low, then penumbra will be underestimated. 
This highlights the importance of defining perfusion and diffusion thresholds to accurately 
identify potentially salvageable tissue following stroke.  
 
To date, there are no consistent thresholds in use in clinical (Bandera et al, 2006) or pre-
clinical  stroke  research.  In  clinical  research,  thresholds  of  perfusion  and  diffusion 
abnormality have been calculated to identify the ischaemic penumbra and predict stroke 
outcome.  In  a  retrospective  study  of  37  stroke  patients,  where  DWI,  PWI  and  MR 
angiography had been performed within 6 hours of stroke onset, an ADC threshold of 80% 
of contralateral hemispheric ADC was applied to identify the region of ischaemic injury 
(Thomalla et al, 2003).  This group also performed perfusion imaging using contrast agent 
bolus  tracking,  where  a  gadolinium  based  contrast  agent  was  administered  into  the 
patient‟s  circulation  intravenously.  A  time-intensity  curve  was  constructed  from  the 
changes  in  signal  intensity  as  the  contrast  agent  passed  through  the  circulation.  The 
perfusion deficit was defined using the time to peak (TTP) of the contrast agent with a TTP 
delay of greater than 4 seconds compared to the contralateral hemisphere used to define 
hypoperfused tissue. These results are in agreement with earlier studies which reported that 
a TTP delay of between 4 and 6 seconds was the best predictor of hypoperfused tissue 
which would progress to infarction without reperfusion (Neumann-Haefelin et al, 1999).   95 
However, this TTP delay threshold was later challenged by Sobesky et al (2005), who 
compared the ability of perfusion MR to identify the penumbra with PET and reported that 
a TTP delay threshold of 4-6 seconds grossly overestimated the PET defined penumbra. 
The  greatest  challenge  when  establishing  perfusion  deficit  thresholds  is  to  define  the 
penumbra  with  the  exclusion  of  benign  oligaemic  tissue  to  prevent  overestimation  of 
potentially salvageable tissue. 
 
The perfusion deficit can also be defined by parameters other than TTP delay but there is 
no consensus on which perfusion parameter to use clinically to define the perfusion deficit. 
It has been reported that the volume of penumbra quantified by the mismatch technique 
can vary considerably depending on the perfusion parameter used to define hypoperfused 
tissue (Kane et al, 2007). In a study of 32 patients, these authors demonstrated that the 
proportion of those patients presenting with perfusion-diffusion mismatch varied from 9% 
to 72% using 10 different MRI methods to detect the perfusion deficit in each patient. The 
lack  of  a  validated  method  to  define  the  perfusion  deficit  will  impact  on  patient 
management  where  the  volume  of  potentially  salvageable  tissue  is  used  to  determine 
suitability for therapy.
  Tmax is the measured TTP of the residual function and many groups 
use  this  parameter  rather  than  TTP  since  it  allows  comparisons  to  be  made  across 
individual stroke patients. Shih and colleagues defined a Tmax delay threshold of between 6 
and 8 seconds as the most effective for the identification of tissue which would proceed to 
infarction without reperfusion by day 7 post stroke onset (Shih et al, 2003). However, 
Olivot et al (2009) defined the penumbra as hypoperfused tissue with a Tmax delay of 4-6 
seconds, in agreement with an earlier clinical study (Tawasaka et al, 2008). Therefore there 
still appears to be some uncertainty with regards to the perfusion thresholds used for the 
clinical identification of the ischaemic penumbra and regarding which parameter is the 
most  appropriate  measure  of  hypoperfused  tissue.  MRI  based  quantitative  measures  of 
perfusion are available, like arterial spin labelling, however, many clinical centres do not 
yet have the facilities available to use this technique. 
 
In rodent stroke models, some groups have defined MRI perfusion and diffusion thresholds 
to define penumbra. Mancuso and colleagues (1995) assessed the relationship between the 
ADC derived lesion and cerebral blood flow, as measured by autoradiography. This group 
defined the ADC lesion as a 15% reduction when compared to the mean ADC value in the 
contralateral hemisphere.  This threshold was selected by examining pre-ischaemic ADC 
maps and diffusion weighted images. Thirty minutes post-MCAO, the ADC-derived lesion 
correlated with a reduced  CBF of ≤25ml/100g/min. In another group, where rats were   96 
subjected to permanent MCAO, the  ADC-derived  lesion at 90  minutes correlated with 
CBF  of  30-35ml/100g/min,  demonstrating  the  temporal  evolution  of  the  ADC  derived 
lesion to incorporate less severely hypoperfused tissue into the lesion as the ADC value of 
ischaemic tissue reduces further over time (Mancuso et al, 1995). 
  
One study group in particular have worked extensively to establish thresholds of tissue 
viability in rat models of middle cerebral artery occlusion. Early studies by this group 
identified an absolute ADC threshold value of 0.55 x 10
-3 mm
2/sec, when the ADC lesion 
at 2 hours post-MCAO most closely matched the TTC defined final infarct at 24 hours 
post-occlusion (Dardzinski et al, 1993). In later studies by this group (Shen et al, 2003; 
Meng et al, 2004) ADC and CBF thresholds were established by adjusting the respective 
thresholds  until  the  ADC-derived  and  PWI-defined  perfusion  deficit  at  3  hours  post-
MCAO were closely matched to the final infarct, defined at 24 hours post-MCAO by TTC 
processing of the brain. The absolute ADC threshold defined by this group was 0.53 ± 0.03 
x 10
-3 mm
2 /sec, which equates to a 30 ± 2% reduction in ADC compared to the mean ADC 
value of the contralateral hemisphere. The abnormal perfusion threshold was defined as 
0.30 ± 0.09ml/g/min, which is a 57 ± 11% reduction in CBF, as compared with the mean 
contralateral  hemisphere  values.  Therefore,  pixels  on  ADC  and  CBF  maps  which  fall 
below  these  thresholds  defined  the  regions  of  ischaemic  injury  and  hypoperfusion, 
respectively. These maps were then co-registered to define areas of perfusion-diffusion 
mismatch and therefore to identify the potentially salvageable penumbra. Later in the same 
year this group published another paper, using the same methods, to establish an absolute 
ADC threshold and a percent reduction ADC threshold relative to the mean ADC of the 
contralateral hemisphere (Kazemi et al, 2004). Optimum ADC thresholds were established 
as  those  which  provided  the  best  correlation  between  ADC-  and  TTC-derived  lesion 
volume estimates. They defined the absolute ADC threshold value as 0.47 x 10
-3 mm
2 /sec 
and  the  percent  ADC  reduction  threshold  at  33%,  which  is  in  agreement  with  their 
previous reports. 
 
Li et al (2000) used a different approach to define ADC thresholds for the prediction of 
final  infarct  volume  following  permanent  MCAO  in  the  rat.  They  defined  an  ADC 
threshold  specific to each time point post-MCAO. The threshold derived  ADC  lesions 
were correlated with the final infarct volume which was derived by TTC staining 24 hours 
post MCA occlusion. By 210 minutes following onset of ischaemia, the ADC lesion had 
fully evolved and at later time points the thresholds were unchanged. The authors state that 
defining a range of thresholds at various time points will allow prediction of the  final   97 
infarct volume as little as 25 minutes post-ischaemia and enables early prediction of stroke 
outcome. At early time points, the ADC derived lesion will include both injured tissue and 
penumbra. As the ADC values further decrease, the penumbra will become incorporated 
into the final infarct.  
 
Other methods used to define perfusion and diffusion thresholds in rat models of focal 
cerebral ischaemia include using the empirical rule of mean ± 2SD from baseline ADC and 
CBF values of the ipsilateral hemisphere (Foley et al, 2010). In addition, ADC lesion area 
has been defined as the area in which ADC values decreased below a threshold value of 2 
standard  deviations  from  mean  contralateral  ADC  values  (Hoehn-Berlage  et  al,  1995). 
Hoehn-Berlage and colleagues reported that when reductions in ADC were matched to the 
corresponding areas of ATP depletion determined by bioluminescence imaging, the area of 
energetic  failure  corresponded  to  a  23% reduction  in  ADC.  Both  Hoehn-Berlage  et  al 
(1995) and Kohno et al (1995) reported a 70% reduction in CBF was associated with ATP 
depletion and progression to infarction. Foley et al (2010) also defined the perfusion deficit 
using  a  CBF  threshold  of  70%  reduction  from  baseline  ipsilateral  CBF  using  voxel 
analysis. 
 
To date, perfusion and diffusion thresholds have only been established in normotensive rat 
strains. Differences in lesion evolution between strains following experimental stroke may 
mean that thresholds defined in one rat strain may not be applicable to other rat strains, 
particularly  those  with  genetic  stroke  risk  factors,  like  the  spontaneously  hypertensive 
stroke-prone  rat  (SHRSP).  Bardutzky  et  al  (2005)  demonstrated  differences  in  the 
evolution of the ADC-derived lesion in Sprague-Dawley and Wistar Kyoto rats (WKY), 
the normotensive control strain  from which SHR and SHRSP were derived. Following 
permanent  MCAO  induced  by  intraluminal  filament,  the  ADC-derived  lesion  rapidly 
evolves over the first 3 hours and has fully evolved by the 3 hour time point in Sprague-
Dawley rats. However, at 3 hours post-MCAO in Wistar Kyoto rats, the ADC lesion is still 
evolving. It may therefore be inappropriate to use the same ADC and CBF thresholds for 
both strains if the ADC lesion is continuing to evolve beyond the 3 hour time point in 
Wistar Kyoto rats. Therefore it is of utmost importance that thresholds of perfusion and 
diffusion  abnormality  are  established  for  each  strain  used  in  experimental  stroke, 
particularly  since  the  evolution  of  the  ischaemic  lesion  can  vary  between  strains. 
Furthermore, each laboratory should aim to establish their own in-house thresholds for 
each strain of rat and each model used to induce focal cerebral ischaemia. This will serve 
to reduce the influence of additional variables, such as strain and stroke model differences,   98 
and surgical technique, on the results obtained by using thresholds defined by other study 
groups.  Inter-strain thresholds would allow accurate identification of the penumbra and 
prediction of final infarct regardless of the rat strain used. Furthermore, when assessing the 
efficacy  of  potential  stroke  therapies,  one  must  be  confident  that  the  thresholds  of 
abnormality  are  accurate  to  allow  cross  strain  tissue  salvage  to  be  evaluated.  This  is 
becoming  increasingly  important  since  in  order  to  demonstrate  therapeutic  efficacy, 
potential treatments should be assessed using a range of experimental stroke models with 
and without stroke co-morbidities before being translated to clinical trial. Unfortunately 
this  has  not  been  commonplace  and  may  have  contributed  to  the  poor  outcomes  of 
neuroprotective drugs in clinical trials (O‟Collins et al, 2006; Crossley et al, 2008; Howells 
et al, 2010). 
 
Study Aims 
The  aims  of  this  study  were  to  define  strain-specific  MRI  perfusion  and  diffusion 
thresholds  in  the  SHRSP  and  WKY  rat.  These  thresholds  would  then  be  applied  to 
quantitative  perfusion  and  diffusion  data  acquired  in  the  acute  phase  following 
experimental  stroke to  allow  the  temporal  evolution  of  ischaemic  injury  and  perfusion 
deficit to be assessed and compared between the strains. 
 
3.2 Methods 
 
3.2.1 Animal Preparation and Surgical Procedures 
 
SHRSP and WKY rats aged 8-10 weeks of age, were obtained from inbred colonies within 
the Institute of Cardiovascular and Medical Sciences within the University of Glasgow. 
From 11 weeks of age until surgery, systolic blood pressure was measured and recorded 3 
times weekly as previously described (Chapter 2.4.4). The mean systolic blood pressure for 
each rat was calculated and the data were compiled to compare the mean systolic blood 
pressure of each strain. 
 
From this group of animals, age-matched (16-20 weeks) male WKY (n=13) and SHRSP 
(n=16)  weighing  250-350g,  were  anaesthetised,  intubated  and  artificially  ventilated 
(Chapter 2.1.1). The ventral surface of the right and left hindlimbs, the chest and the neck 
were shaved using an electric shaver. All rats were then given an intraperitoneal injection 
of 0.4ml of atropine sulphate (600µg/ml, Martindale Pharmaceuticals, UK) which is an 
anti-muscarinic drug used to prevent bronchial secretions building up in the airways for the   99 
duration of the experiment. The right femoral artery was cannulated to allow continuous 
monitoring of heart rate and MABP (Biopac) with regular blood sampling every hour to 
ensure  blood  pH,  PaCO2  and  PaO2  (Bayer,  Rapidlab  248)  were  maintained  within  the 
physiological  range.  Body  temperature  was  assessed  by  a  rectal  thermocouple  and 
maintained at 37±0.5ºC.           
 
Permanent focal cerebral ischaemia was then induced as previously described (Chapter 
2.1.2), where a silicon tipped filament was advanced along the internal carotid artery to 
block  the  origin  of  the  middle  cerebral  artery.  The  filament  was  secured  in  place  by 
electrocoagulation of the  incision site  located within the external carotid artery stump, 
using  diathermy  forceps.  The  neck  was  stitched  using  a  4-0  silk  suture.  Electrode  gel 
(Sigma) was applied onto the shaved area of the left hindlimb and the right and left sides of 
the  chest  to  allow  placement  of  ECG  leads.  The  rat  was  then  disconnected  from  the 
ventilator and was immediately transferred to the MRI cradle where the intubation tube 
was reconnected to a ventilator to maintain anaesthesia. 
 
3.2.2  MRI Scanning Protocol 
 
 The rat was secured within the cradle by tooth and ear bars, to restrict head movement, 
and  was  then  transferred  to the  MRI  scanner  where  a  4-channel  phased  array  surface 
receiver coil was placed on the head. Body temperature was maintained during the MRI 
scanning  procedure  by  a  closed  circuit  thermal  jacket  and  was  monitored  by  a  rectal 
thermocouple. 
 
Once a pilot sequence had been obtained to ensure correct geometry, a 4-shot spin-echo 
echo  planar  imaging  (EPI)  DWI  scan  (TE=22.5ms,  TR=4000.3ms,  matrix=96x96, 
FOV=25x25mm, 3 directions=x, y, z, B-values=0 and 1000s/mm
2, 8 coronal slices; 1.5mm 
thick) was performed at 30 minutes post-MCAO to allow generation of quantitative ADC 
maps for assessment of ischaemically injured tissue. DWI scans were then repeated on the 
hour from 1 to 4 hours post-MCAO. 
 
Non-invasive quantitative cerebral blood flow (CBF) measurements were carried out on 6 
coronal slices within the MCA territory (slices  2-7 of the DWI scan) using  a  form of 
continuous arterial spin labelling (cASL) based on a train of adiabatic inversion pulses 
(Moffatt et al, 2005).
 The sequence employs a spin-echo EPI imaging module (TE=20ms, 
TR=7000ms, matrix=96x96, FOV=25x25mm, slice thickness 1.5mm, 16 averages, 4 shots)   100 
preceded by 50 hyperbolic secant inversion pulses in a 3 second train. Inversion pulse 
frequency offset and gradient strength were set to provide 10mm wide label/control bands 
centred at ±30mm from the centre of the imaging slice. For quantification of CBF maps, T1 
maps  were  also  acquired,  using  an  EPI  inversion  recovery  sequence  (TE=20ms, 
TR=10000ms,  matrix=96x96,  FOV=25x25mm,  slice  thickness  1.5mm,  16  averages,  4 
shots, using 16 inversion times from 200ms to 7700ms). CBF maps and T1 maps were 
acquired every hour for 4 hours post-MCAO. 
DWI scans across 8 coronal slices were acquired within 2 minutes. The ASL scans for each 
coronal slice took 7 minutes to acquire. Therefore, within each hour, ASL scans could only 
be acquired to match slices 2-7 of the DWI scan. 
 
3.2.3  Animal Recovery 
 
At the end of the 4  hour data acquisition session, the rat was removed  from the MRI 
scanner within the cradle. When the rectal thermocouple, the thermal jacket, ECG leads 
and  the  ear  bars  were  removed,  the  rat  was  disconnected  from  the  ventilator  and 
immediately transferred back into the operating theatre where it was reconnected to the 
ventilator to maintain anaesthesia. The dose of isoflurane was reduced to 1% to aid the 
speed of recovery when anaesthesia was withdrawn. The suture of the right hindlimb was 
cut and the tissue was pulled back to reveal the femoral artery. The ligatures were cut and 
the cannula was removed. The vessel was sealed by electrocoagulation using diathermy 
probes. The hindlimb wound was then re-sutured. At this point, the isoflurane and nitrous 
oxide were turned off and the rat was allowed to breathe 100% oxygen for a period of 15-
20 minutes to aid recovery from anaesthesia. When the rat had been breathing against the 
ventilator for around 5 minutes, the intubation tube was disconnected from the ventilator. 
If the rat continued to breathe unassisted for another 5 minutes then the intubation tube was 
carefully removed. However, if the animal‟s breathing was inconsistent, then the intubation 
tube was reconnected to the ventilator until it could breathe unaided. Once the rat was 
recovering from the effects of anaesthesia and was attempting to move, it was transferred 
to a recovery cage. The cage was lined with absorbent pads instead of sawdust, which may 
irritate the wounds of the rat. Bedding and a cardboard tube were also placed in the cage to 
enrich the rat‟s environment with free access to water and soft diet. The soft diet consisted 
of rat chow pellets with had been softened with warm water and mixed with egg custard 
and rice baby food (Heinz). All animals were individually housed following surgery and 
their general condition was assessed at least 4 times throughout the working day and was 
recorded.   101 
                       
 
At 24 hours following surgery, animals were re-anaesthetised and transferred to the MRI 
scanner where anaesthesia was maintained via a face mask (2% isoflurane in 70/30 N20/02 
mixture) and a RARE T2 weighted sequence was acquired to allow calculation of final 
infarct  volume  (Chapter  2.2.3).  Animals  were  then  sacrificed  by  perfusion-fixation 
(Chapter 2.1.3). 
 
3.2.4  MRI Data Analysis 
 
Quantitative  ADC  maps,  in  units  of  square  millimetres  per  second,  were  generated  in 
Paravision 5 software and subsequently processed using Image J software to produce an 
ADC map for each of the 8 coronal slices. Quantitative CBF maps (ml/100g/min) for each 
of  6  coronal  slices  were  generated  at  each  time  point  using  the  following  equation 
(Williams et al, 1992): 
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where  is the inversion pulse efficiency (0.8),  is the blood tissue partition function 
(assumed to be 0.9).  S
control and S
label   are the signal intensity from the control and labelled 
images,  acquired  with  inversion  pulses  applied  above  the  head  and  in  the  neck, 
respectively.  
 
The labelled ASL image was subtracted from the control image and the resulting image 
was then divided by the control image to produce a relative CBF map. The relative CBF 
map was then divided by the T1 map of the same coronal slice to produce a quantitative 
CBF map in units of millilitres per 100g of tissue per min (ml/100g/min).  
 
Final infarct at 24 hours post-stroke was defined and calculated as previously described 
(Chapter 2.2.3).The hyperintense area was manually delineated on the T2     slices which 
anatomically corresponded to the 6 ADC (slices 2-7) and CBF slice maps and multiplied 
by the slice thickness. The final infarct volume was then corrected for brain swelling and 
compression  of  the  contralateral  hemisphere.  Final  infarct  was  also  expressed  as  a 
percentage of the ipsilateral hemisphere (%HLV) to correct for any differences in brain   102 
volume  between the strains (Gerriets et al 2004). The  following  equation was used to 
define the %HLV and correct for oedema (Gerriets et al, 2004): 
 
 
 
 
The absolute ADC threshold for each rat was determined by applying a range of increasing 
threshold values to the quantitative ADC maps acquired at 4 hours post-MCAO to generate 
ADC-derived lesion volume across the 6 coronal slices. This was achieved by manually 
delineating the ipsilateral and contralateral hemispheres on each coronal slice and using the 
histogram function within Image J to count the number of pixels within a given range for 
both hemispheres on each slice (0-2 x 10
-3 mm
2/sec for ADC).  These data were exported 
to Excel where the ADC threshold was adjusted to count the number of pixels below each 
threshold. The total  number of pixels across the 6 slices was converted to an  area  by 
multiplying the number of pixels by the area of a pixel (0.0678mm
2) and lesion volume 
was calculated by multiplying the total area by slice thickness (1.5mm). The threshold 
value  which  generated  a  lesion  volume  which  was  equal  to  the  oedema-corrected  T2 
derived  final  infarct  volume  across  the  same  anatomically  matched  coronal  slices  was 
identified as the specific ADC threshold for each rat. The same technique was used to 
define the absolute CBF threshold  for each rat, where Image J was used to count the 
number of pixels within the range of -100-400ml/100g/min. Negative perfusion  values 
were generated in some pixels with low or zero flow as a consequence of subtracting the 
magnitude images (S
control, S
Label), where the signal difference was comparable to image 
noise (Karlsen et al, 1999).  These negative ASL-derived CBF values were assumed to 
represent zero flow.   
In  Excel,  the  CBF  threshold  was  adjusted  until  the  volume  of  the  threshold  defined 
perfusion deficit on the 4 hour quantitative CBF maps across 6 coronal slices, matched the 
volume of the corrected final infarct (Figure 3-1). The 4 hour post-MCAO time point was 
used to match the ADC and CBF lesion volumes with the 24 hour final infarct volume as 
previous studies have shown that the DWI defined ischaemic core has 
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Figure 3-1. ADC and CBF thresholds adjusted to match the volume of ischaemic injury and 
perfusion deficit with the T2 defined final infarct at 24 hours post-MCAO. The data presented 
are from a representative WKY rat and show the ADC and CBF thresholds applied to quantitative 
ADC and CBF maps of a coronal slice acquired at 4 hours post-MCAO. The ADC threshold defines 
ischaemic injury (shown in white) and the CBF threshold defines the perfusion deficit (shown in 
red). The T2 defined infarct is delineated in red outline. 
 
 
fully evolved by 3 hours post-MCAO and correlates well with final infarct at 24 hours 
post-MCAO (Reith et al, 1995; Li et al, 2000). Therefore, in the present study, we assumed 
that by 4 hours post-MCAO there is no further lesion expansion. The individual ADC and 
CBF thresholds for each rat were compiled to generate mean thresholds for WKY and 
SHRSP.  The  mean  ADC  and  CBF  thresholds  for  each  strain  were  then  applied 
retrospectively to the  quantitative  ADC and  CBF  maps acquired at each time point to 
calculate ADC-derived lesion and PWI perfusion deficit volumes at each time point over 
the first 4 hours following stroke.  
 
Quantitative ADC and CBF values of the contralateral hemisphere were also determined in 
each rat from 1-4 hours post-MCAO using Image J. Using quantitative ADC and CBF 
maps at each time point, the ADC and CBF values of each pixel across the contralateral 
hemisphere of the 6 coronal slices were summed and divided by the total number of pixels. 
This generated a mean ADC or CBF value for the contralateral hemisphere for each rat 
from  1-4  hours  post-MCAO.  Pixels  located  in  the  ventricles  of  the  contralateral 
hemisphere were excluded from the calculation to prevent their influence on mean ADC 
and CBF values, since the slow flow of CSF throughout the ventricular system results in 
high ADC and low CBF values which are not representative of the parenchyma. The ADC 
and CBF thresholds for each rat were then expressed as the percentage reduction from   104 
contralateral ADC and CBF respectively, at 4 hours post-MCAO. The relative ADC and 
CBF thresholds for each rat were then compiled to generate mean relative ADC and CBF 
thresholds for each strain. 
 
In addition, total brain volume was determined in each rat from 1-4 hours post-MCAO 
using Image J software. The area of the ipsilateral and contralateral hemisphere on each of 
the 6 coronal slices was manually delineated to determine the volume of the ipsilateral and 
contralateral  hemispheres.  These  volumes  were  added  together  to  calculate  total  brain 
volume across the 6 slices. 
 
3.2.5  Statistical Analysis 
 
All statistical analyses were undertaken using GraphPad Prism software and all data are 
presented as mean ± SD. An unpaired t-test was used to assess potential strain differences 
in mean systolic blood pressure, final infarct volume, % HLV and threshold values. The 
temporal  evolution  of  ischaemic  injury,  perfusion  deficit,  physiological  parameters, 
hemispheric  volume  and  contralateral  CBF  for  each  strain  were  assessed  by  Repeated 
Measures  ANOVA,  with  Bonferroni‟s  multiple  comparisons  post-test.  Temporal 
comparisons between strains were assessed by 2-way ANOVA with Bonferroni‟s post-test. 
Level of statistical significance was set at p<0.05. All analyses were undertaken blind to rat 
strain. Each rat was given a numbered code which was only broken on the completion of 
all data analysis. 
 
 
3.3  Results 
 
 
3.3.1  Mortality and Excluded Animals 
 
 
Two out of twelve WKY rats and five out of fifteen SHRSP rats died overnight before final 
infarct could be determined by T2 weighted imaging at 24 hours post-MCAO. Examination 
of the brains of the rats which died revealed large infarcts with extensive brain swelling. 
Another SHRSP rat was sacrificed during the acute phase following stroke when DWI 
revealed that the animal had suffered a spontaneous stroke prior to middle cerebral artery 
occlusion.  A  WKY  rat  was  also  excluded  as  DWI  showed  a  small  subcortical  lesion, 
indicating  incomplete  occlusion  of  the  middle  cerebral  artery.  This  animal  was  then 
euthanased. Therefore, the ADC and CBF thresholds were generated from the animals   105 
which  successfully  recovered  until  24  hours  post-MCAO  and  demonstrated  complete 
occlusion of the middle cerebral artery, where both cortical and subcortical injury was 
evident (WKY: n=10, SHRSP: n=10). However, the calculated  thresholds were applied 
retrospectively  to  all  rats  to  determine  the  acute  evolution  of  ischaemic  injury  and 
perfusion deficit (WKY: n=12, SHRSP: n=15). 
 
3.3.2  Systolic BP and Physiological Parameters 
 
 
All SHRSP rats were severely hypertensive compared to the normotensive control strain 
WKY  in the weeks prior to the induction of experimental stroke. Mean systolic  blood 
pressure  was  significantly  higher  in  SHRSP  (183±12mmHg,  n=15)  than  WKY 
(133±9mmHg, n=12, P<0.0001) (Figure 3-2). All of the WKY rats used in the present 
study were normotensive and mean systolic pressure recorded for each rat ranged from 
117mmHg to 147mmHg. All of the SHRSP rats in the present study demonstrated severe 
hypertension, with mean systolic blood pressure ranging from 165mmHg to 202mmHg. 
 
Throughout the duration of surgical procedures and the 4 hour MRI scanning period, all 
physiological parameters were maintained within physiological range in both WKY and 
SHRSP (P>0.05, Table 3-1). All parameters were comparable between the strains during 
the  entire  experimental  procedure  (P>0.05),  with  the  exception  of  mean  arterial  blood 
pressure and arterial PO2, which were significantly higher in the hypertensive strain at all 
time points (P<0.05). It is unknown why arterial PO2 was higher in SHRSP as the same 
anaesthetic regime and ventilation parameters were used for all rats in the study and were 
adjusted as necessary. In WKY rats, MABP ranged from 85±5mmHg to 93±7mmHg and 
in  SHRSP  rats  MABP  ranged  from  105±10mmHg  to  109±10mmHg,  illustrating  that 
arterial  blood  pressure  was  kept  within  a  narrow  range  throughout  the  experimental 
procedure.  
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Figure  3-2.  Mean  systolic  blood  pressure  of  WKY  and  SHRSP  rats.  Mean  systolic  blood 
pressure was measured in WKY (n=12) and SHRSP (n=15) rats using the non-invasive tail cuff 
method. Mean systolic blood pressure was measured at least 3 times weekly prior to experimental 
stroke. The data presented show the mean systolic blood pressure of each rat as measured over 
the 3 weeks prior to stroke surgery. *p<0.0001, unpaired t test. 
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Physiological 
Parameter                  
Baseline  1 hour  4 hours 
WKY       
Body Temp 
(
oC)  
36.9±0.4  37.0±0.5  37.0±0.3 
MABP 
(mmHg) 
85±5  92±7  89±7 
Heart Rate 
(bpm) 
342±23  351±25  358±19 
Blood pH  7.42±0.04  7.35±0.04  7.37±0.03 
PaO2  (mmHg)  119±18  119±23  124±19 
PaCO2  
(mmHg) 
39±6  44±5  41±6 
SHRSP       
Body Temp 
(
oC) 
36.8±0.4  37.1±0.3  37.0±0.4 
MABP 
(mmHg) 
109±10  106±9  107±10 
Heart Rate 
(bpm) 
348±28  358±33  359±20 
Blood pH  7.43±0.06  7.40±0.04  7.41±0.03 
PaO2  (mmHg)  147±27  158±31  148±24 
PaCO2  
(mmHg) 
39±4  41±7  38±3 
 
 
 
Table 3-1. Physiological parameters of anaesthetised WKY (n=12) and SHRSP (n=15) measured 
prior to permanent middle cerebral artery occlusion (baseline) and 1 and 4 hours following surgery. 
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3.3.3  Brain and Final Infarct Volume 
 
 
Brain volume, across the 6 coronal slices, was smaller in SHRSP compared to WKY but 
the difference in brain volume between strains was not statistically significant at any time 
point from 30 minutes to 4 hours post-MCAO (P>0.05). There was also no evidence of 
brain  swelling  in  the  acute  phase  in  either  strain,  as  brain  volume  did  not  change 
significantly over the 4  hour time course. In  WKY,  brain  volume was stable  from 30 
minutes  (1115±55mm
3)  to  4  hours  post-MCAO  (1115±54mm
3,  P=0.56).  Similarly  in 
SHRSP, brain volume was also unchanged from 30 minutes (1063±30mm
3) to 4 hours 
post-MCAO  (1060±33mm
3,  P=0.17).  The  volume  of  the  ipsilateral  hemisphere  was 
unchanged from 30 minutes to 4 hours post-MCAO in both WKY and SHRSP (P>0.05). In 
WKY, the  volume of the  ipsilateral  hemisphere was relatively  stable  from 30  minutes 
(560±28mm
3) to 4 hours post-MCAO (564±29mm
3, P>0.05). Similarly, in SHRSP, the 
volume of the ipsilateral hemisphere was maintained from 30 minutes (543±16mm
3) to 4 
hours post-MCAO (547±15mm
3, P>0.05). 
 
SHRSP demonstrated a significantly larger infarct volume at 24 hours post-MCAO than 
WKY  (387±55mm
3  vs  303±59mm
3,  P=0.004,  infarct  volume  of  SHRSP  and  WKY, 
respectively,  Figure 3-3A). Expressed  as  a percentage of  the  ipsilateral  hemisphere,  in 
SHRSP, 72±9% of the ipsilateral hemisphere was infarcted, compared to 53±10% in WKY 
rats  (P=0.0002,  Figure  3-3B).  Difference  in  infarct  volume  between  strains  was 
particularly evident in the more caudal brain slices, where the infarct area was substantially 
larger in SHRSP compared to WKY (Figure 3-4). In SHRSP, the infarct extended further 
in the rostral and caudal planes than demonstrated in WKY. Substantial swelling of the 
ipsilateral hemisphere was evident in both strains by 24 hours post-MCAO in addition to 
compression  of  the  contralateral  hemisphere.  Ipsilateral  swelling  and  contralateral 
compression were observed to a greater degree in the hypertensive strain (Figure 3-4). 
 
3.3.4  Strain Specific Perfusion and Diffusion Thresholds 
 
The mean ADC value of the whole contralateral hemisphere across the 6 coronal slices was 
not significantly different between the strains and did not change significantly over the 4 
hour time course. In WKY, mean contralateral ADC was 0.76±0.02 x 10
-3 mm
2/sec at 1 
hour post-MCAO and was not significantly different at 4 hours (0.77±0.01 x 10
-3 mm
2/sec, 
P>0.05). Similarly, in SHRSP, mean contralateral ADC was maintained at 0.76±0.01 x 10
-3 
mm
2/sec from 1-4 hours post-MCAO.    109 
 
 
 
 
 
 
Figure 3-3. Final infarct in SHRSP and WKY rats at 24h following permanent occlusion of the middle cerebral artery. Final infarct was expressed as a volume 
(A) and as a percentage of the ipsilateral hemisphere (B). Both methods were corrected for swelling of the ipsilateral hemisphere and compression of the contralateral 
hemisphere. Horizontal line denotes the mean. *P<0.01, unpaired t tests. WKY; n=10, SHRSP; n=10.  
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Figure 3-4. The spatial distribution of infarct area at 24h post-stroke in SHRSP and WKY rats following permanent MCAO. Representative MRI T2-weighted 
images are shown for each strain to illustrate the spatial distribution of the infarct at 24h post-MCAO. The 8 coronal slices shown are representative of the rostro-
caudal extent of the territory supplied by the MCA which was examined using T2-weighted imaging. The infarct area was determined by manually delineating the 
hyperintense area on each of 16 coronal T2 slices. Infarct volume was determined across the T2 slices which anatomically matched the 6 coronal slices used to 
calculate the ADC-derived lesion and the CBF-defined perfusion deficit. Eight of the sixteen slices are shown, with and without the infarct outlined in red.    111 
The  absolute  ADC  threshold  for  WKY,  determined  from  final  infarct  volume,  was 
0.61±0.03 x 10
-3 mm
2/sec, representing a 21±4% reduction from mean contralateral ADC 
at 4 hours post-MCAO.  The calculated ADC threshold for the hypertensive strain was 
0.59±0.03  x  10
-3  mm
2/sec,  which  represents  a  23±4%  reduction  from  the  mean 
contralateral ADC  value. Both the absolute and the % reduction ADC thresholds were 
comparable between the strains (P>0.05, Figure 3-5A).  
 
Mean contralateral CBF was not significantly different between WKY and SHRSP and did 
not  change  significantly  over  the  4  hour  time  course  in  either  strain.  In  WKY,  mean 
contralateral  CBF  remained  relatively  stable  from  135±23ml/100g/min  at  1  hour  post-
MCAO to 124±21ml/100g/min at 4 hours (P=0.1). In SHRSP, mean contralateral CBF was 
unchanged from 1-4 hours post-MCAO (113±22ml/100g/min and 116±13ml/100g/min at 1 
hour and 4 hours post-MCAO, respectively, P=0.6).  
The mean CBF threshold determined from final infarct volume in WKY rats was 23±8 
ml/100g/min, which was an 81±7% reduction in flow from the 4 hour contralateral CBF 
value. The calculated CBF threshold for SHRSP was 36±13 ml/100g/min, representing a 
70±9% reduction from 4 hour contralateral CBF. Both the absolute and % reduction CBF 
thresholds were significantly higher for SHRSP than WKY (P<0.05, Figure 3-5B).                       
 
3.3.5  Acute Evolution of Ischaemic Injury 
 
The mean absolute ADC thresholds were applied to the 30 minutes-4 hour ADC maps to 
assess the acute evolution of ischaemic injury in WKY and SHRSP. The thresholded ADC 
maps at 4 hours post-MCAO matched well spatially with the 24 hours T2 infarct in both 
strains. The area of ischaemic injury identified by application of the strain specific ADC 
threshold was comparable to the hypointense areas on ADC maps across the 6 coronal 
brain  slices  being  examined.  Similarly,  the  threshold  defined  areas  of  injured  tissue 
matched well with the hyperintense infarct area on T2 slices (Figure 3-6).  
 
At all time points following MCAO, ADC-derived lesion volume was significantly larger 
in  SHRSP  than  WKY  and  this  was  evident  from  as  early  as  30  minutes  post-MCAO 
(WKY; 203±70mm
3, SHRSP; 336±63mm
3, P<0.001). The ADC-derived  lesion  volume 
increased significantly over the 4 hour time course in both strains (P<0.001, Figure 3-7).  
In SHRSP, ADC-derived ischaemic injury increased from 336±63mm
3 at 30 minutes, to 
410±56mm
3  at  4  hours  post-MCAO.  In  WKY,  the  ADC-derived  lesion  evolved  from 
203±70mm
3 at 30 minutes following stroke, to 311±57mm
3 at 3 hours, at which point the 
lesion volume reaches a plateau. This suggests that using this model of stroke, the    112 
 
 
 
 
 
   
 
Figure 3-5. Strain-specific MRI diffusion (A) and perfusion thresholds (B) calculated in WKY and SHRSP rats following permanent MCAO. Thresholds were 
calculated by adjusting the diffusion and perfusion thresholds on quantitative ADC and CBF maps until the volume of the ADC-derived lesion and the perfusion deficit 
at 4h post-MCAO matched the volume of the T2 defined final infarct at 24h. *p<0.05, unpaired t test.
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Figure 3-6.  Ischaemic injured tissue at 4 hours post-MCAO as determined by strain-specific diffusion thresholds. ADC thresholds were adjusted until the 
ADC-derived lesion matched the volume of the corrected final infarct, defined by manually delineating the hyperintense areas on T2 weighted images at 24h post-
MCAO (shown in red). The data shown are from a representative SHRSP and WKY rat.    114 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-7.  The  acute  evolution  of  ischaemic  injury  in  SHRSP  (n=15)  and  WKY  (n=12) 
following permanent MCAO. Strain-specific ADC thresholds were applied to quantitative ADC 
maps acquired from 30min to 4h post-MCAO to determine the temporal evolution of ischaemic 
injury. *p<0.01, 2-way ANOVA with Bonferroni’s post-test. 
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Figure 3-8. ADC-derived ischaemic injury in SHRSP and WKY rats at 30 minutes following permanent MCAO. Strain-specific ADC thresholds were applied to 
quantitative ADC maps acquired at 30 minutes post-MCAO to assess the spatial distribution of ischaemic injury between strains. The area of ischaemic injury is 
depicted by white shading on 6 coronal brain slices within the territory of the middle cerebral artery. The data presented are from a representative SHRSP and WKY 
rat.   116 
    
    
Figure 3-9. ADC profiles of the ipsilateral hemisphere in SHRSP and WKY rats from 1-4h post-MCAO. The graphs show the mean number of pixels with a 
particular ADC value from 0-1.6 x 10
-3 mm
2/sec. The calculated ADC threshold for each strain is shown by the dotted line, where the SHRSP ADC threshold is shown 
in red (0.59 x 10
-3 mm
2/sec) and the WKY ADC threshold is shown by the blue dotted line (0.61 x 10
-3 mm
2/sec). The data presented show the mean data for each 
strain.
1h post-MCAO  2h post-MCAO 
3h post-MCAO  4h post-MCAO   117 
evolution of ischaemic injury is complete by 3 hours following MCAO in the WKY.  The 
observed greater area of ischaemic injury in SHRSP is particularly evident in the most 
caudal coronal brain slices, especially in slices 2 and 3 (Figure 3-8).  
 
These results are also illustrated by the pixel analysis of ADC maps of the entire ipsilateral 
hemisphere of WKY and SHRSP, where the hypertensive strain had a greater proportion of 
pixels with low ADC values. In both strains, the number of pixels which fall below the 
strain-specific  ADC  threshold  increases  over  time  as  the  ischaemic  core  expands.  The 
ipsilateral  ADC  profile  of  WKY  has  a  biphasic  shape  which  allows  clear  distinction 
between injured and normal tissue. However, this biphasic profile is only evident in the 
SHRSP at 1 h post-MCAO and at later time points the biphasic shape is lost as most of the 
hemisphere becomes incorporated into the core of ischaemic injury (Figure 3-9). These 
ADC profiles demonstrate that ischaemic injury is greater in SHRSP compared to WKY, 
irrespective of the application of a ADC threshold to quantify the  ADC-derived  lesion 
volume.  
 
3.3.6  Acute Evolution of Perfusion Deficit 
 
 
The mean absolute CBF thresholds were applied to the quantitative CBF maps acquired 
from 1-4 hours post-MCAO to determine the acute evolution of the perfusion deficit for 
each strain. There was also good spatial matching between the thresholded 4 hour CBF 
maps and the 24 hour T2 final infarct, where the threshold defined hypoperfused area on 6 
coronal slices matched well with the hyperintense area on corresponding T2 slices (Figure 
3-10).  
 
At  all  time  points  following  stroke,  the  perfusion  deficit  was  significantly  greater  in 
SHRSP than WKY (P<0.001, Figure 3-11). At 1 hour following stroke, a perfusion deficit 
of 368±45mm
3 was observed in SHRSP, compared to 273±69mm
3 in WKY rats (Figure 3-
12). The greater perfusion deficit observed in the SHRSP was particularly evident on the 
caudal slices 2 and 3, where the hypoperfused area was substantially larger (Figure 3-12).  
 
A significant increase in the volume of perfusion deficit over the 4 hour time course was 
observed in both strains. In WKY, the perfusion deficit increased from 273±69mm
3 at 1 
hour  post-MCAO  to  318±65mm
3  by  4  hours  (P<0.001;  Figure  3-11).  In  SHRSP,  the 
volume of perfusion deficit increased from 368±45mm
3 at 1 hour to 411±48mm
3 at 4 hours 
post-stroke (P<0.001). There was no significant difference in the growth of the perfusion  118 
 
 
Figure 3-10. Quantitative CBF maps displaying hypoperfused tissue at 4 hours post-MCAO. CBF thresholds were adjusted until the volume of CBF defined 
perfusion deficit matched the volume of the oedema-corrected final infarct, defined by manually delineating the hyperintense areas on T2 weighted images at 24 hours 
post-MCAO (shown in red). The data shown are from a representative SHRSP and WKY rat.   119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-11.  Temporal  evolution  of  the  perfusion  deficit  following  permanent  MCAO  in 
SHRSP  (n=15)  and  WKY  (n=12)  rats.  Strain-specific  perfusion  thresholds  were  applied  to 
quantitative CBF maps to compare the volume of hypoperfused tissue  between  strains and to 
assess the acute evolution of the perfusion deficit from 1-4h post-MCAO. *p<0.01, 2-way ANOVA 
with Bonferroni’s post-test. 
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Figure 3-12. The perfusion deficit observed in SHRSP and WKY rats at 1h following permanent MCAO. Strain-specific CBF thresholds were applied to 
quantitative CBF maps acquired at 1h post-MCAO to assess the spatial distribution of hypoperfused tissue between strains. The perfusion deficit is depicted by red 
shading on 6 coronal brain slices within the territory of the middle cerebral artery. The data shown are from a representative SHRSP and WKY rat.  121 
     
   
   
Figure 3-13. Cerebral blood flow profiles of the ipsilateral (A) and contralateral hemisphere (B) in SHRSP and WKY rats from 1-4h post-MCAO. 
The figures show the CBF values of each pixel in the ipsilateral and contralateral hemispheres at 1 and 4h post-MCAO. The strain specific CBF thresholds are 
indicated by the dotted vertical lines. The mean SHRSP threshold (36ml/100g/min) is shown by the red dotted line and the WKY threshold (23ml/100g/min) is shown by 
the blue dotted line.
1h post-MCAO  4h post-MCAO 
1h post-MCAO 
A 
B deficit between strains over the first 4 hours post-stroke. In SHRSP, the perfusion deficit 
increased by 43±27mm
3 compared to an increase of 48±20mm
3 in WKY (P=0.65). 
 
 These results are also illustrated by the CBF pixel profiles of the ipsilateral hemisphere of 
WKY and SHRSP, where the hypertensive strain had a greater proportion of pixels with 
low CBF values. In both strains, the number of pixels which fall below the strain-specific 
CBF threshold increases over time, as hypoperfused tissue becomes incorporated into the 
perfusion deficit (Figure 3-13A). The CBF profiles also demonstrate that a greater number 
of pixels have a low CBF value compared to WKY, irrespective of the application of a 
ADC  threshold  to  quantify  the  ADC-derived  lesion  volume.  The  CBF  profiles  of  the 
contralateral hemisphere show that the vast majority of pixels have a CBF value above the 
strain specific CBF thresholds (Figure 3-13B). In addition, the contralateral CBF profiles 
are similar between the strains and do not change over time. 
 
3.4 Discussion 
 
This  is  the  first  study  to  define  strain-specific  thresholds  of  diffusion  and  perfusion 
abnormality in a clinically relevant rodent stroke model with recognised risk factors. In-
house ADC and CBF thresholds of abnormality were established for the SHRSP and WKY 
strain  based  on  final  infarct  volume  at  24  hours  post-stroke,  defined  by  T2-weighted 
imaging. The mean calculated thresholds were retrospectively applied to MRI diffusion 
and perfusion data to compare the acute evolution of ADC-derived ischaemic injury and 
CBF defined perfusion deficit in the SHRSP and the normotensive control strain, WKY.  
 
The  calculated  ADC  thresholds  were  comparable  between  the  strains,  with  thresholds 
associated with a 23% and 21% reduction in ADC for SHRSP and  WKY respectively. 
These  thresholds  are  similar  to those  reported  previously  in  Wistar  rats  by  examining 
metabolic failure following MCAO (Hoehn-Berlage et al, 1995; Olah et al, 2001) where an 
ADC threshold of 77% of control corresponds with the breakdown of energy metabolism. 
However, the ADC thresholds calculated in the present study, differ from those determined 
in  Sprague-Dawley  rats  where  a  30%  reduction  in  ADC  was  reported to  predict  final 
infarct volume (Shen et al, 2003; Foley et al, 2010). Similarly, an ADC threshold of 30% 
reduction was reported in male Sprague-Dawley rats within our laboratory, using the same 
methodology as described in the present study (TA Baskerville, unpublished observations). 
Furthermore, using a method similar to the one employed in the present study, Shen and 
colleagues matched the 3 hour lesion volumes with the TTC (2,3,5-triphenyltetrazolium   123 
chloride) defined final infarct at 24 hours post-MCAO in Sprague-Dawley rats and found 
that a 30% reduction in ADC matched final infarct. Similarly, a 30% reduction in ADC 
was determined using the empirical rule (by calculating the mean ± 2SD of the mean ADC 
prior to stroke) in Sprague-Dawley rats (Foley et al, 2010). These studies suggest that the 
threshold for ischaemic injury may be different between rat strains since ADC thresholds 
calculated by various study groups using different methods in Sprague-Dawley rats are 
consistently less severe than those determined in Wistar Kyoto rats.  
 
The  perfusion  threshold  calculated  for  Wistar  Kyoto  rats  in  the  present  study 
(23ml/100g/min) is lower than the perfusion threshold calculated previously in Sprague-
Dawley rats (30ml/100g/min, Shen et al, 2003). In addition, the present study shows that 
the mean CBF threshold was significantly different between SHRSP (70% reduction from 
contalateral CBF) and WKY rats (81% reduction from contralateral CBF). This suggests 
that SHRSP may have a greater sensitivity to ischaemia than the normotensive control 
strain. It has been previously reported that in vitro, cortical neurons from SHRSP are more 
vulnerable in hypoxic conditions than those of WKY, with a significantly greater rate of 
cell death following 36 hours of hypoxia (Tagami et al, 1998).  The strain-specific CBF 
thresholds calculated in the present study from the T2-defined final  infarct at 24 hours 
differ from those previously determined in Wistar rats (Hoehn-Berlage et al, 1995) where a 
40% reduction in ipsilateral CBF was associated with tissue acidosis. Our CBF thresholds 
also differ from those determined previously in Sprague-Dawley rats (Shen et al, 2003) 
where  a  threshold  of  57%  reduction  in  CBF  was  defined.  Furthermore,  data  from  our 
laboratory show that a 63% reduction in CBF predicts final infarct at 24 hours post-MCAO 
in male Sprague-Dawley rats (TA Baskerville, unpublished observations). 
 
One factor which may influence the calculation of CBF thresholds in the present study is 
the  temporal  evolution  of  the  perfusion  deficit.  The  CBF  threshold  was  defined  by 
matching the volume of perfusion deficit to the final infarct but the data show that the 
perfusion deficit increased from 1-4 hours post-MCAO. It was assumed that the volume of 
perfusion deficit would be relatively stable over the 4 hour time course in agreement with 
previous studies where a similar method was used to define perfusion thresholds (Shen et 
al, 2003; Meng et al, 2004). In the present study it was assumed that there would be no 
further recruitment of hypoperfused tissue into the perfusion deficit but this may not be the 
case  and  the  perfusion  deficit  could  expand  beyond  the  4  hour  time  point.  Further 
expansion of the perfusion deficit would render the calculated CBF thresholds invalid as in 
this study the CBF threshold was adjusted until the volume of hypoperfused tissue at 4   124 
hours post-MCAO matched the volume of the final infarct at 24 hours, with the assumption 
that there is no further expansion of the perfusion deficit at later time points. However, 
withdrawal of anaesthesia at 4 hours post-MCAO would result  in an  increase  in  mean 
arterial blood pressure in both strains which may support CBF in the ipsilateral hemisphere 
and prevent further increase in the size of the perfusion deficit. 
 
Many factors can influence the calculation of viability thresholds, including methods used 
(autoradiography, MRI sequences), rat strain, stroke model and surgical technique.  The 
technique used by Shen et al (2003), where ADC and CBF thresholds were established 
after 3 hours of permanent MCAO where the volume of ADC abnormality and perfusion 
deficit matched the volume of the TTC-defined final infarct at 24 hours, has recently been 
criticised. Foley et al (2010) argue that this technique may create bias in their results as it 
assumes that the ADC derived lesion has fully evolved to encompass the entire perfusion 
deficit by 3 hours post-MCAO but later time points were not examined to confirm that 
there was no further growth beyond this time point. This criticism can also be directed at 
the present study, although thresholds were matched at the 4 hours time point instead of the 
3 hour time point used by Shen et al (2003). It would have been desirable to acquire MRI 
data for up to 6 hours to assess the evolution of perfusion deficit and ischaemic injury but 
this would have caused additional problems. Firstly, keeping animals under anaesthetic for 
that length of time is likely to increase the mortality rate and would have reduced the 
likelihood of successful recovery to 24 hours post-MCAO. Mortality rate in SHRSP was 
high when anaesthetic was maintained for 4 hours of MRI scanning, with one in every 
three rats failing to survive, resulting in unacceptable levels of morbidity and mortality. 
Secondly,  after  4  hours  of  permanent  MCAO,  any  further  increases  in  the  volume  of 
perfusion deficit and ischaemic injury is likely to result from vasogenic oedema, as the 
integrity of the blood-brain barrier becomes compromised, resulting in a shift of water 
from the vasculature to the brain (Ayata et al, 2002). Previous work from our study group 
where the MRI scanning procedure was extended to 6 hours post-MCAO in non-recovery 
experiments demonstrated that ADC lesion volume is maximal in WKY and SHRSP by 4 
hours (McCabe et al, 2009). 
 
The present study demonstrates that final infarct, determined at 24 hours by T2-weighted 
imaging, is significantly larger in SHRSP than WKY. This is in agreement with previous 
studies  which  have  reported  an  increased  sensitivity  to  experimental  stroke  in  SHRSP 
(Coyle & Jokelainen, 1983; Jeffs et al, 1997; Carswell  et al, 1999; Marks et al, 2001; 
McGill et al, 2005; McCabe et al, 2009). The present study has also shown that despite   125 
comparable ADC thresholds, ADC-derived ischaemic injury was greater in SHRSP than 
WKY over the initial 4 hour time course. This confirms earlier reports from our laboratory, 
where the ADC lesion was significantly greater in SHRSP compared to WKY from 1-6 
hours post-MCAO (McCabe et al, 2009). McCabe et al (2009) reported that within the first 
hour following permanent MCAO, the volume of ADC derived ischaemic injury in SHRSP 
(275±75mm
3) was significantly larger than in WKY (171±30mm
3, P<0.05) and increased 
significantly over time in both strains (P<0.05).  
 
The extent of ischaemic injury demonstrated in SHRSP in the present study cannot solely 
be attributed to the development of severe hypertension in this strain, since an increased 
sensitivity  to  experimental  stroke  is  observed  in  young  SHRSP  before  the  onset  of 
hypertension (Coyle & Jokelainen, 1983). These authors demonstrated that SHRSP aged 
35-40 days displayed a large cortical lesion following permanent MCAO induced by the 
method of Tamura et al (1981). In age-matched WKY rats, the lesion was significantly 
smaller.  Other  genetic  factors  which  may  contribute  to  increased  ischaemic  injury  in 
SHRSP  include  increased  levels  of  oxidative  stress,  where  it  has  been  reported  that 
superoxide  dismutase  activity  is  reduced  in  SHRSP  compared  to  WKY,  resulting  in 
increased  levels  of  superoxide  anions  (Kishi  et  al,  2004).  More  recently  it  has  been 
demonstrated that levels of 20-hydroxyeicosatetraenoic acid (20-HETE) are twice as high 
in  the  cerebrovasculature  of  SHRSP  compared  to  WKY.    20-HETE  is  a  potent 
vasoconstrictor which contributes to increased stroke sensitivity in SHRSP by mediating 
endothelial  dysfunction  and  increasing  oxidative  stress  by  stimulating  superoxide 
production (Cheng et al, 2008). Inhibition of 20-HETE has been shown to significantly 
reduce infarct volume in SHRSP (Dunn et al, 2008).  
 
A heightened inflammatory response may also have contributed to the increased  infarct 
volume observed in the present study. Previously, Marks and colleagues reported that the 
activation of  microglia  following permanent focal cerebral  ischaemia, was significantly 
higher  in  SHRSP  compared  to  WKY  rats.  In  the  region  of  the  ischaemic  core,  183 
activated microglia were identified per mm
2, compared to 156/mm
2 in WKY rats (Marks et 
al, 2001). Activated microglia can release neurotoxins including oxygen radicals, nitric 
oxide and glutamate, which can lead to lipid peroxidation, oedema and necrosis. 
 
In  addition,  dysfunction  of  the  BBB  may  also  have  contributed  to  the  larger  infarcts 
observed in SHRSP. It has been demonstrated that there is an alteration in the polarity of 
endothelial cells of the BBB prior to stroke onset and this may predispose the SHRSP to   126 
stroke-induced breakdown of the BBB (Lippoldt et al, 2000). This may also contribute to 
the increased brain swelling observed in the hypertensive strain in the present study, where 
swelling of the  ipsilateral  hemisphere and  compression of  the contralateral  hemisphere 
were more apparent in SHRSP than WKY.  
 
The results also show that the CBF-defined perfusion deficit was significantly larger in 
SHRSP compared to WKY from 1-4 hours following stroke. The larger perfusion deficit 
exhibited by the hypertensive strain may be attributable to the higher CBF threshold in 
SHRSP, where a greater volume of tissue will fall below the perfusion threshold, compared 
to WKY rats. A CBF threshold of 50ml/100g/min has been reported previously in the SHR 
rat strain, when ischaemia persists for at least 3 hours (Jacewicz et al, 1992). This study 
highlights that rat strains may have different viability thresholds, particularly those strains 
which have underlying stroke risk factors, like the SHR and SHRSP. In addition, impaired 
blood flow through collateral vessels which connect the three major cerebral arteries in 
each  hemisphere  is  likely  to  contribute  to  the  increased  perfusion  deficit  in  SHRSP. 
Although the number of collateral  vessels  is the same  between the strains,  it has  been 
reported that the internal diameter of anastomoses is reduced in SHRSP, therefore reducing 
vasodilator capacity following MCAO and contributing to the larger infarct size observed 
in the hypertensive strain (Coyle & Heistad, 1987).  
 
Furthermore, the results demonstrate that the perfusion deficit significantly increases from 
1-4 hours following stroke in both the WKY and SHRSP strains. This has been previously 
reported in a previous study from our laboratory, where the perfusion deficit  in SHRSP 
significantly  increased  from  1-6  hours  post-MCAO  (McCabe  et  al,  2009).  This  study, 
which used published ADC and CBF thresholds, examined the area of perfusion deficit on 
a single coronal slice within the territory of the MCA and showed that in SHRSP, the 
perfusion deficit increased from 44±9mm
2 at 1 hour to 49±7mm
2 at 6 hours post-MCAO 
(P=0.01). However, in WKY, the area of perfusion deficit on the same coronal slice was 
unchanged from 1-6 hours post-MCAO. This finding differs from those reported in the 
present study where both the SHRSP and WKY strains display a significant increase in 
perfusion deficit in the acute phase following permanent MCAO. However, McCabe et al 
(2009)  only  examined  CBF  on  a  single  coronal  slice  within  the  MCA  territory  and 
therefore would not have detected any increases in perfusion deficit which may have been 
evident on brain slices located further rostrally and caudally. The increase in perfusion 
deficit which was observed in both strains in the present study was unlikely to result from 
global  changes  in  CBF  as  a  result  of  prolonged  anaesthesia  as  the  data  shows  that   127 
contralateral CBF did not change significantly over the 4 hour time course in either WKY 
or SHRSP.  The  temporal  increase  in  perfusion  deficit  suggests  that there  is  a  gradual 
failure of collateral blood supply over time in SHRSP and WKY rats. This may occur as a 
result  of  disruption  of  the  blood-barrier  barrier,  where  water  will  be  drawn  from  the 
collateral vessels, thereby reducing blood flow to hypoperfused tissue on the boundary of 
the perfusion deficit. As blood flow to this region of tissue declines, it will become more 
severely hypoperfused and will fall below the CBF threshold and consequently become 
incorporated into the perfusion deficit.  
 
It  is  particularly  interesting  that  this  apparent  failure  of  collateral  flow  occurs  in  both 
SHRSP and WKY. It is unsurprising that the perfusion deficit increases over time in the 
hypertensive strain as it is well established that the SHRSP exhibits an impaired collateral 
flow and increased dysfunction of the blood-brain barrier, as previously discussed. Both of 
these factors would therefore contribute to expansion of the perfusion deficit over time. It 
has  been reported that the severity of  blood-brain  barrier disruption and  brain oedema 
correspond  with  the  duration  and  severity  of  ischaemia  (Todd  et  al,  1986).  This  may 
explain why there appears to be evidence of collateral failure in WKY, as despite being 
normotensive, the WKY strain exhibits larger infarcts following permanent MCAO than 
other normotensive strains like the Sprague-Dawley rat. Data from our laboratory show 
that Sprague-Dawley rats, subjected to the same experimental procedure as described in 
this  chapter,  demonstrate  a  final  infarct  volume  of  208±48mm
3,  which  is  significantly 
lower than that observed in WKY rats in the present study (303±59mm
3, P=0.001). In 
Sprague-Dawley  rats  the  CBF  defined  perfusion  deficit  was  relatively  stable  from  1-4 
hours post-MCAO (TA Baskerville, unpublished observations). This  suggests that there 
may  be  structural  or  physiological  differences  between  normotensive  rat  strains  which 
could contribute to the observed differences in the severity of ischaemia between WKY 
and  Sprague-Dawley  rats.  To  date,  the  potential  differences  in  the  structural  and 
physiological characteristics of collateral blood vessels in WKY and Sprague-Dawley rats 
has yet to be examined. The failure of collateral blood supply in WKY suggested by the 
data in the present study, conflicts with previous reports where collateral vessels in WKY 
rats vasodilate to restore flow to levels comparable with the contralateral hemisphere one 
month after permanent MCAO (Coyle & Heistad, 1987). However, these authors used a 
different model of MCAO, where the artery was occluded distally by drilling through the 
skull to expose the  middle cerebral  artery, which was then tied using a  nylon  ligature 
(Coyle, 1982). This model induces the formation of a small cortical lesion and reduced 
brain  swelling  as  a  result  of  craniectomy  and  therefore  the  demands  on  the  collateral   128 
vessels is markedly reduced and collateral blood supply is sufficient to maintain blood 
supply and prevent infarction. 
 
Summary 
In summary, the present study  has defined strain-specific MRI perfusion and diffusion 
thresholds in SHRSP and WKY rats following permanent MCAO. These thresholds were 
retrospectively applied to acute MRI data to assess and compare the temporal evolution of 
ischaemic  injury  and  perfusion  deficit  in  both  strains.  SHRSP  rats  demonstrated  a 
significantly  larger  infarct  at  24  hours  post-MCAO,  confirming  previous  reports  of 
increased sensitivity to experimental stroke in the hypertensive strain. Despite comparable 
ADC thresholds, the absolute CBF threshold in SHRSP was significantly higher, indicating 
a  greater  sensitivity  to  ischaemia  compared  to  WKY.  The  volume  of  ADC-derived 
ischaemic injury and perfusion deficit was significantly greater in SHRSP from 1-4 hours 
post-MCAO and increased significantly over time in both strains.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4. 
A comparison of penumbra calculation methods to identify 
potentially salvageable tissue in SHRSP and WKY rats 
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4.1 Introduction 
 
Positron emission tomography (PET) remains the “gold-standard” imaging modality for 
penumbra  detection,  identifying  penumbral  tissue  on  the  basis  of  specific  metabolic 
parameters (Sobesky et al, 2005) but the radiation exposure, complex logistics and costs of 
PET  limit  its  wider  use.  Perfusion-diffusion  mismatch  is  widely  used  to  identify  the 
penumbra, both in clinical and basic stroke research (Heiss, 2010). In acute stroke, MR 
diffusion weighted imaging (DWI) can identify tissue in which diffusion is restricted as a 
result of cytotoxic oedema,  leading to a reduction  in the apparent diffusion coefficient 
(ADC) value of the tissue. This evidence of brain injury is used within perfusion-diffusion 
mismatch methodology to represent the irreversibly damaged ischaemic core. Perfusion 
weighted imaging (PWI) delineates the perfusion deficit, identifying hypoperfused tissue 
destined to proceed to infarction and the mismatch between the PWI defined perfusion 
deficit  and  DWI  defined  ischaemic  core  is  used  to  provide  an  approximation  of  the 
ischaemic  penumbra:  potentially  salvageable  tissue  with  a  finite  lifespan  which  will 
proceed to infarction over time.  
 
At present, there is no consensus on which MRI measure of cerebral blood flow to use 
clinically or what threshold to apply to determine the perfusion deficit. It has been reported 
that the volume of penumbra quantified by the mismatch technique can vary considerably 
depending  on  the  perfusion  parameter  used to  define  hypoperfused  tissue  (Kane  et  al, 
2007). In a study of 32 patients, these authors demonstrated that the proportion of those 
patients presenting with perfusion-diffusion mismatch varied from 9% to 72% using 10 
different MRI methods to detect the perfusion deficit in each patient. This will impact on 
patient  management  where  the  volume  of  potentially  salvageable  tissue  is  used  to 
determine suitability  for therapy.
  This report highlights the need  for agreement  in the 
method used to identify potentially salvageable tissue in stroke patients in clinical research.  
 
In pre-clinical research there is a notable absence of literature examining the PWI/DWI 
mismatch methodology and studies investigating the use of PWI and DWI data to define 
penumbra are urgently required. In addition, there is a lack of pre-clinical data examining 
the effect of potential neuroprotective strategies on the evolution of the mismatch defined 
penumbra.  In  this  respect,  the  perfusion-diffusion  mismatch  model  has  been  relatively 
underused and may yet prove to be a useful tool in the development of stroke therapies in 
experimental animal models.  
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In experimental stroke models using MRI, mismatch volume is commonly calculated by 
subtracting  the  ADC  lesion  volume  from  the  volume  of  perfusion  deficit  without  any 
anatomical co-registration (Meng et al, 2004; Bråtane et al, 2009; Henninger et al, 2009). 
This  method  provides  no  information  on  the  location  or  spatial  distribution  of  the 
penumbra and therefore may be of limited use when examining the temporal evolution of 
potentially salvageable tissue following experimental stroke. 
 
Furthermore, there  are  limited  data  examining  the  lifespan  of  the  penumbra  in  animal 
models  with  genetic  stroke  risk  factors.  Legos  and  colleagues  reported  that  SHR  rats 
demonstrated no evidence of perfusion-diffusion mismatch as early as 1 hour following 
MCAO. At the same time point, Sprague-Dawley rats exhibited a substantial volume of 
mismatch  tissue  (Legos  et  al,  2008).  Similarly,  Letourneur  and  colleagues  found  that 
perfusion-diffusion  mismatch  volume  was  significantly  reduced  in  SHRs  compared  to 
WKY rats from as early as 30 minutes following permanent focal cerebral ischaemia. An 
alternative  model  of  induced  renovascular  hypertension  in  normotensive  rats,  using  a 
kidney clip procedure was also studied. This group of rats also exhibited a significantly 
reduced mismatch volume compared to normotensive WKY rats (Letourneur et al, 2011). 
 
 At  present,  only  one  study  group  has  compared  the  acute  evolution  of  the  ischaemic 
penumbra in SHRSP and WKY strains but assessment of mismatch was limited to the 
examination of one coronal slice from within the territory of the middle cerebral artery 
(McCabe et al, 2009). Multi-slice determination of  mismatch volume  has  not yet been 
assessed  in  WKY  and  SHRSP.  However,  previous  reports  suggest  that the  extent  and 
lifespan  of  the  ischaemic  penumbra  may  be  reduced  in  SHRSP  compared  to  the 
normotensive control, WKY. 
 
Study Aims 
The  aims  of  the  study  were  firstly,  to  assess  and  compare  three  different  methods  of 
calculating penumbra volume to evaluate the strengths and limitations of each method. The 
second aim was to compare the extent and lifespan of the ischaemic penumbra following 
permanent MCAO in SHRSP and WKY rats.  
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4.2 Methods 
 
4.2.1 Data Analysis 
 
Determination of Penumbra Volume 
The MRI data generated from the study in Chapter 3 were used to assess penumbra in 
SHRSP  (n=15)  and  WKY  (n=12)  rats  following  permanent  MCAO.  Strain-specific 
perfusion  and  diffusion  thresholds  were  applied  to  quantitative  ADC  and  CBF  maps 
acquired over the first 4 hours post-MCAO. This allowed determination of the volume of 
ADC-derived ischaemic injury and the volume of CBF-defined perfusion deficit over 6 
coronal brain slices for both strains at each time point, as previously described in Chapter 
3. Penumbra volume was assessed in 3 ways: 
 
1.  By volumetric perfusion-diffusion mismatch, where the volume of ADC-derived 
ischaemic injury was subtracted from the volume of the perfusion deficit at each 
time point from 1-4 hours post-MCAO. 
 
2.   Spatial assessment of the perfusion-diffusion mismatch was carried out on each of 
the  6  coronal  slices.  Using  Image  J  and  Matlab®  software,  the  strain  specific 
perfusion and diffusion thresholds were applied to the quantitative CBF map and 
ADC map, respectively, for each coronal slice. The ADC-derived area of ischaemic 
injury was overlaid onto the thresholded CBF map and the remaining perfusion 
deficit was manually delineated and measured as mismatch tissue. The ventricles 
were excluded when delineating the mismatch area. The mismatch areas on each 
slice  were  combined  and  multiplied  by  slice  thickness  (1.5mm)  to  generate 
mismatch volume. This was repeated for each time point post-MCAO. 
 
3.  Penumbra  volume  was  determined  by  measuring  the  growth  of  the  volume  of 
ADC-derived  ischaemic  injury over time. This  was achieved  by subtracting the 
ADC-derived lesion volume at each time point, from 30 minutes to 4 hours post-
MCAO, from the final infarct at 24 hours, defined by T2 weighted imaging. ADC 
lesion growth was therefore only assessed in rats which survived to 24 hours post-
MCAO (WKY: n=10, SHRSP: n=10).  
 
All MRI data analyses were undertaken blind to rat strain. The data from each animal 
were identified by a numbered code, which gave no indication as to strain identity. The   133 
code was broken on the completion of all data analysis to allow assessment of potential 
strain differences. 
 
Pixel-by-Pixel Analysis 
Pixel-by-pixel analysis was undertaken to evaluate the ADC and CBF values of each pixel 
of  the  ipsilateral  and  contralateral  hemispheres  across  6  coronal  slices  using  Matlab® 
software (Mathworks Inc). Quantitative ADC and CBF maps were prepared for pixel-by-
pixel analysis using ImageJ software. ROIs of each hemisphere were generated and used to 
split  the  ADC  and  CBF  maps  for  each  coronal  slice  into  ipsilateral  and  contralateral 
hemispheres. The ADC and CBF maps for each of the 6 coronal slices were put together in 
a stack for each hemisphere at each time point from 1-4 hours post-MCAO. The ADC and 
CBF hemispheric stacks for each rat were uploaded into Matlab® and the strain specific 
ADC and CBF thresholds were inserted into the following command: 
 
ThresholdMRI(„ADC_ipsi.tif‟,„CBF_ipsi.tif‟,„ADC_contra.tif‟,„CBF_contra.tif‟,ADC 
threshold,CBF threshold) 
 
Matlab® software defined four tissue compartments: (1) a „normal‟ compartment, where 
pixels had a ADC and CBF value above threshold; (2) a „core‟ compartment, where pixels 
had  a  ADC  and  CBF  value  which  were  below  the  thresholds;  (3)  a  „mismatch‟ 
compartment,  where  ADC  was  above  the  diffusion  threshold  but  CBF  was  below  the 
perfusion threshold; and (4) a „negative-mismatch‟ compartment, where ADC was below 
the threshold and CBF was above the threshold.  
The number of pixels in each compartment in each hemisphere across 6 slices at each time 
point was calculated by Matlab®. This allowed the total area of each compartment to be 
determined by multiplying the total number of pixels by the area of a pixel (0.0678m
2). 
The volume of each compartment was then calculated by multiplying the total pixel area 
by slice thickness (1.5mm). 
 
The mean CBF of the negative mismatch tissue compartment was also assessed at each 
time point for both SHRSP and WKY. For each rat, the area of negative mismatch on each 
slice  was  selected  as  a  region  of  interest  (ROI).  The  ROI  was  then  restored  onto the 
quantitative CBF map of the appropriate slice at the same time point using ImageJ and the 
CBF value of each pixel in the ROI was determined. This was performed for each of the 6 
coronal slices and mean CBF was calculated by summing the CBF value for each pixel and 
dividing by the total number of pixels.    134 
4.2.2 Statistical Analysis 
 
All statistical analyses were undertaken using GraphPad Prism software and all data are 
presented as mean ± SD. The temporal evolution of mismatch volume and ADC-derived 
lesion  growth  for  each  strain  were  assessed  by  Repeated  Measures  ANOVA,  with 
Bonferroni‟s multiple comparisons post-test. Temporal comparisons in mismatch volume 
and ADC-derived lesion expansion between strains were assessed by 2-way ANOVA with 
Bonferroni‟s post-test. A comparison of penumbra volume by the 3 different calculation 
methods for each strain was also assessed by 2-way ANOVA with Bonferroni‟s post-test. 
Level of statistical significance was set at p<0.05. 
 
4.3 Results 
 
In  order  to  examine  the  differences  between  the  three  different  methods  of  penumbra 
calculation, it is important to identify the effect of time on the two components which are 
used to determine penumbra volume; the ADC-derived lesion volume and the perfusion 
deficit. As previously described in Chapter 3, there is a significant increase in the volume 
of ADC-derived ischaemic injury and the volume of the perfusion deficit over the first 4 
hours post-MCAO in SHRSP and WKY. 
 
4.3.1 Volumetric Perfusion-Diffusion Mismatch 
 
Determination of perfusion-diffusion mismatch volume by the simple subtraction method 
revealed a limited volume of penumbra in both SHRSP and WKY, even at the earliest time 
point examined. At 1 hour post-MCAO, mismatch volume was comparable between the 
strains (22±59mm
3 and 31±50mm
3 in WKY and SHRSP respectively, P>0.05, Figure 4-
1A). The volume of perfusion-diffusion mismatch did not change significantly over time in 
WKY.  This  is  likely  to  be  attributable  to  the  temporal  increase  in  perfusion  deficit 
observed in both strains, as the ADC-derived lesion and the perfusion deficit both expand 
over time (see Discussion section for greater detail). In WKY, mismatch volume decreased 
from 22±59mm
3 at 1 hour to 7±34mm
3 at 4 hours post-MCAO (P=0.24). However, in 
SHRSP, mismatch volume decreased significantly from 31±50mm
3 at 1 hour to 1±33mm
3 
at 4 hours post-MCAO (P=0.01). There was no significant difference in mismatch volume 
between the strains at any time point (P=0.63). The data were highly  variable  in  both 
strains, as illustrated by the high standard deviations observed in both WKY and SHRSP at 
all time points post-MCAO (Figure 4-1). 
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Figure  4-1.  Perfusion-diffusion  mismatch  volume  in  SHRSP  and  WKY  rats  following 
permanent MCAO.  Mismatch volume was calculated by a simple subtraction method, where the 
volume of ADC-derived ischaemic injury was subtracted from the volume of perfusion deficit. There 
was no significant difference in mismatch volume between the strains (2-way ANOVA, P=0.63). 
Data are displayed as mean±SD, WKY; n=12, SHRSP; n=15.  
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4.3.2 Spatial Assessment of Mismatch Volume 
 
Pixel-by-pixel analysis of quantitative ADC and CBF maps revealed that the core tissue 
compartment was significantly larger in SHRSP compared to WKY at all time points post-
MCAO (Figures 4-2A, 4-3 & 4-4). At 1 hour post-MCAO, core tissue in SHRSP was 
284±48mm
3 compared to 193±49mm
3 in WKY (P<0.001, Figure 4-2A). The ischaemic 
core expanded significantly from 1-4 hours post-MCAO in both strains. In WKY, core 
tissue  increased  from  193±49mm
3  at  1  hour  to  263±41mm
3  at  4  hours  post-MCAO 
(P<0.001,  Figure  4-2A).  Similarly,  in  SHRSP,  the  ischaemic  core  increased  from 
284±48mm
3 at 1 hour to 354±46mm
3 at 4 hours post-MCAO (P<0.001, Figure 4-2A). The 
differing profiles of the ipsilateral and contralateral hemispheres are illustrated in Figures 
4-4 & 4-5. In the ipsilateral hemisphere, the majority of pixels are located in the „core‟ 
quadrant in both WKY and SHRSP. However, as expected in the contralateral hemisphere, 
the vast majority of pixels are located within the „normal‟ quadrant.  
 
Spatial assessment of perfusion-diffusion mismatch produced larger volumes of penumbral 
tissue in both WKY and SHRSP. At 1 hour post-MCAO, mismatch volume was larger in 
WKY  compared  to  SHRSP  but  this  was  not  statistically  significant  (43±43mm
3  and 
36±15mm
3 in WKY and SHRSP respectively, P>0.05). The volume of perfusion-diffusion 
mismatch decreased over time  in  both WKY and SHRSP. In WKY,  mismatch  volume 
decreased from 43±43mm
3 at 1 hour to its lowest value of 27±24mm
3 at 3 hours post-
MCAO (P=0.15) and mismatch volume at 4 hours was 29±18mm
3. In SHRSP, mismatch 
volume significantly decreased from 36±15mm
3 at 1 hour to 23±19mm
3 at 4 hours post-
MCAO  (P<0.05).  However,  there  was  no  significant  difference  in  mismatch  volume 
between  the  strains  at  any  time  point  post-MCAO  (P=0.9,  Figure  4-2B).The  spatial 
distribution of mismatch tissue was similar in WKY and SHRSP. In both strains, mismatch 
tissue  was  mainly  located  in  the  cortex.  Perfusion-diffusion  mismatch  was  particularly 
evident on the rostral and caudal slices, where a larger mismatch area was exhibited on 
caudal slices 2 and 3 in both WKY and SHRSP. There was also evidence of mismatch on 
the  most  rostral  slice  (slice  7)  in  both  strains.  However,  there  was  little  evidence  of 
mismatch tissue on coronal slices 4, 5 and 6 and this was particularly evident in SHRSP 
(Figure 4-3). In both strains, there was evidence of a limited volume of existing perfusion-
diffusion mismatch at 4 hours post-MCAO.  
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Figure 4-2. Pixel-by-pixel analysis of ADC and CBF values following permanent MCAO in SHRSP & WKY rats. Pixel-by-pixel analysis defined the ischaemic 
core, where pixels fall below the strain specific ADC and CBF thresholds (A). Mismatch was defined where pixels had an ADC value above threshold but CBF fell 
below the strain-specific CBF threshold (B). Data are presented as mean±SD, WKY; n=12, SHRSP; n=15. *p<0.0001, 2-way ANOVA with Bonferroni’s Multiple 
comparisons post-test. 
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Figure 4-3. Pixel-by-pixel analysis of ADC and CBF values in WKY and SHRSP following permanent MCAO. The data shown are from a representative SHRSP 
and WKY rat. Pixel-by-pixel analysis identified four tissue compartments: normal tissue, where ADC and CBF values are above threshold; core tissue (blue shading), 
where ADC and CBF are below threshold; perfusion-diffusion mismatch (yellow shading), where ADC is normal and CBF is below threshold and negative mismatch 
(orange shading), where CBF is normal and ADC is below threshold. Note the larger ventricles in WKY compared to SHRSP.  
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Figure 4-4. Pixel-by-pixel analysis of ADC and CBF values in the ipsilateral hemisphere at 1 hour following permanent MCAO. The data shown are from a 
representative WKY (A) and SHRSP (B). The mean ADC and CBF thresholds for each strain are shown by the dotted lines. Pixels are assigned to one of four 
quadrants depending on their ADC and CBF value: normal, core, mismatch or negative mismatch. 
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Figure 4-5. Pixel-by-pixel analysis of ADC and CBF values in the contralateral hemisphere at 1 hour following permanent MCAO. The data shown are from a 
representative WKY (A) and SHRSP (B). The mean ADC and CBF thresholds for each strain are shown by the dotted lines. Pixels are assigned to one of four 
quadrants depending on their ADC and CBF value: normal, core, mismatch or negative mismatch. 
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4.3.3 Negative Mismatch 
 
Pixel-by-pixel  analysis  also  revealed  evidence  of  negative  mismatch  tissue,  where  the 
ADC-derived lesion expands outside the boundary of the perfusion deficit, in both WKY 
and SHRSP (Figures 4-3 & 4-4). Negative mismatch tissue was identified in both strains at 
all time points following MCAO. Greater negative mismatch volumes were recorded in 
WKY but differences between the strains were not statistically significant. At 1 hour post-
MCAO, negative mismatch volume was 55±17mm
3 in WKY compared to 41±19mm
3 in 
SHRSP (P>0.05, Figure 4-6). The volume of negative mismatch tissue was persistent and 
did not change significantly over the 4 hour time course in either strain (P>0.05, Figure 4-
6). In WKY, negative mismatch volume was maintained from 55±17mm
3 at 1 hour to 
53±20mm
3 at 4 hours post-MCAO (P>0.05). In SHRSP, mismatch volume persisted from 
41±19mm
3 at 1 hour to 42±11mm
3 at 4 hours post-MCAO (P>0.05, Figure 4-6). Negative 
mismatch tissue was identified on all 6 coronal slices and was found sub-cortically at the 
boundary of the ischaemic core in both strains (Figure 4-3). 
 
Analysis of CBF values revealed negative mismatch tissue was significantly hypoperfused 
compared to contralateral CBF in both strains but blood flow was significantly higher than 
the strain specific CBF thresholds (Figure 4-7). In WKY at 1 hour post-MCAO, CBF in 
negative mismatch tissue was 49±4 ml/100g/min compared to 135±23 ml/100g/min in the 
contralateral hemisphere (P<0.001), and significantly higher than the strain-specific CBF 
threshold (23±8 ml/100g/min, P<0.001, Figure 4-7A). Similarly, in SHRSP at the same 
time point, negative mismatch tissue was 71±9 ml/100g/min compared to a contralateral 
CBF  of  113±22  ml/100g/min  (P<0.001),  and  significantly  higher  than  the  SHRSP 
perfusion threshold (36±13 ml/100g/min, P<0.001, Figure 4-7B). 
 
4.3.4 Penumbra determined from ADC-derived lesion expansion 
 
The volume of the ADC-derived lesion increased over time in both strains as the penumbra 
became incorporated into the ischaemic core, until it matched the final (oedema-corrected) 
infarct volume. ADC lesion enlargement can therefore be used to indirectly measure the 
penumbra. Expansion of the ADC-derived lesion decreased with time and by 3 hours post-
stroke, the lesion matched the final (oedema-corrected) infarct volume in both strains. In 
SHRSP, penumbra volume, derived from ADC lesion volume versus final infarct volume, 
was 43±45mm
3 at 30 minutes and decreased in size to 0±44mm
3 at 3 hours post-MCAO 
(P<0.001).  In  WKY,  penumbra  volume  was  106±73mm
3  at  30  minutes,  declining   142 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. The temporal evolution of negative mismatch tissue in SHRSP and WKY rats 
following permanent MCAO. Negative mismatch represents tissue where CBF is above threshold 
and  ADC  is  below  threshold  and  identifies  expansion  of  the  ADC-derived  lesion  beyond  the 
boundaries  of  the  perfusion  deficit.  There  was  no  significant  difference  in  negative  mismatch 
volume between the strains (2-way ANOVA, p>0.05). Data are displayed as mean±SD, WKY;  
n=12, SHRSP; n=15.  143 
 
 
 
 
 
 
Figure 4-7. Perfusion in the region of negative mismatch compared to the contralateral hemisphere in WKY and SHRSP. The dotted line demarcates the mean 
CBF threshold for each strain. Negative mismatch CBF vs contralateral CBF *p<0.001, 2-way ANOVA with Bonferroni’s post-test. Negative mismatch vs strain-specific 
CBF threshold +p<0.001, 1-sample t test. Data are presented as mean±SD, WKY; n=12, SHRSP; n=15). 
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significantly over time to 0±41mm
3 at 3 hours post-MCAO (P<0.001). Penumbra volume 
was significantly higher in WKY compared to SHRSP at 30 minutes post-MCAO 
(43±45mm
3 vs 106±73mm
3, for SHRSP and WKY respectively, P<0.05, Figure 4-8) but 
was not significantly different between the strains at later time points. There was no 
significant difference in penumbra volume between the strains calculated using ADC 
expansion from 1-4 hours post-MCAO (P>0.05, Figure 4-9). 
 
The  ADC-derived  lesion  evolves  in  an  annular  pattern,  whereby  the  lesion  expands 
relatively uniformly at its boundary and expansion of the ADC lesion is evident across all 
6 coronal slices in both WKY and SHRSP. (Figure 4-10).  The ADC-derived lesion and 
perfusion deficit expand in a similar anatomical direction in both strains from 1-4 hours 
post-MCAO (Figure 4-10). 
 
4.3.5 Comparing penumbra calculation methods 
 
Volumetric  analysis  generated  lower  volumes  of  mismatch  tissue  compared  to  spatial 
assessment  in  both  strains  from  1-4  hours  post-MCAO  (Figure  4-11).  However,  this 
difference did not reach the level of statistical significance at any time point. In WKY, 
mismatch volume defined by spatial assessment was 2 fold larger than mismatch volume 
determined by the volumetric method at 1 hour post-MCAO (43±43mm
3 vs 22±59mm
3, for 
spatial  and  volumetric  assessment  respectively,  P>0.05,  Figure  4-11A).  However,  in 
SHRSP at the same time point, mismatch volume identified by spatial assessment was 
comparable  to  the  mismatch  volume  defined  by  volumetric  assessment  (36±15mm
3  vs 
31±50mm
3, for spatial and volumetric assessment respectively, P>0.05, Figure 4-11B). In 
addition, the volumetric data were more variable than the data analysed using the spatial 
method in both WKY and SHRSP. In WKY, the coefficient of variation for the volumetric 
method was 268% compared to 100% for the spatial assessment method at 1 hour post-
MCAO. Similarly, in SHRSP at the same time point, the coefficient of variation was larger 
for the volumetric mismatch method compared to the spatial assessment method (161% vs 
42% for volumetric and spatial assessment, respectively).
 
 
There  was  no  significant  difference  in  penumbra  volume  calculated  by  volumetric  or 
spatial perfusion-diffusion mismatch or ADC expansion from 1-4 hours post-MCAO in 
both strains (P>0.05, Figure 4-11). However, at 1 hour post-MCAO, penumbra volume as 
measured by ADC growth was higher than mismatch volume in both SHRSP and WKY. In 
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Figure 4-8. Growth of ischaemic injury from 30 minutes to 24 hours post-MCAO in SHRSP 
and WKY rats. Line denotes the mean. *p<0.05, Student’s unpaired t test. WKY; n=10, SHRSP; 
n=10. 
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Figure 4-9. Growth of the ADC-derived lesion from 30 minutes to 4 hours post-MCAO. The 
ADC lesion at each time point was  subtracted from final (oedema corrected) infarct volume to 
calculate the volume of penumbra in WKY (n=10) and SHRSP (n=10) following permanent MCAO. 
Data are presented as mean±SD. *p<0.05, 2-way ANOVA with Bonferroni’s post-test.  
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Figure  4-10.  Comparison  of  potentially  salvageable  penumbra  at  1  hour  post-MCAO  as 
determined by perfusion-diffusion mismatch (using pixel-by-pixel method) and ADC lesion 
expansion in a representative SHRSP and WKY rat. Pixel-by-pixel analysis assigns pixels to a 
tissue compartment according to the ADC and CBF value of each pixel. Penumbra volume was 
also defined by growth of the ADC-derived lesion, where penumbra at 1 hour post-MCAO can be 
defined by subtracting the ADC lesion at 1h from the ADC lesion at 4 hours post-MCAO, which 
matches the final infarct at 24 hours. The spatial distribution of the areas of perfusion deficit growth 
from 1-4 hours post-MCAO are also shown. 
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Figure 4-11. Comparison of the 3 methods used to define penumbra in SHRSP and WKY rats following permanent MCAO. Penumbra volume was determined; 
1. by volumetric perfusion-diffusion mismatch, where the volume of ADC-derived ischaemic injury is subtracted from the volume of perfusion deficit (blue, WKY: n=12, 
SHRSP: n=15). 2. spatially, where mismatch area is manually delineated on each of 6 coronal slices to determine total mismatch volume (red, WKY: n=12, SHRSP: 
n=15). 3. by growth of the ADC-derived lesion, where the ADC lesion at each time point from 30 minutes to 4 hours post-MCAO was subtracted from the final, oedema-
corrected infarct volume at 24h (green, WKY: n=10, SHRSP: n=10). 
 
A  B 
WKY  SHRSP WKY, ADC expansion defined penumbra was 65±41mm
3 compared to 43±43mm
3 and  
22±59mm
3 as determined by spatial and volumetric mismatch, respectively, although this 
was not statistically significant (P>0.05, Figure 4-11A). Similarly, in SHRSP at 1 hour 
post-MCAO, ADC expansion-defined penumbra was 41±45mm
3 compared to 36±15mm
3 
and 31±50mm
3 as determined by spatial and volumetric mismatch, respectively (P>0.05, 
Figure 4-11B). At later time points, as penumbra volume, defined by ADC lesion growth, 
declines,  penumbra  defined  by  spatial  assessment  of  mismatch  volume  persists  until  4 
hours.  
 
The  ADC-derived  lesion  evolves  in  an  annular  pattern,  whereby  the  lesion  expands 
relatively  uniformly  at  its  boundary  (Figure  4-10).  The  anatomical  location  of  the 
penumbra  defined  by  this  method  therefore  differs  from  that  identified  by  perfusion-
diffusion mismatch, where the penumbra is found almost exclusively within the cortex 
(Figure 4-10). 
 
4.4 Discussion 
 
Clinical research has recognised the need for a consensus in the method used to identify 
potentially  salvageable  tissue  in  stroke  patients,  as  well  as  the  need  for  universally 
accepted thresholds of tissue abnormality (Bandera et al, 2006). The perfusion-diffusion 
mismatch method of penumbra determination has yet to be validated in clinical and pre-
clinical stroke research.  This study is the first to compare different methods to define the 
ischaemic  penumbra  in  a  clinically  relevant  rodent  stroke  model  with  recognised  risk 
factors. Strain-specific diffusion and perfusion thresholds were retrospectively applied to 
MRI  data  to  define  the  ADC  lesion  and  perfusion  deficit  used  to  calculate  mismatch 
volume (volumetrically or spatially) during the acute phase of stroke in the SHRSP and its 
normotensive  control  strain,  WKY.  In  addition  to  perfusion-diffusion  mismatch,  the 
ischaemic  penumbra  was  determined  indirectly  by  assessing  expansion  of  the  ADC-
derived lesion over time. 
 
Previous studies have reported a reduced volume of penumbral tissue in rat models with 
stroke  risk  factors.  Following  permanent  MCAO  induced  by  intraluminal  filament, 
perfusion-diffusion mismatch was assessed over time in spontaneously hypertensive (SHR) 
and renovascular hypertensive WKY (RH-WKY) and normotensive WKY rats. Mismatch 
volume  was  comparable  in  both  hypertensive  groups  at  30  minutes  post-MCAO 
(66±25mm
3 and 55±17mm
3 in SHR and RH-WKY respectively), however, at the same   150 
time point, normotensive WKY rats exhibited a significantly larger volume of mismatch 
tissue (117±14mm
3, P<0.01) (Letourneur et al, 2011). The mismatch volumes reported by 
this study group are comparable to the volume of penumbra reported in the present study at 
30 minutes post-MCAO using the ADC lesion expansion method, where penumbra was 
significantly  larger  in normotensive WKY compared to the hypertensive SHRSP strain 
(106±73mm
3 and 43±45mm
3 in WKY and SHRSP respectively). However, Letourneur and 
colleagues reported that mismatch defined penumbra volume was significantly larger in 
normotensive WKY compared to SHR and RH-WKY at all time points, from 30 minutes 
to  4  hours  post-MCAO.  This  differs  from  the  findings  of  the  present  study  where, 
penumbra  volume  was  only  significantly  higher  in  WKY  compared  to  SHRSP  at  30 
minutes  post-MCAO  and  at  all  later  time  points  there  was  no  significant  difference 
between the strains, irrespective of the penumbra calculation method used. This suggests 
that there may only be an increased potential for tissue salvage in the WKY within the first 
hour following stroke, compared to SHRSP, where penumbra salvage may be limited at all 
acute time points following permanent MCAO.  
 
Furthermore, Legos and colleagues found no evidence of perfusion-diffusion mismatch in 
SHR  rats  from  1-3  hours  following  permanent  MCAO  and  the  DWI  lesion  at  1  hour 
matched the  final  infarct at 24 hours (Legos et al, 2008). The  authors demonstrated a 
significant mismatch volume in normotensive Sprague-Dawley rats up to 2.5 hours post-
MCAO.  However,  the  SHR  and  Sprague-Dawley  groups  cannot  be  directly  compared 
since  SHRs  underwent  distal  MCAO  by  electrocoagulation  while  Sprague-Dawley  rats 
underwent proximal MCAO by intraluminal filament. Nevertheless, these studies suggest 
that  hypertensive  rat  strains  may  have  a  limited  potential  for  tissue  salvage  following 
permanent MCAO.   
 
Previously,  only  one  study  has  compared  penumbra  in  SHRSP  and  WKY  rat  strains. 
McCabe  and  colleagues  reported  that  perfusion-diffusion  mismatch  was  significantly 
reduced in SHRSP compared to WKY at 1 hour following permanent MCAO (McCabe et 
al,  2009).  However,  mismatch  was  only  assessed  on  a  single  coronal  slice  within  the 
territory of the MCA and this limitation was recognised by the authors. Mismatch area in 
SHRSP was 3±6mm
2 compared to 10±4mm
2  in  WKY (P<0.05). This differs  from the 
present  study,  where  there  was  no  significant  difference  in  mismatch  volume,  defined 
spatially and volumetrically, at 1 hour post-MCAO. The advantage of the present study is 
that the volume of mismatch (rather than area) was assessed across 6 slices covering the   151 
MCA territory and therefore a more accurate assessment of differences in mismatch tissue 
was determined.   
 
Mismatch volume has previously been determined in rodent stroke models by volumetric 
analysis (Meng et al, 2004; Bråtane et al, 2009; Henninger et al, 2009) and by spatial co-
registration of MRI perfusion and diffusion images (Letourneur et al, 2011). In the current 
study,  spatial  assessment  of  penumbra  gave  rise  to  a  small  but  measurable  mismatch 
volume in SHRSP and WKY and although the SHRSP strain demonstrated a significantly 
larger perfusion deficit and ADC-derived lesion, mismatch volume was not significantly 
different  between  strains  from  1-4  hours  post-MCAO.  However,  volumetric  analysis 
revealed a smaller mismatch volume in both strains. It has been reported previously in 
clinical  research,  that  simple  arithmetic  subtraction  of  the  DWI  lesion  from  the  PWI 
defined  perfusion  deficit  underestimates  penumbral  mismatch  by  40%  compared  to 
mismatch calculated by co-registering DWI and PWI (Ma et al, 2009). In addition, these 
authors reported that underestimation of  mismatch  by the simple volumetric  method is 
exacerbated over time, as the ischaemic core expands to encompass the penumbra. 
 
In the present study, pixel-by-pixel analysis revealed the presence of negative mismatch 
tissue,  where  the  ADC-derived  ischaemic  lesion  expands  beyond  the  boundary  of  the 
perfusion deficit. The phenomenon of negative mismatch has been identified previously in 
rodent stroke models
 (Foley et al, 2010; Letourneur et al, 2011). Foley and colleagues 
defined tissue with a low ADC value and CBF above threshold, as a compartment of high-
flow  infarction.  The  term  high-flow  infarction  may  be  misleading  as  tissue  in  this 
compartment  may  be  hypoperfused relative to control CBF  but  is above the perfusion 
threshold (as shown in Figure 4-8). In addition, the tissue cannot be classed as infarct since 
it  is  being  examined  in  the  first  4  hours  following  stroke.  There  is  both  clinical  and 
preclinical evidence that the ADC lesion has the capacity to return to normal ADC values 
following reperfusion within the first few hours following stroke (Minematsu et al, 1992; 
Hasegawa  et  al,  1994;  Kidwell  et  al,  2000).  Nevertheless,  Foley  and  colleagues 
consistently identified tissue which was below their calculated ADC threshold and above 
their  CBF  threshold  in  the  acute  time  period  post-MCAO  in  Sprague-Dawley  rats.  
Similarly, Letourneur and colleagues detected a tissue compartment which they defined as 
inverse  perfusion-diffusion  mismatch,  where  ADC  is  reduced  but  perfusion  is  normal. 
However, this study group only detected inverse mismatch tissue in hypertensive SHRs 
and RH-WKYs and did not identify inverse mismatch tissue in the normotensive control 
strain, WKY (Letourneur et al, 2011). This differs from the results of the present study,   152 
where negative mismatch was identified in SHRSP and in WKY. However, these authors 
demonstrated  evidence  of  inverse  mismatch  tissue  located  subcortically,  in  a  similar 
anatomical location as reported in the present study. 
 
Despite reports of negative mismatch tissue in the preclinical literature, the physiological 
basis of this tissue compartment has yet to be discussed. Negative mismatch tissue may 
potentially  occur  as  a  consequence  of  peri-infarct  spreading  depolarisations  from  the 
ischaemic core, which may increase cellular injury independently of cerebral blood flow, 
therefore extending the outer boundary of injured tissue beyond the perfusion deficit. High 
levels of potassium ions and glutamate in the ischaemic core can actively propagate tissue 
depolarisation, ionic imbalances and glutamate release into adjacent tissue and it has been 
reported that in rats, peri-infarct depolarisations can originate in the striatum (Hartings et 
al, 2003). This may explain the location of negative mismatch tissue observed in this study 
and by others (Foley et al, 2010; Letourneur et al, 2011). Increased levels of potassium 
ions and glutamate can induce vasodilatation, where glutamate acts via several calcium 
dependent  mechanisms  (Drake  &  Iadecola,  2007).  This  may  increase  blood  flow  in 
hypoperfused  tissues  at  the  boundary  of  the  ischaemic  core  and  contribute  to  the 
phenomenon of negative mismatch.  Flow independent infarct growth has been reported 
both  in  human  stroke  patients  (Heiss  et  al,  2001)  and  more  recently,  in  rodent  stroke 
models,  where  at  12  hours  post  MCAO,  9%  of  brain  tissue  was  necrotic  but  did  not 
demonstrate  any  flow  restrictions  (Woitzik  et  al,  2009).  In  addition,  the  extracellular 
concentration  of  excitatory  amino  acids  and  free  radicals  produced  by  severely 
hypoperfused tissue within the  ischaemic  core may  be  increased  by  cytotoxic oedema, 
enhancing the spread of detrimental effects to neighbouring tissue, and contributing to 
expansion of the core (Loubinoux et al, 1997).  This illustrates how the influence of toxic 
mediators is not restricted to their site of origin and can influence tissue which does not fall 
below the critical blood flow threshold. 
 
It has been previously suggested that the phenomenon of negative mismatch arises from 
intersubject variations associated with the use of fixed perfusion and diffusion thresholds 
(Shen et al, 2003). However, the present study demonstrated that although the negative 
mismatch  tissue  compartment  is  hypoperfused  relative  to  the  contralateral  hemisphere, 
blood flow is significantly higher than the CBF threshold calculated for each strain. This 
eliminates  the  possibility  that  negative  mismatch  tissue  arises  solely  as  a  result  of 
inaccuracy in determining perfusion thresholds and suggests that it is a true phenomenon 
which can be detected in acute stroke.    153 
In the present study, negative mismatch tissue is consistently identified in the sub cortex, 
particularly in the region of the caudate putamen and the globus pallidus. This finding is in 
agreement with previous reports, where negative mismatch tissue was found in a similar 
anatomical  location  (Foley  et  al,  2010;  Letourneur  et  al,  2011).  In  the  present  study, 
negative mismatch tissue was consistently identified across all 6 coronal slices. However, 
Letourneur and colleagues only detected inverse perfusion-diffusion mismatch on coronal 
slices  located within the core of the MCA territory, equivalent to slices 4, 5 and 6 as 
defined in the present study. 
The volume of negative mismatch tissue was comparable between the strains and did not 
change  over  time.  This  finding  is  in  agreement  with  Foley  et  al  (2010)  who  recently 
reported  the  persistence  of  negative  mismatch  tissue  over  the  first  4  hours  following 
permanent MCAO.   
 
Although  the  volumetric  analysis  method  can  be  used  to  provide  a  quick  and  simple 
measure of penumbra, the inclusion of negative mismatch tissue by this method limits its 
use, as penumbra volume may be underestimated. Conversely, the volumetric mismatch 
method may overestimate penumbra as the ventricles are included as a component of the 
perfusion deficit. Study groups who have used this method have failed to report whether 
they excluded the ventricles (Meng et al, 2004; Bråtane et al, 2009; Henninger et al, 2009). 
This  may  have  a  major  influence  on  strain  comparisons  of  penumbra  volume.  This  is 
particularly  evident  when  comparing  WKY  and  SHRSP,  since  the  ventricles  are 
substantially  larger  in  WKY,  as  observed  in  the  present  study.  However,  this  did  not 
appear  to  influence  strain  comparisons  in  this  study  as  mismatch  volume  was  not 
significantly  different  in  SHRSP  and  WKY.  However,  it  is  still  an  important  point  to 
consider, as failure to exclude the ventricles could potentially contribute to false positive 
results when comparing perfusion-diffusion mismatch in SHRSP and WKY rat strains.  
 
 In  addition,  the  volumetric  method  provides  no  information  regarding  the  anatomical 
location of penumbra or its extent throughout the territory of the middle cerebral artery. 
Furthermore, there is greater variability in the data analysed using the volumetric method 
compared to spatial assessment of mismatch. This may arise due to intersubject variation in 
the  volume  of  negative  mismatch  tissue  which  is  included  when  using  the  volumetric 
mismatch  method.  The  concept  of  negative  mismatch  does  not  apply  with  the  spatial 
mismatch method since only regions of perfusion deficit which show no ADC abnormality 
are included in the calculation of penumbra. Using this method, the volume and anatomical 
location of the penumbra can be determined throughout the MCA territory and temporal   154 
changes in the evolution of ischaemic injury and the region of hypoperfused tissue can be 
investigated,  making  it  a  much  more  informative  method  than  simple  arithmetic 
subtraction of the two volumes.  
 
Despite its widespread use as a research tool, the mismatch model has been criticised for 
the inclusion of benign oligaemic tissue within the perfusion deficit and for the assumption 
that the diffusion lesion represents irreversibly damaged infarct core, when it has been 
demonstrated that the DWI lesion can be completely or partially reversed if reperfused 
within 3 hours of stroke (Minematsu et al, 1992; Hasegawa et al, 1994; Kidwell et al, 
2000), although more recent data suggest that only a small component of the DWI lesion is 
reversible.  Chemmanam and colleagues reported that only 6 out of 93 stroke patients 
demonstrated minor regions of DWI lesion reversal when acute DWI data was compared to 
subacute  DWI  or  T2  weighted  images  acquired  at  90  days  following  stroke  onset 
(Chemmanam  et  al,  2010).  Criticisms  of  the  PWI/DWI  mismatch  model  led  to  the 
construction of a revised technique where thresholds are used to distinguish between the 
perfusion deficit and benign oligaemic tissue and also recognises that a component of the 
DWI  lesion  may  be  salvaged  and  therefore  comprises  a  component  of  the  penumbra 
(Kidwell et al, 2003). 
 
In clinical research, DWI lesions provide an approximation of ischaemic injury, whereas 
more  often  in  experimental  stroke  research,  the  ADC-derived  lesion  is  favoured. 
Calculating growth of the DWI or ADC lesion over time is an alternative indirect method 
of determining potentially salvageable tissue and this technique has been used in clinical 
research  to  examine  infarct  growth  and  define  penumbra  in  patients  where  perfusion 
imaging was unavailable (Dani et al, 2010). Karonen et al, (2000) reported a significant 
correlation  between  DWI  lesion  growth  and  the  zone  of  hypoperfused  tissue  at  the 
boundary of the iachaemic core, which correlated significantly with infarct growth over the 
following  week  in  16  stroke  patients.  Furthermore,  these  authors  reported  that  infarct 
growth correlated significantly with clinical outcome.   Conversely Butcher et al (2005) 
failed to identify a significant correlation between mismatch volume and infarct growth. 
The correlation between DWI lesion growth and mismatch volume may be dependent on 
the perfusion parameter, as these conflicting studies used different parameters to define the 
hypoperfused region. Karonen et al, assessed tissue hypoperfusion using SPECT, while 
Butcher  and  colleagues  used  contrast  agent  bolus  tracking  to  acquire  MRI  perfusion 
weighted images.  
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The DWI lesion growth method provides a retrospective analysis of penumbral volume as 
the DWI lesion must proceed to infarction to allow salvageable tissue at a particular time 
point post-stroke to be calculated. Therefore, although a useful research tool, this method is 
unsuitable for identifying patients suitable for acute stroke therapy. In addition, Dani et al 
(2010) recognised that this method could potentially overestimate penumbra due to acute 
tissue swelling. However, in the present study, during the acute phase (within the first 4 
hours) there was no evidence of brain swelling, which could influence the calculation of 
lesion growth, as discussed in the previous chapter. 
 
Penumbra as assessed by ADC lesion growth provides no information regarding temporal 
alterations in the volume of perfusion deficit and therefore limits the use of this method. 
Serial imaging in our study revealed an increase in the volume of perfusion deficit over the 
first 4 hours post-MCAO in both SHRSP and WKY, as described in detail in the previous 
chapter. Temporal increases in perfusion deficit of a similar magnitude to the growth in 
ADC lesion will result in a persistence of penumbra volume over time as demonstrated by 
spatial mismatch analysis, with some existing penumbra being recruited into ischaemic 
core, as new tissue is incorporated into penumbra. Differences in the anatomical location 
of the penumbra as defined by the spatial mismatch method and ADC lesion expansion can 
be explained by the increase in perfusion deficit over time. Growth of the ADC-derived 
lesion volume at each time point does not take into account the evolving perfusion deficit 
since it is derived from diffusion data at a later time point or the final infarct volume at 24 
hours. In contrast, spatial assessment of mismatch volume uses the perfusion deficit at that 
each  time  point  and  therefore  provides  a  snapshot  of  hypoperfused  tissue  capable  of 
responding to reperfusion or neuroprotective intervention.  
 
Summary 
The results from this study demonstrate that the hypertensive SHRSP strain may have a 
reduced  potential  for  penumbra  salvage  compared  to  the  normotensive  control,  WKY. 
However, this is only evident within the first hour following stroke onset. At later time 
points, from 1-4 hours post-MCAO, neither strain exhibits a significant penumbra volume 
and there is no significant difference in penumbra volume between the strains, irrespective 
of  the  method  used  to  calculate  penumbra.    The  results  of  this  study  have  also 
demonstrated  that  volumetric  assessment  of  mismatch  determines  a  lower  volume  of 
mismatch tissue, compared to the spatial assessment method, where a measurable volume 
of penumbra is detected in both strains. ADC lesion expansion was also examined but this 
method does not utilise perfusion data and can only be used retrospectively. The method   156 
used to detect penumbra is crucial in pre-clinical MRI research, particularly if assessing 
potential  therapeutic  strategies  to  salvage  penumbra,  and  clinically,  where  penumbral 
volume is used as a criterion for identifying those patients who are most likely to benefit 
from thrombolytic therapy or for recruitment of patients into clinical trials. On the basis of 
the results of the present study, the spatial assessment method is the  most informative 
method of penumbra determination, as it utilises both perfusion and diffusion data and 
allows spatial evaluation of mismatch. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5. 
The effect of NADPH oxidase inhibition with apocynin on 
stroke outcome following permanent and transient ischaemia 
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5.1 Introduction 
 
Oxidative stress pathways are a major mediator of irreversible cellular injury following 
ischaemic  stroke.  Ischaemia  induces  the  generation  of  free  radical  species  which 
overwhelm  the  endogenous  scavenging  capacity  of  cellular  antioxidant  defences.  Free 
radical  species  contribute  to  cellular  injury  by  mediating  enzyme  inactivation,  protein 
denaturation, lipid peroxidation and damage to DNA and cytoskeletal components (Brouns 
& De Deyn, 2009). In addition to the reactive oxygen species, superoxide (O2
-), hydroxyl 
(OH
-)  and  the  non  radical,  hydrogen  peroxide  (H2O2),  a  number  of  reactive  nitrogen 
species are generated following cerebral ischaemia. These include nitric oxide (NO), which 
has a protective role by mediating vasodilatation to increase cerebral blood flow. However, 
increased levels of superoxide under ischaemic conditions reduce the bioavailabity of nitric 
oxide and therefore limit its vasoprotective action. Superoxide and endothelium derived 
nitric  oxide  react  to  form  peroxynitrite  (OONO
-),  which  is  a  highly  reactive  nitrogen 
species which also contributes to cellular injury. 
 
Under normal physiological conditions, superoxide is constitutively produced and can act 
as a cell signalling molecule to influence the tone and proliferation of vascular smooth 
muscle cells (Miller et al, 2006). However, superoxide has poor membrane permeability 
due to its negative charge and it has a very short half life which may limit its direct impact 
on vascular function under normal conditions (Miller et al, 2006). Nevertheless, superoxide 
can promote vasodilatation of cerebral microvessels although under ischaemic conditions, 
it  generally  promotes  vasoconstriction  by  inactivating  endothelial  nitric  oxide  synthase 
(Paravacini et al, 2004). 
 
Until recently, it was widely accepted that under ischaemic conditions, mitochondria were 
the major source of reactive oxygen species, such as superoxide. However, recent evidence 
suggests  that  NADPH  oxidase  is  the  principal  source  of  superoxide  anions  during 
ischaemia (Brennan et al, 2009). NADPH oxidases are a family of enzyme complexes with 
the sole function of generating reactive oxygen species. Each isoform of NADPH oxidase 
is  distinguished  by  the  membrane  spanning  catalytic  subunit  that  it  utilises  to transfer 
electrons from NADPH to molecular oxygen to generate superoxide (Selemidis et al,  
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Figure 5-1. The cellular distribution of NADPH oxidase isoforms in the vascular wall. Nox1, 
Nox2, Nox4 and Nox5 are expressed in endothelial cells (EC). Adventitial fibroblasts express Nox2 
and Nox4 and vascular smooth muscle cells (VMSCs) express Nox1 and Nox4. Reproduced from 
Selemidis et al (2008). 
 
 
 
 
 
 
   160 
2008). Four isoforms of NADPH oxidase are expressed in the vascular wall (Figure 5-1). 
Nox1 is expressed in endothelial and vascular smooth muscle cells; Nox2 is expressed in 
endothelial cells and adventitial fibroblasts; Nox4 is expressed in vascular smooth muscle 
cells, adventitial fibroblasts and endothelial cells and Nox5 is expressed in endothelial cells 
only (Selemidis et al, 2008). In addition, the Nox2 isoform is also expressed in neutrophils, 
macrophages, T cells and platelets. However, the specific role of reactive oxygen species 
derived from each isoform in stroke is unclear (Miller et al, 2006). Localisation studies 
have  demonstrated  that  Nox2  and  Nox4  are  highly  localised  in  the  hippocampus  and 
cerebral  cortex  of  mouse  brain,  with  Nox2  upregulation  following  stroke  reported  to 
contribute to oxidative stress-induced neuronal cell death (Serrano et al, 2003; Vallet et al, 
2005). 
 
The role of NADPH oxidase in the generation of reactive oxygen species during ischaemia 
has made it an important target for neuroprotection and there is great interest in developing 
therapeutic strategies that target NADPH oxidase-derived reactive oxygen species in the 
treatment  of  vascular  disease.  Apocynin  (4‟-hydroxy-3‟-methooxyacetophenone)  is  a 
methoxy-substituted catechol which was originally  isolated from the roots of Canadian 
hemp in the late 1800s. It is capable of crossing the blood brain barrier (BBB) and has low 
toxicity (Tang et al, 2008). It inhibits NADPH oxidase activity by blocking the association 
of cytosolic components (i.e. the  migration of the cytosolic p47phox subunit) with the 
membrane bound catalytic core (Stolk et al, 1994). However, the mechanism of action of 
apocynin is not well understood and it is not yet clear whether it inhibits NADPH oxidase 
directly or by blocking the activity of an upstream element which leads to assembly of the 
enzyme (Selemidis et al, 2008). Furthermore, there is evidence to suggest that apocynin is 
a  pro-drug  and  requires  activation  by  cellular  myeloperoxidase  activity  to  form 
metabolically active diapocynin, before it can inhibit NADPH oxidase subunit assembly 
(Simons et al, 1990; Stolk et al, 1994).  
 
Inhibition of NADPH oxidase by apocynin has been shown to have neuroprotective effects 
in rodent stroke models. However, to date, all the published studies evaluating the efficacy 
of apocynin have used transient ischaemia models and there are no reports of the efficacy 
of  apocynin  treatment  following  permanent  cerebral  ischaemia.  Wang  and  colleagues 
demonstrated the protective effect of apocynin in a global ischaemia-reperfusion model, 
where apocynin protected against oxidative stress in the hippocampus of the gerbil (Wang 
et  al,  2006).  In  a  mouse  transient  focal  cerebral  ischaemia  model,  pre-treatment  with 
apocynin  reduced  brain  superoxide  levels  at  24  hours  post-ischaemia  (Jackman  et  al,   161 
2009).    Significant  improvements  in  stroke  outcome  have  been  reported  following 
apocynin  treatment  in  mouse  ischaemia-reperfusion  models,  where  infarct  volume  has 
been reduced by up to 50% of control groups at 24 hours post-MCAO (Tang et al, 2008; 
Chen et al, 2009). Similar results have been observed in rat ischaemia-reperfusion models. 
Tang and colleagues observed a significant reduction in infarct volume at 24 hours post-
MCAO  following  apocynin  administration  1  hour  hour  after  stroke  onset  in  Sprague-
Dawley  rats.  NADPH  oxidase  activity  and  superoxide  levels  were  also  significantly 
reduced  (Tang  et  al,  2007).  More  recently,  Genovese  and  colleagues  reported  that 
intraperitoneal  administration  of  5mg/kg  apocynin  5  minutes  prior  to  reperfusion 
significantly improved behavioural outcome and reduced both cortical and striatal damage 
compared to vehicle-treated rats (Genovese et al, 2011).  
 
Despite these encouraging reports, there is a lack of pre-clinical studies examining the 
potential neuroprotective effects on animals with stroke risk factors. To date,  only one 
group has evaluated apocynin in an animal model with a known stroke risk factor, in this 
case, age. It was reported that apocynin treatment exhibited a neuroprotective effect in 
young  rats,  however,  when  administered  to  aged  rats,  apocynin  exacerbated  ischaemic 
injury  and  increased  mortality  rate  (Kelly  et  al,  2009).  Furthermore,  NADPH  oxidase 
inhibition with apocynin  has  yet to be evaluated  in rodent stroke models  with genetic 
stroke risk factors, such as hypertension. It is essential that all potential neuroprotective 
therapies are assessed in animal models with stroke co-morbidities before being considered 
for  clinical  trial,  to  improve  the  likelihood  of  a  favourable  outcome  in  human  stroke 
patients. The Stroke Therapy Academic Industry Roundtable (STAIR) recommended the 
use  of  preclinical  models  with  stroke  co-morbidities  following  the  repeated  failures  of 
stroke therapies in clinical trials. The predominant use of homogenous animal models with 
optimised physiological variables is believed to be a factor in the failure of translation from 
bench to bedside (Saver et al, 2009).  
 
Oxidative  stress  in  the  vasculature  has  been  associated  with  genetic  and  experimental 
hypertension. In SHR rats it has been reported that expression of NADPH oxidase subunits 
is increased, as well as increased activity of the enzyme in the vasculature (Zalba et al, 
2000).  This  leads  to  increased  production  of  superoxide  anions  which  can  reduce  the 
bioavailability of nitric oxide by promoting the formation of peroxynitrite (Figure 5-2) 
resulting in dysfunction of the endothelium and impaired vasodilatation (Alexander et al, 
2000). It has also been demonstrated that NO bioavailability is reduced in aged WKY and 
SHRSP compared to young rats. An increase in superoxide production in aged WKY and    162 
 
 
 
 
 
 
 
 
 
Figure  5-2.  The  role  of  oxidative  stress  in  vascular  dysfunction.  Hypertension  induces 
increased expression and activity of NADPH oxidase leading to enhanced production of superoxide 
anions (O2
-) (shown in green) and subsequently, nitric oxide (NO) bioavailabilty is reduced with 
increased formation of peroxynitrite (OONO
-). Increased levels of oxidative stress in hypertension 
contribute to vascular dysfunction by inhibiting endothelium-mediated vasodilatation and increasing 
vascular tone, which exacerbates hypertension. Modified from Didion et al (2008). 
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SHRSP may contribute to the reduced NO bioavailability by scavenging (Hamilton et al, 
2001). In addition, SHRSPs demonstrate increased levels of 20-HETE, which is a potent 
vasoconstrictor which further promotes the generation of superoxide (Cheng et al, 2008;  
Dunn  et  al,  2008).  Increased  levels  of  superoxide  in  SHRSP  also  arise  as  a  result  of 
reduced activity of SOD (Kishi et al, 2004). Furthermore, the activity of endothelial nitric 
oxide synthase (eNOS) is impaired in SHRSP compared to WKY rats (Yoshitomi et al, 
2011).  All  of  these  factors  contribute  to  the  increased  levels  of  oxidative  stress 
demonstrated  by  SHRSP  and  therefore  this  strain  may  be  particularly  amenable  to 
neuroprotection by inhibition of NADPH oxidase with apocynin.  
 
Study Aims 
 
The aims of this study were: 
 
(1) to assess the effects of apocynin treatment on stroke outcome following permanent 
MCAO 
(2) to  assess  the  effects  of  apocynin  treatment  on  stroke  outcome  in  a  model  of 
transient focal ischaemia 
(3) to evaluate the influence of apocynin treatment on the acute evolution of penumbral 
tissue in a rat model displaying known stroke risk factors (SHRSP) using the MRI 
perfusion-diffusion mismatch model 
 
5.2 Methods 
 
5.2.1 Power Calculations 
 
The sample size in each treatment group was determined prior to the commencement of 
each study using a priori power analysis calculator (http://www.stat.ubc.ca/~rollin/st/ssize). 
Based on the reductions in infarct volume with apocynin treatment reported previously 
(Tang et al, 2007; Genovese et al, 2011), to detect a 35% reduction in infarct volume with 
a common standard deviation (σ) of 20, would require a sample size of 6 rats in each 
group, where the type I error rate (α) is 0.05 and the power is 0.80. 
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5.2.2 Apocynin Dosage 
 
Low (5mg/kg) and high dose (30mg/kg) apocynin treatment was evaluated in this study. 
These doses were selected due to the disparity in apocynin dosage reported in previous rat 
studies, where some  study groups administered apocynin  intraperitoneally at a dose of 
50mg/kg  (Tang  et  al,  2007),  while  other  investigators  demonstrated  neuroprotective 
efficacy using smaller doses of apocynin, up to 5mg/kg (Kelly et al, 2009; Genovese et al, 
2011).  
 
Apocynin was dissolved in 0.1% dimethylsulphoxide (DMSO). The vehicle used was 0.1% 
DMSO.  The  rats  in  all  studies  discussed  in  this  chapter  received  5  mg/kg  apocynin, 
30mg/kg apocynin or 1.5ml of 0.1% DMSO (vehicle). In the permanent MCAO study 
(Study  1)  rats  received  treatment  by  intraperitoneal  injection.  In  the  transient  MCAO 
studies (Studies 2 and 3) treatment was administered intravenously. 
 
5.2.3 Randomisation and Blinding 
 
Allocation of rats to treatment group was randomised using a random number generator 
(http://www.randomization.com). Each rat was given a number and the generator randomly 
allocated a treatment of vehicle, low dose or high dose apocynin to each number. A copy 
of this treatment schedule was kept by 3 colleagues within the department. On the day of 
each  experiment, the  rat  was  weighed  and  the  volume  of  5mg/kg  and  30mg/kg  to  be 
administered was calculated and written on the back of an experimental procedures card 
along with 1.5ml of vehicle. Prior to drug administration, one of the three colleagues with 
the treatment schedule would prepare the appropriate drug treatment by drawing up the 
appropriate volume of drug into a 2ml syringe following consultation of the experimental 
procedures card. Sticky tape was then wrapped around the syringe to conceal the volume 
of drug. The unused eppendorfs and the flask containing the vehicle were then returned to 
the  freezer  and  the  fridge  respectively.  These  procedures  ensured  total  blinding  of  the 
treatment administered to each animal. At the end of the experiments, when all behavioural 
assessments had been performed and all data analysis pertaining to stroke outcome had 
been analysed, the treatment administered to each animal was revealed. This prevented any 
bias when analysing the stroke outcome data.  
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5.2.4 Permanent Focal Ischaemia (Study 1) 
 
Male WKY rats (n=24) aged 12-16 weeks and weighing 270-330g were used in this study. 
Rats were randomly allocated to one of the three treatment groups as described previously: 
1.5ml vehicle (0.1% DMSO) (n=8), 5mg/kg apocynin (n=8), 30mg/kg apocynin (n=8). On 
the day prior to surgery, vibrissae evoked forelimb placement was assessed as described in 
Chapter 2 to ensure that rats showed no limb preference or neurological impairment.  
On the day of surgery, rats were initially anaesthetised in an anaesthetic chamber where 
5%  isoflurane  was  administered  in  a  30%/70%  mixture  of  oxygen  and  nitrous  oxide, 
respectively. Once deeply anaesthetised, rats were immediately transferred to a face mask 
where surgical anaesthesia was maintained with 2-2.5% isoflurane delivered in a 30%/70% 
mixture of oxygen and nitrous oxide. The face mask was secured by to the cork surgical 
board using sticky tape. Body temperature was measured by a rectal thermocouple and 
maintained at 37±0.5ºC using an angle poise lamp. The neck of the rat was shaved using an 
electric  shaver  and  permanent  focal  ischaemia  was  induced  as  previously  described 
(Chapter 2.1.2), where a silicon tipped filament (diameter 0.31-0.35mm, length 5-6mm, 
Doccol) was introduced into the external carotid artery and advanced along the internal 
carotid artery to block the origin of the middle cerebral artery. The filament was secured in 
place by electrocoagulation of the incision site located within the external carotid artery 
stump,  using  diathermy  forceps.  The  neck  was  stitched  using  4-0  silk  suture.  Drug 
treatment was then administered at 5 minutes post-MCAO by intraperitoneal injection.  
The rat was then allowed to recover from anaesthesia by delivery of 100% oxygen through 
the facemask. When the rat started to move, it was transferred to a recovery cage lined with 
soft absorbent pads and bedding, with a cardboard tube for environmental enrichment. The 
cage was kept in a small quiet room, where temperature was maintained between 22-24
oC. 
Rats were given a soft diet of baby food mixed with rat chow pellets, with water and solid 
chow pellets freely available. The general condition of the rat was assessed at least 3 times 
on the day of surgery and was recorded.  
At  24  hours  post-MCAO,  functional  outcome  was  assessed  using  the  vibrissae-evoked 
forelimb placement test and the modified Bederson Score, as described in detail in Chapter 
2. Following behavioural assessment, the rat was anaesthetised in an anaesthetic chamber 
(5%  isoflurane  in  70/30  N20/02  mixture)  and  transferred  to  the  MRI  scanner  where 
anaesthesia was maintained via a face mask (2% isoflurane in 70/30 N20/02 mixture) and a 
RARE T2 weighted sequence was acquired to allow calculation of final infarct volume 
(Chapter 2.2.3). The rat was then sacrificed by perfusion-fixation (Chapter 2.1.3).  
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5.2.5 Transient Focal Ischaemia (Study 2) 
 
 Male Sprague-Dawley rats (n=24) weighing 300-350g were randomly allocated to one of 
the three treatment groups: 1.5ml vehicle (0.1% DMSO) (n=9), 5mg/kg apocynin (n=8), 
30mg/kg apocynin (n=7). On the day prior to surgery, vibrissae evoked forelimb placement 
was assessed as described in Chapter 2 to ensure that rats showed no limb preference or 
neurological impairment.  
On  the  day  of  surgery,  rats  were  anaesthetised,  intubated  and  artificially  ventilated 
(Chapter 2.1.1). Rats were then given an  intraperitoneal  injection of 0.4ml of atropine 
sulphate  (600mcg/ml)  to  limit  bronchial  secretions  The  ventral  surface  of  the  right 
hindlimb and the neck were shaved using an electric shaver. The right femoral artery was 
cannulated to allow continuous monitoring of heart rate and MABP (Biopac) with blood 
sampling performed 30 minutes prior to MCAO and 30 minutes post-MCAO to ensure 
blood  pH,  PaCO2  and  PaO2  (Bayer,  Rapidlab  248)  were  maintained  within  the 
physiological  range.  The  right  femoral  vein  was  cannulated  to  allow  intravenous 
administration  of  drug  treatment.  It  was  decided  that  intravenous  administration  was 
preferable to intraperitoneal administration to reduce potential variability in the dose of 
drug delivered and to speed up the drug reaching a therapeutic concentration  in the brain. 
Body temperature was measured by a rectal thermocouple and maintained at 37±0.5ºC by 
an angle poise lamp.  
Transient focal ischaemia was induced as previously described in detail (Chapter 2.1.2). In 
brief,  a  silicon  tipped  filament  was  introduced  into  the  common  carotid  artery  and 
advanced along the internal carotid artery to occlude the proximal origin of the middle 
cerebral artery. Drug treatment was administered at 5 minutes following the induction of 
ischaemia by gradually infusing the drug intravenously over a period of 3 minutes. At 1 
hour post-MCAO, the  intraluminal  filament was removed  by  slowly retracting  it using 
curved edge forceps and the incision point was electrocoagulated using diathermy forceps. 
The neck was flushed with sterile saline to clean the surgical area and was then stitched, as 
previously described (Chapter 2.1.2).   
At this point, the dose of isoflurane was reduced to 1% to aid the speed of recovery from 
anaesthesia at the end of surgery. The ligatures around the right femoral artery were cut 
and  the  cannula  was  removed.  The  vessel  was  sealed  by  electrocoagulation  using 
diathermy probes. The same procedure was performed to remove the venous cannula. Care 
was taken when electrocoagulating the artery and vein to preserve flow within the vessel. 
This was achieved by only electrocoagulating the incision point. Restoration of flow within 
the femoral vessels will aid the recovery and minimise post-operative pain. The hindlimb   167 
incision site was then sutured and the rat was allowed to breathe 100% oxygen for a period 
of 15-20 minutes to aid recovery from anaesthesia before removal of the intubation tube, as 
described previously (Chapter 3.1.3). 
The  rat  was  then  placed  in  a  recovery  cage  with  soft  bedding  and  soft  diet.  General 
condition was assessed at least 4 times daily and was recorded. Behavioural testing was 
performed at 24, 48 and 72 hours post-MCAO. The 18-point neurological score assessment 
was followed by vibrissae-evoked forelimb placement and the modified Bederson score. 
Animals were also weighed following behavioural assessment as an additional indicator of 
general condition. At 72 hours post-MCAO, rats were euthanased in an anaesthetic gas 
chamber and the brain was processed for TTC staining as previously described in detail 
(Chapter  2.2.2).  The  TTC  defined  infarct  volume  was  corrected  for  swelling  of  the 
ipsilateral hemisphere using the following equation (Swanson et al, 1990): 
 
Corrected lesion = volume of contralateral   -  ( volume of ipsilateral – lesion volume) 
        volume                      hemisphere                         hemisphere 
 
 
5.2.6 Effect of Apocynin on the Acute Evolution of Ischaemic Injury in the SHRSP 
(Study 3) 
 
In the third study examining the potential neuroprotective effects of apocynin, 12 SHRSP 
rats aged 16-20 weeks, weighing 250-300g, were used. Mean systolic blood pressure was 
determined in the weeks prior to surgery using tail cuff plethysmography (Chapter 2.4.4). 
Rats were randomly allocated to the vehicle group (n=6) or the 5mg/kg apocynin group 
(n=6). Treatment was administered at 5 minutes post-MCAO, which was 55 minutes prior 
to reperfusion. Only one dose of apocynin treatment was evaluated due to time constraints 
and the lower dose was selected on the basis of the results from the previous ischaemia-
reperfusion study.  
 
Rats were initially anaesthetised in an anaesthetic gas chamber, intubated and artificially 
ventilated  as  previously  described  (Chapter  2.1.1)  and  then  given  an  intraperitoneal 
injection of 0.4ml of atropine sulphate (600mcg/ml) to limit bronchial secretions. The right 
femoral  artery  and  vein  were  cannulated  to  allow  for  continuous  monitoring  of 
physiological parameters and drug administration, respectively. Arterial blood sampling 
every hour ensured blood pH, PaCO2 and PaO2 (Bayer, Rapidlab 248) were maintained 
within  the  physiological  range.  Transient  focal  ischaemia  was  induced  (Chapter  2.1.2)   168 
using a silicon tipped filament (diameter 0.31-0.35mm, length 5-6mm, Doccol) which was 
glued to a 30cm length of 2-0 thread at its distal portion. The ligatures around the common, 
internal and external carotid arteries were tied securely to hold the filament in place and to 
prevent blood loss. The neck was sutured and the length of 2-0 thread was allowed to hang 
freely outside the wound.  At 5  minutes post-MCAO, drug treatment was administered 
intravenously over a 3 minute period.  
ECG leads were positioned on the ventral surface of the chest and the left hindlimb and the 
rat was then immediately transferred to the MRI scanner (Bruker, 7T Pharmascan). The rat 
was secured in the cradle by tooth and ears bars and a 4-channel phased array rat head 
surface receiver coil was placed on the head. Body temperature was maintained during the 
MRI scanning procedure by a heat pad placed over the body and was monitored by a rectal 
thermocouple. 
 
Once a pilot sequence had been obtained to ensure correct geometry, a 4-shot spin echo 
planar  imaging  (EPI)  DWI  scan  (TE=22.5ms,  TR=4000.3ms,  matrix=96x96, 
FOV=25x25mm, 3 directions=x, y, z, B-values=0 and 1000s/mm
2, 8 coronal slices; 1.5mm 
thick) was immediately performed and was repeated at 30 minutes post-MCAO to allow 
quantitative ADC map production and assessment of ischaemic injured tissue. This was 
followed by a time of flight (TOF) angiography scan to ensure that the middle cerebral 
artery had been completely occluded. A DWI scan was acquired just prior to reperfusion, 
at 1 hour post-MCAO. The  filament was then retracted while the rat was  in the  MRI 
scanner. This was achieved by pulling the length of 2-0 thread 1.5cm distally, to retract the 
filament from the origin of the middle cerebral artery to permit reperfusion of the MCA 
territory. A TOF angiography scan was then performed to confirm that the left middle 
cerebral artery had reperfused. This was followed by a DWI scan and further DWI scans 
acquired every 30 minutes following reperfusion until 3 hours post-MCAO.  
 
Perfusion weighted images were acquired using a form of continuous arterial spin labelling 
(cASL) based on a train of adiabatic inversion pulses (Moffatt et al, 2005).
 The sequence 
employs  a  spin-echo  EPI  imaging  module  (TE=20ms,  TR=7000ms,  matrix=96x96, 
FOV=25x25mm, slice thickness 1.5mm, 16 averages, 4 shots) preceded by 50 hyperbolic 
secant inversion pulses in a 3 second train. Inversion pulse frequency offset and gradient 
strength were set to provide 10mm wide label/control bands centred at ±30mm from the 
centre of the imaging slice. PWI were acquired for slices 3-6 of the DWI scan, (as time did 
not permit data acquisition across all 8 slices) and were acquired every hour for 3 hours 
post-MCAO. For quantification of CBF maps, T1 maps were also acquired at each hour   169 
post-MCAO,  using  an  EPI  inversion  recovery  sequence  (TE=20ms,  TR=10000ms, 
matrix=96x96, FOV=25x25mm,  slice thickness  1.5mm, 16 averages, 4 shots, using 16 
inversion times).  
 
At 3 hours post-MCAO, the rat was removed from the MRI scanner and transferred back to 
the operating theatre where surgical anaesthesia was maintained. The sutures in the neck 
were cut and the ligatures around the internal carotid artery and the upper common carotid 
artery  were  loosened  to  allow  the  filament  to  be  removed.  The  incision  site  was  then 
electrocoagulated and the remaining ties were removed. The  neck wound was then re-
sutured  and  the  femoral  arterial  and  venous  cannulae  were  removed  and  the  rat  was 
allowed  to  recover  from  surgery  as  previously  described  (Chapter  5.1.4.).  Behavioural 
testing  was  performed  at  24,  48  and  72  hours  post-MCAO.  T2  weighted  images  were 
acquired at 24 hours and at 72 hours post-MCAO, animals were then euthanased and the 
brain  was  processed  for  TTC  staining  (Chapter  5.1.4).  However,  in  this  study,  the  rat 
brains  did  not  fit  into the  rat  brain  matrix  due  to  extensive  brain  swelling.  Therefore, 
following removal from the skull, brains were rinsed in heparinised saline and put into the 
freezer at -46
oC for 15 minutes. The brains were then cut freehand using a razor blade into 
coronal sections, approximately 2mm thick and TTC staining was then performed.   
 
5.2.7 Data analysis 
 
In  all  studies,  infarct  volume  was  corrected  for  brain  oedema  as  previously  described 
(Chapter 2.2.3). In the permanent MCAO study, final infarct volume was assessed at 24 
hours post-MCAO by manual delineation of hyperintense areas on T2 slices, as previously 
described in detail (Chapter 2.2.3). In the transient MCAO studies, infarct volume at 72 
hours  post-MCAO  was  determined  by  manual  delineation  of  infarcted  tissue  on  TTC 
stained brain slices using Image J software (Chapter 2.2.2).  
The acute serial MRI study data were processed to generate quantitative ADC maps and 
CBF maps (Chapter 3.1.4). The calculated SHRSP ADC threshold of 0.59 x 10
-3mm
2/sec 
(determined in Chapter 3) was applied to the quantitative ADC maps acquired at each time 
point to assess the acute evolution of ischaemic injury over the first 3 hours post-MCAO. 
Similarly, the  in-house strain specific CBF threshold of 36ml/100g/min was applied to 
quantitative CBF maps acquired during ischaemia to determine the volume of perfusion 
deficit.  Perfusion-diffusion  mismatch  was  then  measured  across  coronal  slices  3-6  by 
overlaying  the  area  of  ADC  derived  ischaemic  injury  at  1  hour  post-MCAO  onto the   170 
corresponding thresholded CBF map. The remaining perfusion deficit was measured on 
each slice to calculate mismatch volume, with the exclusion of the ventricles. 
 
5.2.8 Statistical Analysis 
 
In the permanent MCAO study, infarct volume at 24 hours post-MCAO was compared 
across  treatment  groups  using  one-way  ANOVA  with  Bonferroni‟s  post-test.  In  the 
transient ischaemia study in Sprague-Dawley rats, infarct volume at 72 hours post-MCAO 
was  also  compared  across  the  3  treatment  groups  using  one-way  ANOVA  with 
Bonferroni‟s  post-test.  Temporal  changes  in  physiological  parameters  within  treatment 
groups were assessed by a paired t test. Differences in physiological parameters between 
treatment groups over time were evaluated using a 2-way ANOVA with Bonferroni‟s post-
test.  
In the MRI transient ischaemia study, systolic BP, infarct volume and mismatch volume 
were compared between groups using an unpaired test. Temporal changes in physiological 
parameters  within  treatment  groups  were  assessed  by  Repeated  Measures  ANOVA.  
Physiological parameters were compared between treatment groups over time using a 2-
way  ANOVA  with  Bonferroni‟s  post-test.  The  temporal  evolution  of  ischaemic  injury 
between groups was assessed by 2-way ANOVA with Bonferroni‟s post-test. Temporal 
changes in ischaemic injury within each treatment group were evaluated using a Repeated 
Measures ANOVA.  
All  data  are  expressed  as  mean±SD  with  the  exception  of  the  behavioural  data.  All 
behavioural  data  were  expressed  as  median  and  interquartile  range  (IQ)  and  treatment 
groups were compared using a non-parametric Mann-Whitney test or Kruskal-Wallis test 
with Dunn‟s post-test. Temporal changes in behavioural outcome within each group were 
assessed by Repeated Measures ANOVA. 
 
5.3 Results 
 
5.3.1 Study 1: Apocynin Treatment in a Model of Permanent MCAO 
 
5.3.1.1 Excluded Animals 
 
Rats were excluded from data analysis if they died before 24 hours post-MCAO or if the 
filament did not advance fully along the internal carotid artery. Two rats from the vehicle 
treated group were excluded from data analysis. One rat died overnight before 24 hours   171 
post-MCAO and it was suspected that the other rat had an incomplete occlusion of the 
MCAO. During stroke surgery, there was some difficulty in advancing the filament along 
the internal carotid artery and as such the filament did not advance the required 22mm. 
Consequently, the data from this rat was not included in the subsequent data analysis. On 
T2 weighted imaging at 24 hours post-MCAO this animal showed evidence of a very small 
stroke.  Consequently,  the  data  from  this  rat  was  not  included  in  the  subsequent  data 
analysis. 
 
5.3.1.2 Final infarct Volume 
 
MRI T2 defined infarct volume at 24 hours post-MCAO was not significantly different 
between treatment groups.  Infarct volume in the vehicle treated group was 301±46mm
3 
compared  to  289±117mm
3  and  240±106mm
3  for  the  5mg/kg  and  30mg/kg  apocynin 
treated groups, respectively (P=0.47, Figure 5-3A). The data were more variable in the 
apocynin treated groups compared to the vehicle treated group, as illustrated by the high 
standard deviations in the apocynin treated groups. In the apocynin treated groups, there 
was one rat in each group which exhibited a very small infarct. In the 5mg/kg apocynin 
group, one rat had an infarct measuring 71mm
3 and in the 30mg/kg apocynin treated group, 
one rat demonstrated a very small infarct of 25mm
3 (Figure 5-3A). It is not known if this 
was a treatment effect or if the rats had an incomplete occlusion of the MCA.  
 
Infarct  was  also  expressed  as  percentage  of  the  ipsilateral  hemisphere.  There  was  no 
significant difference between the treatment groups (43±6% vs 41±17% and 35±16% for 
vehicle, 5mg/kg apocynin and 30mg/kg apocynin treated groups, respectively, P=0.54).  
Figure 5-4 illustrates the spatial distribution of infarcted tissue in a representative rat from 
each treatment group. In all groups, hyperintense infarct tissue is evident across all 16 T2 
slices and is located in the cerebral cortex and sub-cortex. The anatomical extent of the 
infarct is comparable between the treatment groups. 
 
5.3.1.3 Bederson Score 
 
Functional outcome at 24 hours post-MCAO, as assessed by the modified Bederson scale, 
was  not  significantly  different  between  treatment  groups  (P=0.83,  Figure  5-5A).  The 
median score for the vehicle and 5mg/kg apocynin treated groups was 2 (IQ 2, 3) and the 
median score for the 30mg/kg apocynin group was 3 (IQ 2, 3). The rat in the vehicle group 
which died before 24 hours post-MCAO, was included in the Bederson scale analysis.    172 
 
 
 
     
 
Figure 5-3. Final infarct in vehicle and apocynin treated WKY rats at 24h following permanent MCAO with drug treatment administered at 5 min post-MCAO. 
Infarct volume defined by T2 weighted imaging (A) was not significantly different between vehicle treated (n=6) and 5mg/kg (n=8) or 30mg/kg apocynin treated rats 
(n=8) (One-way ANOVA, P=0.47). Infarct expressed as a percentage of the ipsilateral hemisphere was also not significantly different between treatment groups (One-
way ANOVA, P=0.54). The horizontal line denotes the mean. 
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Figure 5-4. The spatial distribution of infarcted tissue in vehicle and apocynin treated rats following permanent MCAO. MRI T2 weighted images (16 coronal 
slices) were acquired at 24h post-MCAO and the hyperintense area was manually delineated on each slice to determine infarct volume. Eight of the sixteen T2 
weighted images from the median rat from each treatment group are shown with the hyperintense areas delineated (vehicle-green, 5mg/kg apocynin-blue, 30mg/kg 
apocynin-red).  
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Figure 5-5. Functional outcome scores of WKY rats at 24h post-MCAO following vehicle or apocynin treatment. Functional outcome was assessed by a 
modified Bederson Score (A): 0=no observable deficit, 1=forelimb flexion, 2=reduced grip strength, 3=circling, 4=no spontaneous activity, 5=dead. Vibrissae-evoked 
forelimb placement was also used to assess outcome, where the number of successful placements of the contralateral forelimb were scored out of 10 attempts (B). 
The horizontal line denotes the median score. No statistically significant differences were found between groups for both functional tests, P=0.8 (Kruskal-Wallis test). 
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5.3.1.4 Vibrissae-evoked Forelimb Placement 
 
Prior  to  stroke  surgery,  all  rats  scored  10  successful  placements  of  the  contralateral 
forelimb out of 10 attempts. Evaluation of functional outcome using the vibrissae-evoked 
forelimb  placement  test,  revealed  that  there  was  no  significant  difference  between  the 
vehicle and apocynin treated groups at 24 hours post-MCAO. (P=0.78, Figure 5-5B). Most 
rats in all three treatment groups performed poorly and were unable to correctly place the 
contralateral forelimb in 10 attempts (Figure 5-5B). The median score for all treatment 
groups was 0, although 3 rats in the low dose apocynin group and one rat in the high dose 
apocynin group scored at least 4 correct placements out of 10 attempts.  
 
5.3.2 Study 2: Apocynin Treatment in a Model of Transient MCAO 
 
5.3.2.1 Mortality 
 
The mortality rate observed in this study following transient ischaemia, was higher than 
that observed in the previous study following permanent MCAO. Three rats died in the 
vehicle treated group (3/9, 33% mortality), two rats died  following  low dose apocynin 
treatment (2/8, 25% mortality) and one rat died in the high dose apocynin group (1/7, 14% 
mortality). These 6 rats died between 24 and 48 hours post-MCAO and were excluded 
from  data  analysis.  All  infarct  data  and  behavioural  data  are  from  the  animals  which 
survived to 72 hours post-MCAO, with the exception of the Bederson scale, where the rats 
which died are also included. 
 
5.3.2.2 Physiological Parameters 
 
During  anaesthesia,  all  physiological  parameters  were  maintained  within  physiological 
range across the three treatment groups, with the exception of arterial PO2. Arterial PO2 in 
all three treatment groups was significantly  higher than the physiological range of 80-
100mmHg (P<0.05, one sample t-test). This is likely to be attributed to the anaesthetic gas 
mixture, where 30% oxygen is used rather than the 21% oxygen found in air. Within each 
treatment  group,  each  physiological  variable  was  maintained  from  30  minutes  before 
stroke onset to 30 minutes post-ischaemia (P>0.05, paired t test). There were no significant 
differences in any of the physiological variables between treatment groups before or after 
the onset of ischaemia (P>0.05, One-way ANOVA, Table 5-1). No change in mean arterial 
blood pressure was observed following intravenous administration of vehicle or apocynin.   176 
 
 
 
 
  30 min pre-MCAO  30 min post-MCAO 
Vehicle treated group     
      Body Temperature (
oC)  37.2±0.3  37.3±0.2 
                    MABP (mmHg)   101±5  105±7 
                Heart Rate (bpm)  371±30  365±24 
                             Blood pH  7.42±0.03  7.40±0.03 
          Arterial PO2 (mmHg)  161±44  168±49 
       Arterial PCO2 (mmHg)  35±3  37±4 
5mg/kg apocynin 
treated group 
   
      Body Temperature (
oC)  37.0±0.3  36.9±0.3 
                    MABP (mmHg)   101±7  108±6 
                Heart Rate (bpm)  361±19  368±27 
                             Blood pH  7.40±0.06  7.37±0.04 
          Arterial PO2 (mmHg)  163±25  171±29 
       Arterial PCO2 (mmHg)  37±4  36±4 
30mg/kg apocynin 
treated group 
   
      Body Temperature (
oC)  37.1±0.4  37.2±0.3 
                    MABP (mmHg)   102±6  106±7 
                Heart Rate (bpm)  372±19  368±22 
                             Blood pH  7.38±0.04  7.40±0.02 
          Arterial PO2 (mmHg)  176±32  165±37 
       Arterial PCO2 (mmHg)  36±6  37±3 
 
 
Table 5-1. Physiological parameters in vehicle and apocynin-treated Sprague-Dawley rats 
before and after the induction of ischaemia by occlusion of the middle cerebral artery. Data 
presented  as  mean±SD,  n=6  per  group.  MABP-mean  arterial  blood  pressure,  bpm-beats  per 
minute.  177 
5.3.2.3 Final Infarct Volume 
 
TTC defined final infarct volume at 72 hours post-MCAO was significantly lower in low 
and  high  dose  apocynin  treated rats  compared  to the  vehicle  treated  group.  In  vehicle 
treated rats, infarct volume was 112±25mm
3, compared to 40±35mm
3 and 46±31mm
3 in 
5mg/kg  and  30mg/kg  apocynin  treated  rats,  respectively  (P<0.01,  Figure  5-6).  This 
represents a reduction in infarct volume of approximately 60% in the apocynin treated 
groups.  There  were  2  apocynin  treated rats  which  did  not  show  a  reduction  in  infarct 
volume compared to the vehicle treated group. One rat which received 5mg/kg apocynin 
had an infarct volume of 108mm
3 and one rat which received 30mg/kg apocynin had an 
infarct volume of 102mm
3 at 72 hours post-MCAO (Figure 5-6).  The infarcts exhibited by 
these rats were comparable to the infarcts observed in the vehicle treated group.  
In the vehicle treated group, infarcted tissue was observed in the cerebral cortex and the 
sub-cortex. The infarct area extended across the territory of the middle cerebral artery. 
However,  in  the  apocynin  treated  groups,  infarcted  tissue  was  mainly  identified  sub-
cortically and did not extend as far in the rostral caudal plane as observed in the vehicle 
treated group (Figure 5-7). 
 
5.3.2.4 Bederson Score 
 
The Bederson scores of the animals which survived to 72 hours post-MCAO are shown in 
Figure 5-8A. There was no significant difference between treatment groups at any time 
point post-MCAO (P>0.05, Kruskal-Wallis test). The  low dose apocynin treated group 
demonstrated less neurological impairment than the high dose apocynin and vehicle treated 
groups at all time points but did not reach the level of statistical significance (vehicle: 2 
(IQ 2, 3), 5mg/kg: 0 (IQ 0, 3), 30mg/kg: 2 (IQ 0, 3) at 24 hours post-MCAO, P>0.05).  
Furthermore, there was no significant change in score from 24 to 72 hours post-MCAO in 
any of the treatment groups (P>0.05, Repeated Measures ANOVA).  
The scores of the animals which died between 24 and 48 hours post-MCAO are shown in 
Figure  5-8B.  The  vehicle  treated  rats  which  died  were  more  severely  neurologically 
impaired than the apocynin treated rats which died.  
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Figure 5-7. TTC defined infarct volume at 72h post-MCAO in vehicle and apocynin treated 
Sprague-Dawley rats.  Drug treatment was administered intravenously 5 min post-MCAO. The 
intraluminal filament was removed after 1h of ischaemia to allow reperfusion until 72h post-MCAO. 
Line denotes the mean. *p<0.01, One-way ANOVA with Bonferroni’s Multiple Comparisons test. 
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Figure 5-7. Spatial distribution of the TTC defined infarct at 72h post-MCAO in vehicle and apocynin treated Sprague-Dawley rats. Infarcted tissue appears 
white and unaffected tissue stains deep red with TTC.    180 
5.3.2.5 Vibrissae-evoked Forelimb Placement 
 
Prior  to  surgery,  all  rats  scored  the  maximum  of  10  successful  placements  of  the 
contralateral  forelimb  out  of  10  attempts.  There  was  no  evidence  of  neurological 
impairment or limb preference in any of the rats used in this study.  
At  all  time  points  post-MCAO,  rats  which  received  low  dose  apocynin  treatment 
performed better than rats in the vehicle and high dose apocynin groups. However, the 
observed improvement in forelimb placement was not statistically significant at any time 
point  (P>0.05,  Kruskal-Wallis  test,  Figure  5-9).  The  improvement  in  function  was 
particularly evident at 24 hours post-MCAO (vehicle: 3 (IQ 0, 9), 5mg/kg: 8 (IQ 2, 10), 
30mg/kg: 5 (IQ 1, 9), P>0.05).  
In the vehicle treated group, the contralateral forelimb placement score was maintained at 3 
successful placements at 24 and 48  hours post-MCAO. This  improved to 4 successful 
placements out of 10 attempts by 72 hours. However, in the apocynin treated groups, the 
number of successful placements decreased over time. In the low dose apocynin group, the 
number of  successful placements decreased  from 8 at 24 hours to 6 at 72 hours post-
MCAO. Similarly, in the high dose apocynin group, the number of successful placements 
reduced from 5 at 24 hours to 3 at 72 hours post-MCAO. The temporal changes in the 
number of successful contralateral placements were not significant in any of the treatment 
groups (P>0.05, Repeated Measures ANOVA). 
 
5.3.2.6 18-point Neurological Score 
 
There was no statistically significant improvement in neurological score between treatment 
groups. However in the low dose apocynin treated animals there was a trend towards an 
improvement in neurological function at all time points post MCAO (P>0.05, Kruskal-
Wallis test, Figure 5-10A). At 24  hours post-MCAO, the  median  score  in the 5mg/kg 
apocynin group was 14 (IQ 11, 17), compared to 12 (IQ 10, 14) in the 30mg/kg apocynin 
group and 10 in the vehicle treated group (IQ 9, 14), P>0.05).  
It was also observed that the general condition of rats in the low dose apocynin group was 
improved compared to rats in the other treatment groups. Rats in the 5mg/kg apocynin 
group demonstrated more  frequent grooming  behaviour, were generally  more alert and 
exhibited  normal  feeding  behaviours  compared  to  rats  in  the  vehicle  and  high  dose 
apocynin groups. 
   181 
 
 
    
 
Figure 5-8. Evaluation of neurological function using a modified Bederson Scale following transient ischaemia in vehicle and apocynin treated Sprague-
Dawley rats. Rats were tested at 24, 48 and 72h post-MCAO. The median scores and the interquartile range are shown for the animals which survived to 72h post-
MCAO (A) (P>0.05, Kruskal-Wallis test). The 24 hour scores of the rats which died between 24 and 48h post-MCAO are also shown (B).  
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Figure 5-9. Assessment of neurological function following transient ischaemia in Sprague-
Dawley rats using the vibrissae-evoked forelimb placement test. Testing was performed at 24, 
48 and 72h post-MCAO in rats treated with vehicle, low dose or high dose apocynin treatment 
following ischaemia. Data presented as median and interquartile range, n=6 per group. P>0.05, 
Kruskal-Wallis test.  
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Figure 5-10. Assessment of functional outcome following apocynin treatment using an 18 point composite neurological scoring system. Rats were tested at 
24, 48 and 72h post-MCAO (A). A maximum score of 18 is achieved when there is no observable deficit. A score of 3 indicates severe neurological impairment. Data 
presented as median and interquartile range, n=6 per group. P>0.05, Kruskal-Wallis test. A statistically significant inverse correlation was found between final infarct 
volume at 72h post-MCAO and neurological score at 72h for all rats (B). Spearman’s non-parametric correlation, r=-0.51, P<0.05. 
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Neurological  score  at  72  hours  post-MCAO  correlated  significantly  with  final  infarct 
volume  at  the  same  time  point  (P<0.05,  Figure  5-10B).  Using  the  non-parametric 
Spearman‟s  correlation,  an  r  value  of  -0.51  demonstrates  that  there  is  an  inverse 
relationship  between  infarct  volume  and  neurological  score,  where  as  infarct  volume 
decreases, neurological score increases. This shows that neurological function is improved 
in rats with smaller infarct volumes, compared to rats with larger infarcts, which are more 
severely functionally impaired. 
 
5.3.3 Study 3: MRI Assessment of the Acute Evolution of Ischaemic Injury in an 
Ischaemia-Reperfusion model in SHRSP rats 
 
5.3.3.1 Systolic Blood Pressure 
 
Tail cuff pleythsmography performed in the weeks prior to surgery revealed that there was 
no significant difference in the mean systolic pressures of the rats in each treatment group. 
Prior  to  stroke  surgery,  mean  systolic  blood  pressure  was  not  significantly  different 
between  groups  of  rats  subsequently  randomised  to  vehicle  and  apocynin  (5mg/kg) 
treatment  (181±25mmHg  and  189±17mmHg  for  vehicle  and  apocynin  treated  rats, 
respectively, P=0.52, Figure 5-11). 
 
5.3.3.2 Mortality 
 
The mortality rate in this study was higher than that observed in the transient ischaemia 
study using Sprague-Dawley rats. Of the 12 SHRSP rats used in this study, 8 rats died 
before the 72 hours end point, representing a 67% mortality rate. In both the vehicle and 
apocynin treated group 4/6 rats died before 72 hours post-MCAO. 5 rats died before 24 
hours post-MCAO and 2 rats died between 24 and 48 hours. One vehicle treated rat was 
euthanased  at  48  hours  post-MCAO  due  to  poor  condition  and  lack  of  spontaneous 
movement. Only 2 rats in each treatment group survived until 72 hours post-MCAO. It was 
therefore decided that the study would not continue further on ethical grounds. However, 
the acute MRI data acquired up to 3 hours post-MCAO are presented for all rats in the 
vehicle treated (n=6) and low dose apocynin treated groups (n=6). 
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Figure  5-11.  Mean Systolic  Blood  Pressure  in  SHRSP  rats.  Tail cuff  plethysmography  was 
performed in the weeks prior to stroke surgery. Mean systolic blood pressure was determined in 
each rat which was then randomly allocated to the vehicle or low dose apocynin treatment group. 
Horizontal line denotes the mean. P>0.05, unpaired t test. 
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5.3.3.3 Physiological Parameters 
 
With the exception of arterial PO2, as previously discussed, all physiological parameters 
were maintained within physiological range in both treatment groups at all time points 
post-MCAO. Arterial PO2 in all three treatment groups was significantly higher than the 
physiological range of 80-100mmHg (P<0.05, one sample t-test). Within each treatment 
group, each physiological variable was maintained from 30 minutes before stroke onset 
(baseline) to 3 hours post-MCAO (P>0.05, Repeated Measures ANOVA). There were no 
significant  differences  in  any  of  the  physiological  variables  between  treatment  groups 
before or after the onset of ischaemia (P>0.05, Two-way ANOVA, Table 5-2).  
 
5.3.3.4 Assessment of Reperfusion 
 
Immediately following the retraction of the intraluminal filament, MR angiography was 
acquired  and  examined  in  order  to  confirm  successful  reperfusion  of  the  left  middle 
cerebral artery. With the exception of one rat in the low dose apocynin treatment group, all 
rats demonstrated successful reperfusion. In the rat which did not reperfuse at 1 hour post-
MCAO, the filament was retracted further following examination of the angiographs at 1 
hour 10 minutes post-MCAO. Another angiography scan was then acquired and examined 
to confirm that the left middle cerebral artery had successfully reperfused. Figure 5-12 
illustrates reperfusion of the left middle cerebral artery. 
 
5.3.3.5 Acute Evolution of Ischaemic Injury 
 
DWI  was carried out in order to determine  if apocynin treatment  influences the acute 
evolution of ischaemic injury following MCAO.  There was no significant difference in the 
volume of ADC defined ischaemic injury at any time point during ischaemia and following 
reperfusion in the vehicle treated and low dose apocynin groups (P>0.05, 2-way ANOVA, 
Figure 5-13). During the period of ischaemia, the volume of ischaemic injury peaked at 
357±63mm
3  and  344±92mm
3  in  the  vehicle  treated  and  apocynin  treated  groups, 
respectively (P>0.05). At 1 hour post-MCAO,  following retraction of the  filament, the 
volume  of  ADC  derived  ischaemic  injury  sharply  declined  to  less  than  a  third  of  the 
volume observed in both groups during ischaemia. Within 30 minutes of reperfusion, the 
volume of ischaemic injury decreased to 101±73mm
3 and 99±82mm
3 in the vehicle treated 
and  apocynin  groups,  respectively  (P>0.05).  By  2  hours  post-MCAO,  the  volume  of 
ischaemic injury began to increase in both groups and by 3 hours post-MCAO, it had    187 
 
 
 
 
 
 
 
  Baseline  1h  2h  3h 
Vehicle          
 Body Temp (
oC)  37.2±0.4  36.8±0.5  36.8±0.3  36.9±0.3 
   MABP (mmHg)  111±11  111±5  113±10  115±6 
            HR (bpm)  369±10  378±23  361±10  357±17 
            Blood pH  7.42±0.05  7.41±0.03  7.37±0.02  7.39±0.04 
     PaO2 (mmHg)  131±14  140±21  142±23  136±18 
  PaCO2 (mmHg)  36±2  39±5  40±4  43±5 
         
5mg/kg 
apocynin 
       
 Body Temp (
oC)  37.1±0.2  36.7±0.3  37.1±0.3  36.9±0.3 
   MABP (mmHg)  109±12  112±10  110±8  110±9 
            HR (bpm)  358±17  355±14  355±17  361±9 
            Blood pH  7.44±0.03  7.38±0.03  7.38±0.03  7.41±0.03 
     PaO2 (mmHg)  136±13  152±14  147±18  141±25 
  PaCO2 (mmHg)  37±1  38±3  41±2  39±3 
 
Table 5-2. Physiological parameters assessed before the induction of ischaemia and at 1, 2 
and 3h post-MCAO in SHRSP rats. Data presented as mean±SD. MABP-mean arterial blood 
pressure, HR-heart rate, PaO2-arterial PO2, PaCO2-arterial PCO2. 
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Figure 5-12. Reperfusion of the middle cerebral artery following 1h of ischaemia.  MR angiography was performed immediately following withdrawal of the 
intraluminal filament at 1h post-MCAO. Restoration of flow in the left middle cerebral artery is highlighted by the arrows. Data is from a representative vehicle treated 
rat.    189 
increased to 149±126mm
3 and 154±121mm
3 in the vehicle and  apocynin treated groups, 
respectively (P>0.05). 
 
The spatial extent of injured tissue was comparable between the treatment groups during 
ischaemia and following reperfusion. During the 1 hour period of ischaemia, injured tissue 
was observed across 8 coronal slices within the MCA territory (Figures 5-14A & B). The 
extent of injury increased between 20 minutes and 1 hour post-MCAO in both groups and 
this was particularly evident on the coronal slices at the rostral and caudal extremities. 
Following reperfusion, ischaemic injury decreased but gradually began to rise by 2 hours 
post-MCAO. Growth of the ADC derived lesion was particularly evident on coronal slices 
3, 4 and 5, which are located within the core of the ischaemic MCA territory.  
 
5.3.3.6 Final Infarct Volume 
 
Statistical  analysis  of  the  infarct  data  was  not  undertaken  because  only  2  rats  in  each 
treatment group survived to the 72 hour end point. In the vehicle treated group, mean 
infarct  volume  was  309mm
3,  compared  to  200mm
3  in  the  apocynin  treated  animals. 
However,  the  difference  in  the  treatment  group  means  was  mainly  due  to  one  of  the 
apocynin treated rats which demonstrated a small infarct of 131mm
3 at 72 hours post-
MCAO.  In  addition,  TTC  staining  was  performed  on  the  brains  of  2  rats  which  died 
overnight before 24 hours post-MCAO. Both rats were apocynin treated and displayed 
large infarcts of 352 and 360mm
3. However, the precise time of death was unknown in 
these rats and the infarct data were excluded from the analysis of final infarct volume at 72 
hours.  
Furthermore, infarct volume at 24 and 72 hours was compared to the volume of ADC 
derived ischaemic injury at 1 hour post-MCAO, just prior to reperfusion (Figure 5-15). In 
the vehicle treated group, one rat demonstrated an infarct volume of 340mm
3 at 72 hours, 
which exceeded the  volume of  ischaemic  injury observed during  ischaemia (271mm
3). 
However, the other vehicle treated rat displayed an infarct at 72 hours which was smaller 
than  the  volume  of  ischaemic  injury  observed  following  1  hour  of  ischaemia  (infarct: 
278mm
3 vs ADC lesion: 331mm
3, Figure 5-15A). This was also observed in both apocynin 
treated rats, where the ADC derived lesion during the 1 hour period if ischaemia was larger 
than  the  infarct  at  72  hours  post-MCAO.  In  one  rat,  the  volume  of  ischaemic  injury 
291mm
3 during  ischaemia and  infarct volume at 72 hours was 268mm
3. The other rat 
demonstrated an ADC derived lesion volume of 178mm
3 and infarct volume at 72 hours 
was 131mm
3 (Figure 5-15B).    190 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-13. The acute evolution of ischaemic injury following reperfusion in vehicle and 
apocynin treated SHRSP rats.  Drug treatment was administered at 5min post-MCAO, which was 
55min prior to reperfusion. The strain specific ADC threshold of 0.59 x 10
-3mm
2/sec was applied to 
quantitative ADC maps to assess ischaemic injury during ischaemia and following reperfusion at 
60min post-MCAO. Dotted line denotes reperfusion by retraction of the intraluminal filament. Data 
presented as mean±SD, n=6 per group. P>0.05, 2-way ANOVA. 
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Figure 5-14A. The spatial distribution of acute ischaemic injury during ischaemia and following reperfusion in a vehicle treated SHRSP. The strain specific 
ADC threshold was applied to quantitative ADC maps to define the extent of injured tissue. Ischaemic injury is shown in white across 8 coronal slices within the territory 
of the MCA.   192 
 
Figure 5-14B. The spatial distribution of ischaemic injury during ischaemia and following reperfusion in a low dose apocynin treated SHRSP. The strain 
specific ADC threshold was applied to quantitative ADC maps to define the extent of injured tissue. Ischaemic injury is shown in white across 8 coronal slices within the 
territory of the MCA.   193 
5.3.3.7 Perfusion-Diffusion Mismatch 
 
Mismatch volume prior to reperfusion at 1 hour post-MCAO, was comparable between 
vehicle treated and apocynin treated rats. In the vehicle treated group, mismatch volume at 
1 hour post-MCAO was 32±17mm
3, compared to a mismatch volume of 31±28mm
3 in the 
apocynin treated group (P=0.91, unpaired t test, Figure 5-16A). The acute MRI data from 
all  6  vehicle  treated  rats  were  used  to  determine  mismatch  volume.  However,  in  the 
apocynin treated group, mismatch data were acquired from 4/6 rats. This was because there 
were problems with the acquisition of perfusion weighted images on the days when 2/6 
animals were being scanned. In one rat, CBF images were only acquired for coronal slices 
3, 4 and 5 due to time restrictions and in the other rat, no perfusion data was acquired 
during ischaemia, as a result of technical difficulties.  
 
Across the 4 coronal slices, mismatch tissue was observed mainly on slice 3 and mismatch 
area decreased on the rostral slices. Mismatch tissue was identified mainly in the cerebral  
cortex  in  both  groups,  although  mismatch  was  also observed  sub-cortically  to  a  lesser 
extent (Figure 5-16B). 
 
5.3.3.8 Functional Outcome 
 
Figure 5-17A shows the Bederson scores at 24 hours post-MCAO for all rats used in the 
study. There was no significant difference in score between the groups (P=0.49, Mann-
Whitney test). In the vehicle treated group, the median score at 24 hours was 4, which 
indicates severe impairment and no spontaneous activity. Three rats in the vehicle treated 
group scored 4 and two of these rats died before 48 hours and the other rat was euthanased 
at 48 hours due to its poor condition. The 2 rats which survived to 72 hours post-MCAO 
demonstrated less severe impairment and scored 2 at 24 hours, where reduced grip strength 
was observed without any circling behaviour. In the apocynin treated group, the median 
score at 24 hours was 5 as 4 rats out of 6 died before 24 hours post-MCAO. Of the two rats 
which survived to the 72 hours end point, one rat scored 2 and the other rat scored 0, 
indicating no observable neurological impairment.  
 
Over the 72 hours time course, the vehicle treated rats did not show any improvement in 
functional outcome, as assessed by the Bederson scale. One apocynin treated rat showed 
no evidence of neurological impairment at any time point and the other apocynin treated  
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Figure 5-15. Acute evolution of ischaemic injury in the rats which survived to 72h post-MCAO.  Row A shows the data from the vehicle treated rats and row B 
shows the data from the apocynin treated rats. Reperfusion was induced at 1h post-MCAO by withdrawal of the filament (dotted vertical line). Oedema-corrected infarct 
volume was defined at 24h post-MCAO by T2 weighted MRI and 72h by TTC staining. 
A 
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Figure 5-16. Perfusion-diffusion mismatch at 1h post-MCAO in vehicle treated and low dose apocynin treated SHRSP rats. Mismatch area was calculated on 4 
coronal slices by superimposing the area of ADC derived ischaemic injury (shown in white) on to the perfusion deficit (shown in red) of the corresponding slice. The 
remaining perfusion deficit was measured on each slice to calculate mismatch volume. Mismatch volume was determined immediately before reperfusion in vehicle 
treated (n=6) and low dose apocynin treated (n=4) SHRSP rats (A). The MRI data shown are from a representative vehicle and apocynin treated rat (B). 
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rat demonstrated an increase in neurological impairment between 24 and 48 hours post-
MCAO, as the observed score increased from 2 to 4 (Figure 5-17B). 
 
Functional outcome was also assessed by an 18-point neurological score and by vibrissae-
evoked forelimb placement. Prior to surgery, all rats demonstrated successful placement of 
the right and left forelimbs and there was no evidence of limb preference or neurological 
impairment.  Figure  5-18  presents  the  data  for  the  rats  in  each  treatment  group  which 
survived  to  72  hours  post-MCAO.  In  one  vehicle  treated  rat,  neurological  function 
improved progressively, where neurological score increased from 11 at 24 hours to 14 at 
72  hours  post-MCAO.  However,  the  other  vehicle  treated  rat  displayed  a  decrease  in 
neurological score (Figure 5-18A).  
 
In the apocynin treated group, one rat exhibited a decrease in neurological score from 8 at 
24 hours to 6 at 48 hours but outcome was improved by 72 hours post-MCAO as the score 
increased to 9. The other apocynin treated rat demonstrated no neurological impairment at 
any time point and achieved the maximum score of 18. This rat also showed no impairment 
in the vibrissae-evoked forelimb placement test and successfully placed the contralateral 
forelimb at every attempt. This rat demonstrated a smaller infarct than the rest of the rats 
which survived, where the infarct at 72 hours was 131mm
3 which was less than 50% of 
infarct volume observed in the other 3 rats which survived to 72 hours post-MCAO. The 
infarct  was  located  sub-cortically,  whereas  the  other  rats  demonstrated  infarcts  which 
incorporated both the cortex and the sub-cortex. Both of the vehicle treated rats and the 
apocynin  treated  rat  which  demonstrated  neurological  impairment,  showed  gradual 
reduction  in  the  ability  to  successfully  place  the  contralateral  forelimb.  This  was 
particularly evident between 24 and 48  hours post-MCAO. These observations conflict 
with  the  18  point  neurological  score,  where  the  functional  outcome  of  these  3  rats 
improved over time. 
 
5.4 Discussion 
 
The results of the studies presented in this chapter characterise the effect of apocynin (an 
NADPH  oxidase  inhibitor)  following  both  permanent  and  transient  focal  cerebral 
ischaemia and in the presence of stroke co-morbidities. We have provided further evidence 
that inhibition of NADPH oxidase with apocynin is neuroprotective following transient 
focal cerebral ischaemia, however no such effect was observed following permanent    197 
 
 
 
 
 
 
Figure 5-17. Functional outcome in vehicle and apocynin treated rats up to 72h post-MCAO. Functional outcome was assessed by a modified Bederson scale. A 
score of 0=no observable deficit, 1=forelimb flexion, 2=reduced grip strength, 3=circling, 4=no spontaneous activity, 5=dead. The scores of all vehicle treated (n=6) and 
apocynin treated rats (n=6) at 24h post-MCAO are shown in figure A. The line denotes the median score. P=0.49, Mann-Whitney Test. Figure B shows the individual 
scores observed in the 2 rats in each treatment group which survived to 72h post-MCAO. 
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Figure 5-18. Functional outcome in vehicle and apocynin treated rats up to 72h post-MCAO. Functional outcome was assessed by an 18 point neurological score 
(A) and by the vibrissae-evoked forelimb placement test (B). In the 18 point assessment, a score of 18 indicates no observable deficit and a score of 3 indicates the 
most severe impairment. The forelimb placement test is scored on the number of successful placements of the contralateral forelimb out of 10 attempts. Therefore, a 
score of 10 depicts no impairment and a score of 0 indicates failure to place the forelimb. The individual scores of the 2 rats in each treatment group which survived to 
72h post-MCAO are shown.  
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cerebral  ischaemia.  In  addition  we  have  shown  that  the  neuroprotective  effect  shown 
following transient cerebral ischaemia is only observed in normotensive rats since no such 
effect was observed in a rat model exhibiting genetic stroke risk factors (SHRSP).  
 
The precise mechanism involved in the neuroprotective action of apocynin is unclear at 
present.  It  has  now  been  widely  accepted  that  apocynin  is  a  pro-drug  which  requires 
activation by myeloperoxidase to form diapocynin which is the metabolically active form 
of the drug (Simons et al, 1990; Ximenes et al, 2007). Since vascular cells do not express 
myeloperoxidase,  it  has  been  proposed  that  the  neuroprotective  action  of  apocynin  is 
mediated by its antioxidant capacity, which may not require dimer formation, and not by 
the  inhibition  of  vascular  NADPH  oxidase  (Heumüller  et  al,  2008).    These  authors 
demonstrated  that  apocynin  failed  to  inhibit  superoxide  generation  in  HEK293  cells 
overexpressing NADPH oxidase isoforms (Nox1, Nox2, Nox4). However, when these cells 
were supplemented with myeloperoxidase, dimerization and activation of apocynin was 
observed  with  inhibition  of  NADPH  oxidase  activity.  Furthermore,  apocynin  failed  to 
inhibit NADPH oxidase activity  and superoxide generation  in  endothelial and  vascular 
smooth  muscle  cells  which  do  not  express  myeloperoxidase.  However,  apocynin 
demonstrated antioxidant effects in vascular cells by inhibiting hydrogen peroxide activity 
and  hydroxyl  formation.  Therefore,  apocynin  demonstrates  free  radical  scavenging 
capability and it may be the antioxidant activity of apocynin which leads to the observed 
neuroprotective effects (Heumüller et al, 2008).   
 
However, the absence of myeloperoxidase in vascular cells may not prevent the oxidation 
of apocynin into it metabolically active form. Vascular cells may possess other peroxidases 
which  can  activate  apocynin  (Touyz,  2008).  It  has  been  previously  demonstrated  that 
horseradish peroxidase induces apocynin dimer formation with subsequent inhibition of 
NADPH oxidase activity (Vejražka et al, 2005). Despite horseradish peroxidase being an 
exogenous peroxidase, this study provides evidence that other peroxidases can influence 
apocynin activity.  
 
It has also been proposed that apocynin may inhibit vascular NADPH oxidase even if these 
cells do not express peroxidases which can activate the drug. It has been demonstrated in 
vivo, that neutrophils secrete myeloperoxidase which can be taken up by endothelial cells 
by the interaction of cytokeratin 1 on the endothelial cell surface (Astern et al, 2007). The 
internalised peroxidase can then activate apocynin leading to inhibition of vascular 
NADPH oxidase (Touyz, 2008, Figure 5-19).   
 
 
 
 
 
 
 
 
 
Figure 5-19. The potential effects of apocynin on phagocytic cells (neutrophil) and non-
phagocytic cells (vascular cell). In neutrophils, apocynin is oxidised by myeloperoxidase (MPO) 
to  form  metabolically  active  dimers  and  trimers.  NADPH  oxidase  activity  is  dependent  on  the 
translocation  of  p47phox/p67phox/p40phox  to  the  cell  membrane  where  the  cytosolic  complex 
interacts with gp91phox and p22phox. Apocynin prevents translocation of the p47phox subunit and 
therefore inhibits superoxide generation mediated by NADPH oxidase. In vascular cells, which do 
not contain endogenous MPO, apocynin acts as an antioxidant, thereby reducing reactive oxygen 
species bioavailability, without inhibiting NADPH oxidase. It may be possible that vascular cells 
possess  non-MPO  peroxidases  that  could  activate  apocynin  to  dimers  and  trimers  to  inhibit 
vascular NADPH oxidase, which is composed of Nox2 or its homologues (Nox1, Nox4, or Nox5) as 
the catalytic subunit. In vivo studies suggest that apocynin in vascular cells could also be activated 
by MPO secreted from neutrophils. Dashed arrows indicate possible effects; →, stimulation; ⊥, 
inhibition. Reproduced from Touyz (2008).  
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The  reduction  in  infarct  volume  observed  following  apocynin  treatment  in  Sprague-
Dawley  rats  following  ischaemia/reperfusion  was  comparable  to  that  shown  in  other 
published studies (Tang et al, 2007). In the present study, infarct volume at 72 hours post-
MCAO was reduced by approximately 60% in apocynin treated rats, following 1 hour of 
ischaemia. Previously, reductions in infarct volume of up to 40% have been observed in 
normotensive  rats  following  apocynin  treatment.  Tang  and  colleagues  reported  a  37% 
reduction  in  infarct  volume  in  Sprague-Dawley  rats  following  apocynin  treatment 
administered at 1 hour post-MCAO (Tang et al, 2007). Similar observations have been 
reported following apocynin treatment in Wistar rats, where infarct volume was reduced by 
40%, when treatment was administered at 2 hours post-MCAO (Genovese et al, 2011). An 
improved  outcome  has  also  been  reported  with  apocynin  treatment  in  mouse  transient 
ischaemia models. Reductions in infarct volume of up to 50% compared to control treated 
mice have been demonstrated. Chen and colleagues reported a 50% reduction in infarct 
volume when apocynin treatment was administered following 70  minutes of  ischaemia 
(Chen et al, 2009) and a similar reduction in infarct volume was reported by Jackman et al 
(2009). However, these authors administered apocynin 30 minutes prior to the induction of 
ischaemia, which reduces the clinical relevance of these findings.  
 
In the permanent MCAO model, apocynin treatment had no significant effect on infarct 
volume or behavioural outcome  in  WKY rats at 24  hours post-MCAO. The  vibrissae-
evoked  forelimb scores observed across the 3 treatment groups were more severe than 
those previously described following permanent occlusion of the MCA in Sprague-Dawley 
rats, where 70-80% of contralateral placements were unsuccessful  from 24 hours post-
MCAO (Schallert et al, 2000). This may be attributable to the larger infarct observed in 
WKY  rats  compared  to  Sprague-Dawley  rats,  as  previously  described  (Chapter  3).  In 
WKY  rats, there  is  more  extensive  injury  in  both the  striatum  and  the  cortex  and  the 
forelimb placement test is sensitive to both cortical and striatal damage (Schallert et al, 
2000). 
 
In  the  present  study,  there  was  a  trend  (not  statistically  significant) towards  improved 
functional outcome with low dose apocynin treatment in Sprague-Dawley rats following 
transient focal ischaemia which was associated with a significantly reduced infarct volume 
at  72  hours  post-MCAO.  The  functional  tests  used  in  this  study  may  not  have  been 
sensitive enough to detect subtle improvements in neurological function. The low dose 
apocynin treated rats exhibited normal feeding and grooming behaviours and their general 
appearance  and  condition  was  improved  compared  to  vehicle  and  high  dose  apocynin   202 
treated rats. However, the modified Bederson scale, the forelimb placement test and the 18 
point neurological score fail to detect these behaviours. It may therefore be advantageous 
for the  benefit of  future studies to develop a composite  functional test which assesses 
feeding  and  grooming  behaviours  in  addition  to  tests  of  general  proprioceptive  and 
sensorimotor capabilities.  
 
All previous studies examining the effects of apocynin in ischaemia-reperfusion models 
have assessed  infarct  volume at 24  hours post-MCAO. However, at this time point  in 
transient  ischaemia  models, the  infarct is still evolving, as demonstrated in the present 
study, where infarct volume increased between 24 and 72 hours (Figure 5-15). Neuronal 
injury following transient cerebral ischaemia is an evolving process which can continue for 
days following stroke (Williams et al, 2004). It has been previously demonstrated in rat 
transient  ischaemia  models  that  delayed  reperfusion  injury  can  contribute  to  the 
development of the infarct beyond 24 hours post-MCAO (Du et al, 1996; Li et al, 2000). 
Therefore, a limitation of the previously published studies with apocynin is that the effect 
on final infarct volume may have not been assessed accurately due to the use of the 24 
hour time point. 
 
In order to increase the likelihood of translation of neuroprotective drugs from bench to 
bedside,  it  is  necessary  to  evaluate  potential  neuroprotective  strategies  in  preclinical 
models  with  stroke  risk  factors,  like  increasing  age  and  hypertension.  The  SHRSP  is 
therefore a suitable rat model for assessing the neuroprotective efficacy of apocynin. It has 
also been demonstrated in this chapter, that apocynin had no protective effect in SHRSP 
rats following 1 hour of ischaemia. Treatment with 5mg/kg apocynin at 5 minutes post-
MCAO did not have any effect on perfusion-diffusion mismatch volume or the evolution 
of  ischaemic  injury  in  SHRSP  rats  during  the  critical  acute  phase  following  stroke. 
Mortality rates were  high, with 67% of rats dying  before the 72  hour end point. This 
prevented statistical analysis of infarct volume between groups since only 2 rats in each 
treatment group survived to 72 hours post-MCAO. Previously, it has been reported that 
apocynin treatment does not improve stroke outcome in aged rats despite an improvement 
in outcome being observed in young rats. Kelly and colleagues demonstrated that apocynin 
treatment worsened stroke outcome in aged rats, where the mortality rate was significantly 
higher in apocynin treated rats (36% mortality) compared to aged vehicle treated rats (14% 
mortality). Apocynin treatment also failed to improve functional outcome or reduce infarct 
volume  at  24  hours  post-MCAO  compared  to  aged  vehicle  treated  rats.  Furthermore, 
oedema  formation  at  24  hours  post-MCAO  was  significantly  higher  in  aged  apocynin   203 
treated rats, where the volume of the ipsilateral hemisphere increased by 20%, compared to 
a  6%  increase  in  aged  vehicle  treated  rats  (Kelly  et  al,  2009).  Aged  rats  demonstrate 
reduced  levels  of  SOD,  increased  generation  of  reactive  oxygen  species  and  reduced 
antioxidant  activity  which  supports  the  „free  radical  theory  of  aging‟  where  increased 
levels  of  oxidative  stress  contribute  to  age-related  diseases  (Harman,  1994).  Increased 
levels of oxidative stress have been reported in the SHRSP and contribute to the increased 
infarct  volume  observed  following  experimental  stroke  compared  to  the  normotensive 
control strain, WKY (Kishi et al, 2004; Cheng et al, 2008; Dunn et al, 2008).  
 
The  present  studies  demonstrate  that  inhibiting  a  component  of  the  oxidative  stress 
pathway with apocynin, improves stroke outcome in normotensive Sprague-Dawley rats 
but  has  no  effect  in  SHRSP  rats.  Given  the  increased  oxidative  stress  response  in  the 
SHRSP it was hypothesised that apocynin treatment may improve outcome by inhibiting 
the  production  of  superoxide  through  NADPH  oxidase  inhibition.    The  fact  that  we 
observed no effect in the SHRSP may be attributable to strain specific differences in the 
expression of NADPH oxidase isoforms. There is some debate regarding the contribution 
of specific isoforms to the generation of reactive oxygen species during ischaemia. It has 
been reported that Nox1 and Nox4 account for the generation of reactive oxygen species 
under physiological conditions (Miller et al, 2005; 2007) and upregulation of Nox2 occurs 
during ischaemia, making it the predominant source of reactive oxygen species (Kahles et 
al,  2007).  Apocynin  is  believed  to  be  selective  for  the  Nox1  and  Nox2  isoforms  by 
preventing  the  translocation  of  p47phox  from  the  cytosol  to  the  Nox1/2  catalytic 
membrane domain (Stolk et al, 1994). Evidence for the Nox2 selectivity of apocynin was 
recently provided by Jackman and colleagues. This group of investigators demonstrated a 
significant neuroprotective effect of apocynin in wild type mice, where stroke outcome 
was  improved  and  superoxide  levels  were  reduced.  However,  no  protective  effect  was 
observed in Nox2-deficient mice. These findings suggest that the neuroprotective effect of 
apocynin was mediated by inhibition of Nox2 containing NADPH oxidase and provide 
evidence for the importance of the Nox2 isoform during ischaemia (Jackman et al, 2009).  
However, Kleinschnitz and colleagues (Kleinschnitz et al, 2010) proposed that Nox4 is the 
most relevant source of reactive oxygen species under ischaemic conditions as it is the 
most abundant vascular isoform in cerebral vessels (Miller et al, 2005) and is upregulated 
in  stroke  (McCann  et  al,  2008).  This  study  group  reported  that  Nox4-deficient  mice 
demonstrated an improved stroke outcome following permanent and transient ischaemia 
compared  to  wild-type  mice.  However,  Nox1-  and  Nox2-deficient  mice  showed  no 
improvement in stroke outcome (Kleinschnitz et al, 2010).    204 
These findings may explain why apocynin treatment did not improve outcome in a model 
of permanent MCAO. If Nox4 is the principal isoform under ischaemic conditions, then 
inhibiting  Nox2  with  apocynin  may  not  significantly  reduce  the  generation  of  reactive 
oxygen  species  and  its  contribution  to  ischaemic  injury.  In  addition,  the  free  radical 
scavenging capabilities of apocynin may not be sufficient to reduce ischaemic damage. 
However, this does not explain the clear neuroprotective effects of apocynin demonstrated 
in transient focal ischaemia models. It may be the case that following reperfusion Nox2 
activity  becomes the predominant source of reactive oxygen species and that apocynin 
mediates  its  neuroprotective  actions  by  inhibiting  Nox2  which  may  be  upregulated 
following  restoration  of  flow.  However,  this  is  highly  speculative  and  the  possible 
upregulation  of  NADPH  oxidase  isoforms  following  reperfusion  has  not  yet  been 
examined. It is interesting to note that all studies which report apocynin neuroprotection 
have employed ischaemia-reperfusion models of focal ischaemia. To date, there are no 
published reports on the effects of apocynin in stroke models of permanent MCAO. This 
may be because of negative findings which have not been published due to publication bias 
towards positive studies.  
 
The  lack of a  neuroprotective effect of apocynin specifically  in SHRSP rats following 
transient focal ischaemia may be related to strain specific differences in NADPH oxidase 
isoform expression. It has been reported that SHRs demonstrate higher levels of Nox4 
mRNA  compared  to  normotensive  WKY  rats  and  this  is  associated  with  enhanced 
cerebrovasodilatation in chronic hypertension (Paravicini et al, 2004). It is therefore not 
unreasonable to speculate that the SHRSP strain, derived by selective breeding from SHR, 
may also exhibit increased expression of Nox4. These data suggest that Nox4 may have a 
protective role  in  hypertension. However, as previously discussed Nox4  is upregulated 
during  ischaemia  and  contributes  to  ischaemic  injury  (Kleinschnitz  et  al,  2010).  In 
hypertensive animals, like the SHRSP, Nox4 may continue to be the principal source of 
reactive oxygen species following reperfusion. Therefore, apocynin treatment would not 
impact on the extent of ischaemic injury.  
 
Furthermore, apocynin treatment failed to prolong the lifespan of the ischaemic penumbra 
in SHRSP, as defined by perfusion-diffusion mismatch at 1 hour post-MCAO. This may be 
attributable,  in  part,  to  the  small  volumes  of  mismatch  tissue  detected  in  this  strain. 
Previously, it has been reported that administration of the selective endothelin antagonist, 
SB 234551, successfully preserved mismatch defined penumbra in normotensive Sprague-
Dawley rats but failed to demonstrate a protective effect in SHR rats, where there was little   205 
evidence  of  mismatch  tissue  at  1  hour  post-MCAO  (Legos  et  al,  2008).  The  lack  of 
penumbral tissue in the SHR and SHRSP strains may therefore limit the potential for tissue 
salvage following stroke in models of genetic hypertension.  
 
It has been reported that increased generation of reactive oxygen species in hypertensive 
rats  contributes  to  the  development  of  arterial  hypertension  by  inducing  endothelial 
dysfunction  (Alexander  et  al,  2000).  Therefore,  inhibition  of  NADPH  oxidase  with 
apocynin  has  been  investigated  as  a  potential  anti-hypertensive  strategy.  However, 
apocynin has no effect on blood pressure in normotensive rats (Li et al, 2003) and there are 
conflicting reports on the ability of apocynin to lower blood pressure in hypertensive rats. 
Bäumer and colleagues reported that apocynin treatment lowered systolic blood pressure in 
SHRs  as  effectively  as  the  calcium  channel  blocker,  nifedipine.  SHRs  received  daily 
administration  of  33mg/kg  apocynin  or  nifedipine  (30mg/kg)  for  a  period  of  28  days. 
Within one week of treatment, apocynin significantly reduced systolic blood pressure from 
183±2mmHg to 164±12mmHg (P<0.05) and this treatment effect was maintained over the 
28 day observation period. The antihypertensive effect of apocynin was comparable to the 
effect of nifedipine treatment, where systolic BP had reduced to 166±27mmHg by day 2 
(Bäumer  et  al,  2007).  The  authors  also  observed  that  the  anti-hypertensive  effect  of 
apocynin correlated with reduced vascular ROS levels, increased activity of eNOS and 
increased NO bioavailability, suggesting that the mechanism of action involves inhibition 
of vascular NADPH oxidase. However, these findings conflict with a previous study which 
reported that apocynin treatment over a 3 week period had no significant effect on blood 
pressure in SHR and WKY rats (Paliege et al, 2006). Similarly, Schlüter and colleagues 
also  reported  that  apocynin  treatment  failed  to  reduce  arterial  pressure,  which  was 
measured  via  implanted  radiotelemetric  devices  in  SHR.  Apocynin  treatment  was 
administered orally in the drinking water over a period of 5 weeks and arterial pressure 
continued  to  be  assessed  for  a  further  12  weeks.  Apocynin  treated SHR  demonstrated 
virtually identical arterial pressures as untreated controls over the entire observation period 
(Schlüter  et  al,  2008).  Furthermore,  these  authors  assessed  the  vasodilator  capacity  of 
apocynin in vitro and observed that apocynin dilated arterial segments of SHRs in a dose-
dependent  manner.  However,  the  authors  also  examined  aortic  rings  from  p47phox 
knockout mice and reported an increased sensitivity to apocynin-induced vasodilatation, 
which was then prevented by Rho kinase inhibition. These authors therefore suggest that 
apocynin-mediated vasodilatation is not dependent on NADPH oxidase but involves Rho 
kinase  activity.  It  has  been  reported  previously  that  rho  kinase  activity  contributes  to   206 
infarct volume following experimental stroke (Shin et al, 2007). These findings further 
complicate the already complex mechanism of action of apocynin.  
 
The  dose  of  apocynin  and  the  timing  of  administration  appear  to  be  critical  to  its 
neuroprotective  effects  in  rodent  stroke  models.  It  has  been  reported  that  apocynin 
improves stroke outcome within a narrow dose range. Tang and colleagues reported that 
intravenous  administration  of  2.5mg/kg  apocynin  prior  to  reperfusion,  significantly 
improved  neurological  outcome,  reduced  infarct  volume  and  reduced  the  incidence  of 
cerebral haemorrhage. However, when apocynin was administered at a dosage of 3.75 or 
5mg/kg,  no  improvement  in  stroke outcome  was  observed  and  there  was  an  increased 
incidence of cerebral  haemorrhage  in  both the  ipsilateral and contralateral hemispheres 
compared to vehicle treated controls.  Furthermore, mice treated with 5mg/kg apocynin 
demonstrated a higher mortality rate of 38%, compared to vehicle treated mice (25%), 
whereas mice treated with 2.5mg/kg apocynin had a lower mortality rate (13%).   
These findings are supported by other study groups, where mice pre-treated with 5mg/kg 
apocynin  prior  to  ischaemia  demonstrated  a  significantly  higher  mortality  rate  (41%) 
compared to vehicle treated mice (12%) and those treated with 2.5mg/kg apocynin (0%). 
Interestingly, mice pre-treated with 5mg/kg apocynin and then subjected to sham MCAO 
surgery did not die, suggesting that apocynin is only toxic at this dosage when cerebral 
ischaemia is induced (Jackman et al, 2009). The authors proposed that the higher dose of 
apocynin  may  compromise  NADPH  oxidase  dependent  cerebral  vasodilatation  by 
increased scavenging of H2O2. It has been shown previously that H2O2 mediates NADPH 
oxidase dependent vasodilatation in ischaemic brain regions (Paravicini et al, 2004; 2006).  
 
The  dosage  of  apocynin  is  unlikely  to  account for  the  mortality  rates  observed  in  the 
present studies, as in normotensive rats the mortality rate was higher in vehicle treated 
animals than those treated with apocynin. These results are in conflict with the studies 
previously discussed. However, those studies examined the effects of apocynin in mice and 
there may be species differences in the dose of apocynin required to induce toxic effects. 
The high mortality rate (67%) observed in both vehicle treated and low dose apocynin 
treated SHRSP rats suggest that drug treatment had no influence on mortality rate. It is 
more  likely  that  the  high  mortality  rate  was  attributable  to  brain  swelling  following 
reperfusion. It has been reported that BBB dysfunction may contribute to ischaemic injury 
and extensive brain oedema in SHRSP rats (Yamagata et al, 1997; Lippoldt et al, 2000; 
Ishida et al, 2006).    207 
In  addition,  the  timing  of  administration  appears  to  be  important  when  evaluating  the 
neuroprotective effects of apocynin. Jackman and colleagues reported that administration 
of apocynin 30 minutes prior to ischaemia had a neuroprotective effect. However, when 
apocynin  treatment  was  administered  1  hour  after  reperfusion,  following  30  minutes 
ischaemia, there was no improvement in stroke outcome. These findings therefore suggest 
that the therapeutic potential of apocynin may be limited. However, other study groups 
have reported the neuroprotective effect of apocynin when administered up to 2 hours post-
MCAO  (Genovese  et  al,  2011),  which  is  a  more  clinically  relevant time  point.  In the 
present studies apocynin was administered at 5 minutes post-MCAO, however, the purpose 
of these experiments was to ascertain if apocynin demonstrated neuroprotective efficacy in 
a rat model of genetic hypertension and not to evaluate the potential therapeutic window, 
which would be the next logical step in this series of experiments.  
Another  limitation  of  the  studies  presented  in  this  chapter  is  that  we  did  not  measure 
oxidative stress levels in the either the vasculature or the brain to assess whether apocynin 
treatment reduced oxidative stress levels. This could have been achieved by assessing the 
levels of oxidative stress markers, such as 8-hydroxy-2‟-deoxyguanosine (8-OHdG) and 4-
hydroxy-2-nonenal (4-HNE), using immunohistochemistry.  
Furthermore, apocynin treatment was evaluated in SHRSP rats at a single dose of 5mg/kg. 
This  dose  may  not  have  been  optimal  to  confer  neuroprotection  in  this  strain  despite 
demonstrating  neuroprotective  effects  in  normotensive  Sprague-Dawley  rats.  In  future 
studies, data on dose response should be generated to allow more accurate assessment of 
the effect of apocynin in SHRSP rats. 
 
When  evaluating  the  effect  of  apocynin  on  stroke  outcome,  care  must  be  taken  when 
deciding on the solvent to dissolve the drug, and its concentration. Apocynin is highly 
soluble  (i.e.  to  >1mol/L)  in  non-polar  solvents  such  as  dimethylsulphoxide  (DMSO), 
chloroform and alcohols (Selemidis et al, 2008) and DMSO is commonly used as a solvent 
in  studies  examining  the  effects  of  apocynin  on  stroke  outcome.  However,  DMSO 
demonstrates neuroprotective effects at concentrations ≥ 10%. For example, when 10% 
DMSO was used as a vehicle in mouse models of focal cerebral ischaemia, it demonstrated 
neuroprotective  efficacy  (Alyson  Miller,  personal  communication,  2010).  Furthermore, 
Bardutzky  and  colleagues  (2005)  evaluated  the  neuroprotective  effects  of  DMSO  in  a 
rodent  permanent  stroke  model  and  reported that  administration  of  33%  DMSO  at  60 
minutes post-MCAO prolonged the lifespan of the mismatch defined penumbra. This will 
impact on the findings of Genovese and colleagues, who recently reported an improvement 
in  stroke  outcome  following  apocynin  treatment,  where  10%  DMSO  was  used  as  the   208 
treatment vehicle. Therefore, the improvement in stroke outcome reported by this group 
may be attributable in part to the neuroprotection of DMSO. In the present studies, 0.1% 
DMSO was used as the vehicle to eliminate the possibility of neuroprotective efficacy. 
However,  it  may  have  been  advantageous  to  include  a  saline  treated  control  group to 
compare stroke outcome to the vehicle treated group.  
 
The results of these studies also highlight the need for functional testing in addition to 
measurement of brain injury, when assessing potential neuroprotective therapy. High dose 
apocynin treatment significantly reduced infarct volume following 1 hour of ischaemia in 
Sprague-Dawley rats but there was no improvement in functional outcome. The recovery 
of neurological function and improvement in quality of life are the outcomes which are 
important clinically, rather than a reduction in brain injury alone. On this basis, low dose 
apocynin shows greater potential for clinical efficacy. However, the failure of low dose 
apocynin treatment to prolong the lifespan of the mismatch defined penumbra in SHRSP 
rats, suggests that apocynin may be of limited clinical potential. These results highlight the 
need  for  studies  examining  the  effects  of  potential  neuroprotective  strategies  in  stroke 
models with risk factors. The present study demonstrates that apocynin treatment improves 
stroke outcome in normotensive rats following transient ischaemia but has no effect when 
administered to rats with genetic hypertension. This finding is likely to explain in part the 
failure of successful neuroprotectants to translate to clinical trials, since most pre-clinical 
drug studies use young healthy animals, which have less relevance to the human condition.  
 
Summary 
In the present study we have shown that apocynin does not influence infarct volume or 
functional outcome when administered following permanent focal cerebral ischaemia in 
normotensive rats.  However, following transient cerebral  ischaemia, apocynin reduced 
infarct  volume  and  improve  functional  outcome  when  administered  post-stroke.    In 
contrast, apocynin, when given at a dose that reduced infarct and improved recovery in 
normotensive rats, had no significant effect on the acute evolution of ischaemic damage or 
functional outcome in the hypertensive SHRSP rat.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. 
General Discussion 
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In the crucial first hours of acute ischaemic stroke, identification and salvage of penumbral 
tissue is the ultimate goal of both clinicians and experimental stroke researchers. Positron 
emission  tomography  remains  the  „gold-standard‟  imaging  modality  for  identifying  the 
ischaemic  penumbra  in  stroke  research  but  its  use  is  limited  by  the  complex  logistics 
associated  with  this  technique.  Consequently,  MRI  is  now  commonly  used  in  clinical 
research  to  identify  the  penumbra  as  a  result  of  its  widespread  availability  and  less 
complex  logistics  then  PET.  However,  defining  penumbra  using  the  MRI  perfusion-
diffusion  mismatch  technique  presents  its  own  difficulties.  Penumbra  may  be 
overestimated by the inclusion of benign oligaemic tissue and may be underestimated by 
the assumption that the diffusion lesion represents irreversibly injured tissue, which is not 
necessarily the case as DWI lesion reversal has been demonstrated both in animal models 
and stroke patients (Minematsu et al, 1992; Hasegawa et al, 1994; Kidwell et al, 2000). In 
addition, few study groups have determined perfusion and diffusion thresholds to define 
penumbra and there is a lack of consensus on appropriate thresholds and the parameters 
used to define hypoperfused tissue. 
 
The findings in this thesis demonstrate that a single perfusion and diffusion threshold may 
not be appropriate for all rat strains since we have shown different values calculated in a 
rat  model  that  displays  stroke  co-morbidities  compared  with  normotensive  rats.  Strain 
differences in threshold values may lead to an over- or underestimation of penumbra. This 
will impact on preclinical drug studies, where salvage of the penumbra is used to evaluate 
drug  efficacy  across  different  rat  strains.  Therefore,  it  is  important  that  perfusion  and 
diffusion thresholds are defined in each rat strain used in preclinical stroke research. The 
calculated diffusion threshold for identifying ischaemically injured tissue was comparable 
in SHRSP and the normotensive control strain WKY. However, the absolute perfusion 
threshold was significantly higher in the hypertensive strain, which may indicate that the 
SHRSP is more sensitive to ischaemia than WKY. Therefore, it would be inappropriate to 
apply  the  same  perfusion  threshold  to  define  the  perfusion  deficit  across  different  rat 
strains, particularly those strains which exhibit stroke co-morbidities, like the SHRSP. The 
perfusion and diffusion thresholds determined in WKY and SHRSP in the present study 
also  differ  significantly  from those previously defined  in  Sprague-Dawley rats using a 
similar method (Shen et al, 2003). In addition, the thresholds calculated in this thesis also 
differ from those defined in our laboratory in male and female Sprague-Dawley rats using 
the same method. In both male and female Sprague-Dawley rats a perfusion threshold of 
63% reduction from mean contralateral CBF defined the perfusion deficit (TA Baskerville, 
unpublished observations). These data differ from the perfusion thresholds determined in   211 
SHRSP and WKY rats (70% and 81% reduction from mean contralateral CBF for SHRSP 
and WKY, respectively). The diffusion thresholds determined in male and female Sprague-
Dawley rats were comparable between the sexes, where a 27% and 30% reduction from 
mean contralateral ADC values defines the volume of ischaemic injury in male and female 
rats, respectively. However, these thresholds differ from the diffusion thresholds defined in 
SHRSP and WKY rats (23% and 21% reduction from mean contralateral ADC for SHRSP 
and WKY, respectively). This suggests that Sprague-Dawley rats may be less sensitive to 
reductions  in  ADC  values  and  this  may  explain,  in  part,  the  smaller  infarct  volumes 
observed in this strain compared to SHRSP and WKY rats. These data further highlight the 
need for strain-specific thresholds of perfusion and diffusion abnormality.  
 
The studies presented within this thesis have also highlighted the importance of selecting 
the  method  used  to  define  the  penumbra  using  MRI.  Despite  criticism  regarding  the 
inclusion of  benign oligaemic tissue and DWI  lesion reversal on reperfusion, the MRI 
perfusion-diffusion mismatch model continues to be a useful tool for approximating the 
ischaemic penumbra in both clinical and preclinical stroke research. In the present study, 
the  volumetric  mismatch  method  consistently  generated  lower  volumes  of  perfusion-
diffusion mismatch compared to spatially defined mismatch in both SHRSP and WKY 
rats,  although  this  was  not  statistically  significant.  Although  it  is  a  simple  arithmetic 
technique,  the  volumetric  method  does  not  provide  any  information  on  the  extent  and 
location  of  penumbral  tissue,  unlike  the  more  precise  spatial  method,  where  mismatch 
tissue was assessed on each coronal slice. These findings are in agreement with previous 
reports,  where  volumetric  and  spatial  mismatch  methods  were  employed  to  define 
penumbra volume in stroke patients. It was demonstrated that simple arithmetic subtraction 
of the DWI  lesion  from the PWI defined perfusion deficit without any anatomical co-
registration, consistently underestimated penumbra volume by 40% compared to penumbra 
defined by co-registration of DWI and PWI (Ma et al, 2009). On the basis of these results 
and the findings presented in this thesis, it should be recommended that the volumetric 
method  is  not used to define the  mismatch  but rather spatial  assessment of perfusion-
diffusion mismatch is carried out on each coronal slice. 
 
The  studies  presented  in  this  thesis  also  demonstrate  that  the  volumetric  and  spatial 
mismatch methods failed to detect any significant difference in mismatch volume between 
the SHRSP and WKY strains. Mismatch volume was comparable between the strains from 
1-4 hours post-MCAO and there was little evidence of mismatch defined penumbra from 
as  early  as  1  hours  following  stroke onset.  This  suggests  that there  may  be  a  limited   212 
potential for penumbra salvage in both strains. This is in conflict with previous reports 
from our laboratory, where mismatch was significantly reduced in SHRSP compared to 
WKY (McCabe et al, 2009). However, mismatch area was defined only on a single coronal 
slice within the MCA territory in this study. Other authors have also used the mismatch 
technique  to  define  penumbra  in  rat  models  with  stroke  co-morbidities.  There  was  no 
evidence of mismatch as early as 1 hour post-MCAO in SHR rats and administration of a 
selective ETA antagonist following stroke had no effect on final infarct volume at 24 hours 
(Legos et al, 2008). Letourneur and colleagues reported that mismatch volume was reduced 
in  the  SHR  and  renovascular  hypertensive  WKY  rats  (RH-WKY)  compared  to 
normotensive rats up to 4 hours post-MCAO (Letourneur et al, 2011). These results differ 
from the findings of the present study. It may be that the WKY rats used in the Letourneur 
study have a different genetic background to the WKY rats used in the studies described in 
this thesis. This could potentially influence the evolution of ischaemic injury and stroke 
outcome. Furthermore, the authors used the SHR strain which differs from the SHRSP 
strain used in the studies presented in this thesis. It has been demonstrated previously that 
both  of  the  hypertensive  strains  demonstrate  a significantly  larger  infarct  volume  than 
WKY rats following permanent MCAO and in addition, the SHRSP strain exhibits a larger 
infarct than the SHR strain (Duverger & MacKenzie, 1988). However, to date, there are no 
published studies in the literature which have compared mismatch volume in the SHR, 
SHRSP and WKY rat strains. 
 
Criticisms  of  the  perfusion-diffusion  mismatch  model  have  led  to  the  development  of 
alternative  techniques  to  define  the  penumbra  in  acute  ischaemic  stroke  research.  The 
oxygen challenge is a MRI technique which has recently been developed to overcome the 
limitations of the mismatch model, using oxygen as a metabolic biotracer in combination 
with T2* weighted imaging (Santosh et al, 2008). This novel technique should allow a 
more precise evaluation of penumbra on the basis of its metabolic activity and is based on 
the  differing  magnetic  properties  of  deoxyhaemoglobin  and  oxyhaemoglobin  and  is 
currently  being  validated  in  preclinical  and  clinical  research.  Perfusion  CT  is  another 
alternative  imaging  modality  to  detect  the  penumbra.  This  technique  involves  the 
intravenous injection of an iodinated contrast agent and the bolus is tracked through the 
cerebral circulation. However, the radiation dose is a significant issue which needs to be 
considered as the dose required for perfusion CT is higher than that needed for standard 
CT.  Nevertheless,  in  clinical  research  perfusion  CT  may  overtake  perfusion-diffusion 
mismatch due to its cost-effectiveness and the  wide availability of CT scanners  in the 
clinical setting (Heiss & Sorensen, 2009).   213 
The acute evolution of the penumbra was also evaluated retrospectively by assessing the 
growth of the ADC derived lesion. However as previously discussed in  Chapter 4, this 
method is not suitable when examining the lifespan of the penumbra at acute time points as 
tissue  must  proceed  to  infarction  to  allow  retrospective  calculation  of  the  penumbra. 
Nevertheless, this technique has been used in clinical research to provide a retrospective 
approximation  of  the  penumbra  to  compare  with  a  new  MRI  diagnostic  technique  for 
penumbra in patients where perfusion data was not available (Dani et al, 2010). However, 
these authors were aware of the limitations of this method. The findings of the present 
study demonstrate that ADC lesion growth was significantly larger in WKY compared to 
SHRSP at 30  minutes post-MCAO. This suggests that there  is a reduced potential  for 
penumbra  salvage  in  the  SHRSP  strain  within  the  first  30  minutes  following  stroke. 
However, by 1 hour post-MCAO there is no significant difference in ADC lesion growth 
between the strains. 
 
The studies presented in this thesis have also shown that the perfusion deficit increased 
significantly  from  1-4  hours  post-MCAO  in  both  SHRSP  and  WKY  rats.  This  is  an 
interesting finding and may be indicative of a failure of collateral blood supply in both 
strains. Previously, our laboratory has demonstrated that the perfusion deficit increased 
significantly from 1-6 hours post-MCAO in SHRSP but not in WKY rats (McCabe et al, 
2009). One of the limitations of this previous study was that the perfusion deficit was only 
examined on a single coronal slice within the core territory of the MCA and therefore any 
changes in CBF within more rostral or caudal regions with different collateral supply will 
have been missed. It is not surprising that the perfusion deficit increased over time in the 
hypertensive strain, as it has been demonstrated that collateral flow is impaired in SHRSP 
rats (Coyle & Heistad, 1987) and this  is  likely  to contribute to the significantly  larger 
perfusion deficit observed in SHRSP compared to WKY in the studies presented in this 
thesis.  However,  the  temporal  increase  in  perfusion  deficit  observed  in  WKY  was 
somewhat unexpected. This is unlikely to be attributable to changes in blood pressure as 
mean arterial blood pressure and arterial PCO2 and PO2 did not change significantly during 
surgery or the 4 hour MRI scanning period. This finding suggests that the normotensive 
control strain experiences some impairment of collateral blood supply following stroke. 
Our  laboratory  has also demonstrated a small temporal  increase  in perfusion deficit  in 
Sprague-Dawley  rats,  although  not  statistically  significant.  It  would  be  interesting  to 
compare the collateral blood supply of the WKY to other normotensive rat strains, such as 
the  Sprague-Dawley  rat,  to  assess  any  potential  strain  differences.  To  date,  214 
 
 
 
 
 
Figure 6-1. Temporal evolution of ischaemic injury and perfusion deficit in SHRSP, WKY and Sprague-Dawley rats. The volume of ischaemic injury is significantly 
higher in SHRSP and WKY rats compared to male and female Sprague-Dawley rats (S-D) from 30min to 4h post-MCAO (A). The volume of perfusion deficit is significantly 
higher in SHRSP and WKY rats compared to male and female S-D rats. All data are presented as mean±SD. *p<0.001 (SHRSP vs male and female S-D), +p<0.05 (WKY 
vs male and female SD), 2-way ANOVA with Bonferroni’s post-test. WKY; n=12, SHRSP; n=15, Female S-D; n=10, Male S-D; n=9. 
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no such study has been undertaken. If indeed, the collateral vessels of the WKY rat differ 
in number, distribution, diameter or vasoreactivity compared to other normotensive strains, 
it may help to explain why, when exposed to the same ischaemic insult, the volume of 
ischaemic injury and perfusion deficit are significantly larger in WKY rats compared to 
Sprague-Dawley rats, as discussed previously in Chapter 3 (Figure 6-1). The experimental 
procedures  and  conditions  within  our  laboratory  were  identical  for  the  studies  of  both 
normotensive  rat  strains  (although  the  data  were  produced  by  two  investigators).  The 
results demonstrated a greater extent of injury in WKY compared to Sprague-Dawley rats. 
The differences observed following focal cerebral ischaemia between normotensive rats 
strains warrants further investigation and it may be useful for further studies examining the 
SHRSP strain to also include the Sprague-Dawley rat as an additional control strain, as 
well as the WKY rat. 
 
Rats are commonly used in animal models of stroke due to similarities to man with respect 
to their  cerebral  anatomy  and  physiology.  Furthermore, the  use  of  specific  and  inbred 
strains  improves  homogeneity  in  outcome  measures,  the  cost  of  purchasing  and 
maintaining them is relatively low compared to larger mammals and there is a greater level 
of social acceptance in the use of rodents in preclinical research (Sicard & Fisher, 2009). 
However, there are disadvantages in using rats to model human neurological diseases. Rats 
have a small region of subcortical white matter which makes it difficult to study white 
matter and model lacunar infarction (Carmichael, 2005). In addition, rodents demonstrate 
rapid  behavioural  recovery  following  experimental  stroke  which  is  not  relevant  to  the 
clinical situation and many neurological deficits are difficult to assess (Sicard & Fisher, 
2009).  Furthermore,  rodents  possess  small  lissencephalic  brains  which  are  not  directly 
comparable  to  the  large  gyrencephalic  brains  of  humans.  However,  the  use  of  larger 
species, like dogs, pigs and primates, is more relevant to the clinical situation as these 
species offer the advantage of having large gyrencephalic brains with proportions of grey 
and white matter which resemble that observed in humans (Howells et al, 2010, Figure 6-
2).  
 
Rodent stroke models have led to a better understanding of the mechanisms involved in the 
underlying  pathophysiology  of  stroke  and  the  identification  of  numerous  targets  for 
neuroprotective  therapy  (Mergenthaler  et  al,  2004).  To  date,  the  results  of  over  7,000 
studies examining the neuroprotective effects of over 1,000 therapeutic interventions have 
been published (O‟Collins et al, 2006) but unfortunately there has been a notable failure of 
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Figure 6-2. Brain size and gyral complexity in mammal species. Reproduced from Howells et 
al (2010).  
 
   217 
translation  from  bench  to  bedside  and  thrombolytic  therapy  with  recombinant  tissue 
plasminogen  activator  remains  the  only  successful  pharmacological  treatment  in  acute 
ischaemic  stroke  (NINDS,  1995).  There  are  many  factors  which  may  explain  why 
neuroprotective  drugs  demonstrate  efficacy  in  experimental  stroke  models  but  fail  to 
translate to human stroke patients. In some preclinical  studies, therapy  is administered 
prior to stroke onset and this does not reflect the clinical situation, where some stroke 
patients may not be diagnosed until many hours following stroke (Röther, 2008). In the 
study presented in this thesis, apocynin treatment was administered 5 minutes following 
stroke, which is not a particularly clinically relevant time point. However, the purpose of 
the studies was to assess if apocynin demonstrated a neuroprotective effect  
and the next logical step in this series of experiments would be to delay administration to 
determine  the  therapeutic  time  window.  Unfortunately,  time  constraints  did  not  permit 
such a study to be undertaken. 
 
Furthermore,  there  are  significant  anatomical,  physiological  and  metabolic  differences 
between humans and small rodents. Small rodents require higher drug doses on a mg/kg 
body weight basis compared to larger mammals and this means that effectivedoses cannot 
simply be translated from preclinical studies to clinical trial (Braeuninger & Kleinschnitz, 
2009).  In  addition,  the  ischaemic  lesion  induced  in  experimental  models  is  highly 
reproducible but a heterogenous population of stroke patients with a wide range of stroke 
severity and etiology is included in clinical trials.  
 
Selecting the most appropriate stroke model is also important. Models which require a 
craniectomy, like the electrocoagulation method of distal middle cerebral artery occlusion 
(Tamura et al, 1981), are traumatic and do not mimic the clinical situation. Therefore, 
embolic and intraluminal thread models of middle cerebral artery occlusion may be more 
relevant to human stroke and also offer the significant advantage of permitting reperfusion 
(Braueninger & Kleinschnitz, 2009). However, the infarct produced by the intraluminal 
filament and the embolic model may be variable due to incomplete occlusion. In particular, 
infarcts produced by embolic models are generally less reproducible than those produced 
by the intraluminal filament and electrocoagulation models of MCAO due to variations in 
clot stability and the final lodgement of the embolus (DiNapoli et al, 2006). 
 
Poor  study  design  may  also  contribute  to  the  failure  of  translation  of  neuroprotective 
strategies from preclinical research to clinical trial. Only a minority of published studies 
reporting neuroprotection have reported randomised treatment allocation and blinding of   218 
investigators  (Worp  et  al,  2005).  A  previous  meta-epidemiological  study  examined  13 
meta-analyses  of  experimental  stroke  studies  and  reported  that  those  studies  where 
induction of ischaemia was unblinded reported greater treatment effects than those studies 
which  were  blinded  (Crossley  et  al,  2008).  This  demonstrates  evidence  of  bias  in 
preclinical stroke research when evaluating potential therapeutic strategies. In the studies 
presented  in this thesis evaluating the potential  neuroprotective effect of apocynin, the 
allocation of rats to treatment groups was carried out in a randomised manner using a 
random  number  generator,  with  the  investigator  performing  the  stroke  surgery,  drug 
administration and  behavioural assessment (Emma  Reid) completely  blind to treatment 
group until completion of the experiments and data analysis. This limited any bias from the 
results presented in this thesis. Therefore, the improvements observed in stroke outcome 
following apocynin treatment in Sprague-Dawley rats following 1 hour of focal ischaemia, 
are likely to be true treatment effects. However, one source of bias in the studies presented 
in this thesis could not be removed. Although identical in general appearance, WKY rats 
are  larger  than  age-matched  SHRSP  rats  and  this  is  a  limitation  which  could  not  be 
controlled. Therefore the bias of knowing the strain of rat during stroke surgery could not 
be removed. 
 
The  recommendations  of  the  Stroke  Therapy  Academic  Industry  Roundtable  (STAIR, 
1999) were taken into account when designing the studies to evaluate the neuroprotective 
efficacy of  apocynin. Power calculations were performed to determine the group sizes 
necessary  to  detect  a treatment  effect.  Apocynin  efficacy  was  assessed  following  both 
permanent and transient ischaemia and rats with stroke co-morbidities (SHRSP) were used. 
In addition, treatment allocation was randomised and the investigator administering the 
drug and performing behavioural assessment was blind to treatment group. Furthermore, 
perfusion-diffusion  mismatch  was  used  as  an  outcome  measure  when  evaluating  the 
efficacy of apocynin in SHRSP rats.   
 
The results of Chapter 5 demonstrated that apocynin treatment had no effect on stroke 
outcome following permanent MCAO in WKY rats. However, both low and high dose 
apocynin treatment significantly reduced infarct volume by 60% in Sprague-Dawley rats 
following transient ischaemia of 1 hour duration. These findings are in agreement with 
previous  reports  of  the  neuroprotective  effect  of  apocynin  treatment  in  rat  transient 
ischaemia  models,  where  reductions  in  infarct  volume  of  up  to  40%  have  been 
demonstrated (Tang et al, 2007; Genovese et al, 2011). Furthermore, there was a trend 
towards improved  functional outcome with  low  dose apocynin treatment, although this   219 
improvement  did  not  reach  the  level  of  statistical  significance.  However,  the  general 
condition  of  low  dose  apocynin  treated  rats  was  observed  to  be  markedly  improved 
compared to vehicle and high dose treated rats. Therefore, in future studies, it may be 
advantageous to develop a  test of  functional outcome which  incorporates feeding and 
grooming behaviours, in addition to the standard tests of sensorimotor function.  
 
Interestingly, when low dose apocynin treatment was evaluated in the SHRSP strain, it 
failed to confer neuroprotection and a mortality rate of over 60% was observed in both the 
vehicle  treated  and  apocynin  treated  rats.  This  demonstrates  that  although  apocynin 
improved stroke outcome  in  normotensive rats  following 1  hour of  focal  ischaemia,  it 
failed to confer neuroprotection under the same conditions in a rat model with genetic 
stroke  risk  factors.  The  STAIR  guidelines  recommend  the  use  of  perfusion-diffusion 
mismatch  as  an  imaging  biomarker  to  evaluate  the  efficacy  of  potential  therapeutic 
strategies to improve the translation from preclinical to clinical trials (Fisher et al, 2009). 
The use of the mismatch model allowed the effect of apocynin on the acute evolution of 
ischaemic  injury  in  SHRSP  to  be  assessed.  The  failure  of  apocynin  to  confer 
neuroprotection  in  SHRSP  rats  may  be  attributable  to the  possibility  that  Nox4  is  the 
predominant isoform of NADPH oxidase during ischaemia and reperfusion, rather than 
Nox2, which is inhibited by apocynin.  Furthermore, the lack of neuroprotective efficacy 
may also be attributable in part to the small volumes of mismatch tissue observed in the 
hypertensive strain. Therefore, there may be a limited potential for penumbra salvage in 
the SHRSP strain. The efficacy of potential therapeutic strategies may therefore be limited 
in  preclinical  models  with  stroke  co-morbidities.  Kelly  and  colleagues  previously 
demonstrated that apocynin worsened stroke outcome in aged rats, compared to vehicle 
treated controls, where mortality rate was increased from 14% to 36% (Kelly et al, 2009). 
It may be that in aged rats, apocynin is not activated to the active dimer form as it has been 
reported that unactivated apocynin has pro-oxidant effects (Riganti et al, 2006) and this 
may  have exacerbated  ischaemic  injury. The  findings of  Kelly and colleagues and the 
results reported in this may help to explain the failure of neuroprotective agents to translate 
to clinical trial. One of the major failings of preclinical research is the use of young healthy 
animals to assess the potential efficacy of therapeutic interventions. The majority of stroke 
patients recruited into clinical trials are elderly and may suffer from stroke co-morbidities 
such as hypertension, diabetes and atherosclerosis (Braeuninger & Kleinschnitz, 2009). It 
is therefore essential, that when evaluating the therapeutic strategies in preclinical research, 
that  there  should  be  increasing  focus  on  aged  animals  and  animals  with  stroke  co-
morbidities, like the SHRSP strain. However, there are additional problems of increased   220 
mortality when using aged animals and animals with stroke-comorbidities. Furthermore, 
there is an increased cost of housing, feeding and maintenance when using aged animals. 
 
Furthermore, preclinical studies to evaluate potential therapeutic strategies should routinely 
assess stroke outcome by functional testing, in addition to infarct volume. This step is vital 
for  translation  to  clinical  trial  as  a  desirable  outcome  in  human  stroke  patients  is 
determined by the degree of disability and the improvement in quality of life, not solely by 
a reduction in brain injury, as this will not necessarily equate to an improved outcome for 
the patient. The need for combined assessment of brain injury and functional outcome is 
highlighted  by  the  studies  reported  in  this  thesis,  where  low  dose  apocynin  treatment 
significantly reduced infarct volume and improved functional outcome in Sprague-Dawley 
rats  following  1  hour  of  ischaemia.  However,  high  dose  apocynin  treatment  failed  to 
improve  functional  outcome  despite  reducing  infarct  volume  by  60%  compared  to the 
vehicle treated group, although this may be related to the sensitivity of the behavioural 
tests. Furthermore, the design of the study could have been improved by increasing the 
number of rats in each group to increase the the  likelihood of detecting differences  in 
behavioural outcome between groups. However, on the basis of the results presented in this 
thesis, low dose apocynin treatment improves stroke outcome in terms of functionality and 
should be used in future studies rather than the higher dose of apocynin.  
 
In terms of future strategies to salvage brain tissue following stroke, combination therapy 
may be the way forward. The pathophysiological mechanisms are so highly complex that 
targeting a single component of the ischaemic cascade may have a limited effect on stroke 
outcome.  There  is  an  increasing  focus  on  evaluating  the  combined  effects  of 
neuroprotective strategies and thrombolysis with rtPA (Fujiwara et al, 2009, Figure 6-3). 
Any new neuroprotective drug under test should be given in combination  with rtPA or 
tested only in those patients not receiving treatment as it would be unethical to not to give 
eligible patients rtPA. 
 
 An alternative example of a potential combination therapy is magnesium treatment and 
hypothermia. The neuroprotective effects of hypothermia are well established and it is used 
clinically to limit brain ischaemia in comatose cardiac arrest patients (Hypothermia After 
Cardiac arrest Study Group, 2002). Magnesium therapy has also been demonstrated to be 
neuroprotective in animal models of cerebral ischaemia but failed to translate to clinical 
trial, with some evidence that magnesium may be beneficial in lacunar strokes (IMAGES 
Study Group, 2004).     221 
 
 
 
 
 
 
 
 
 
 
Figure 6-3. Hypothetical scenarios for the progression of brain injury following ischaemic 
stroke. In the absence of any treatment the infarct will rapidly evolve leading to permanent injury 
(A). If a neuroprotective drug is administered but it does not alter the ischaemic environment then 
the infarct will progressively expand to reach its maximum volume although growth may be delayed 
by the action of the drug (B). The progression of infarction could be reduced by interventions which 
improve  collateral  blood  flow  to  the  penumbra  or  recanalise  the  ischaemic  territory  (C). 
Neuroprotective drugs may be useful in prolonging the time window for thrombolysis. Reproduced 
from Chavez et al (2009). 
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However,  the  mechanisms  involved  in  the  neuroprotective  effects  of  hypothermia  and 
magnesium therapy are poorly understood. It has been proposed that the neuroprotective 
action  of  magnesium  is  „unmasked‟  at  low  temperatures.  Campbell  and  colleagues 
demonstrated that mild hypothermia and magnesium treatment had no significant effect on 
infarct volume following permanent focal cerebral ischaemia in rats but in combination a 
significant reduction in infarct volume of over 50% compared to vehicle treated groups 
(Campbell  et  al,  2008).  This  apparent  synergistic  effect  of  combination  therapy  may 
explain, in part, the failure of magnesium therapy to translate to clinical trial since patient 
management  in the IMAGES trial did  not involve the active  induction of  hypothermia 
(Meloni et al, 2009). In addition, in the majority of the preclinical studies reporting the 
neuroprotective effect of magnesium therapy, post-ischaemic body temperature was not 
reported. Therefore, it may be possible that spontaneous hypothermia induced the observed 
treatment  effects  (Meloni  et  al,  2009).  In  addition,  magnesium  and  mild  hypothermia 
treatment could potentially be administered in combination with thrombolytic therapy to 
extend  the  therapeutic  time  window  in  acute  ischaemic  stroke  as  magnesium  and 
hypothermia treatment do not alter the enzymatic activity of tPA (Meloni et al, 2009).  
 
An  alternative  therapy  could  involve  the  combination  of  rtPA  with  hypothermia  and 
apocynin.  The results presented in this thesis demonstrated that apocynin improved stroke 
outcome in normotensive rats in combination with reperfusion. Hypothermia may further 
improve stroke outcome. However, it would first have to be determined if apocynin has 
any  detrimental  effect  on  the  enzymatic  activity  of  rtPA  before  combining  these 
treatments.  Apocynin  treatment  could  be  administered  simultaneously  with  rtPA  and 
hypothermia could be induced concurrently by surface cooling.  
To conclude, perfusion-diffusion weighted MRI is an  important imaging  biomarker  for 
identifying potentially salvageable penumbra in clinical and preclinical stroke research and 
in  assessing  the  effect  of  potential  neuroprotective  strategies.  However,  the  findings 
reported in this thesis demonstrate that care should be taken when applying thresholds to 
define hypoperfused and injured tissue, as the present study has shown variability between 
rat strains with and without stroke-comorbidities. The method used to determine penumbra 
should also be taken into consideration and on the basis of the results presented within this 
thesis, spatial co-registration of perfusion and diffusion  lesions appears to be the  most 
informative and precise method to define perfusion-diffusion mismatch. In addition, the 
work  contained  within  this  thesis  has  also  reported that  neuroprotective  therapies  may 
demonstrate  efficacy  in  young,  healthy  rodent  models  of  stroke  but  fail  to  confer 
neuroprotection  in  models  with  genetic  stroke  risk  factors,  like  hypertension.  These   223 
findings highlight the need to evaluate potential therapeutic strategies in a range of animal 
models with stroke risk factors to improve the chance of successful translation to human 
stroke patients. 
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